<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Microbiology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26557111</article-id>
<article-id pub-id-type="pmc">4615951</article-id>
<article-id pub-id-type="doi">10.3389/fmicb.2015.01164</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mediouni</surname>
<given-names>Sonia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/263223/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garibaldi Marcondes</surname>
<given-names>Maria Cecilia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/77023/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Courtney</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McLaughlin</surname>
<given-names>Jay P.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/263406/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valente</surname>
<given-names>Susana T.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/228753/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Infectious Diseases, The Scripps Research Institute</institution>, <country>Jupiter, FL, USA</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Molecular and Cellular Neurosciences, The Scripps Research Institute</institution>, <country>La Jolla, CA, USA</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Metabolism and Aging, The Scripps Research Institute</institution>, <country>Jupiter, FL, USA</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Neuroscience, The Scripps Research Institute</institution>, <country>Jupiter, FL, USA</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Pharmacodynamics, University of Florida</institution>, <country>Gainesville, FL, USA</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: <italic>Venkata S. R. Atluri, Florida International University, USA</italic></p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: <italic>Masanori Baba, Kagoshima University, Japan; Shilpa J. Buch, University of Nebraska Medical Center, USA; Peter S. Silverstein, University of Missouri-Kansas City, USA</italic></p>
</fn>
<corresp id="fn001">*Correspondence: <italic>Susana T. Valente, <email xlink:type="simple">svalente@scripps.edu</email></italic></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>6</volume>
<elocation-id>1164</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2015 Valente, Mediouni, Miller, Marcondes and McLaughlin.</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>Valente, Mediouni, Miller, Marcondes and McLaughlin</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Antiretroviral therapy has dramatically improved the lives of human immunodeficiency virus 1 (HIV-1) infected individuals. Nonetheless, HIV-associated neurocognitive disorders (HAND), which range from undetectable neurocognitive impairments to severe dementia, still affect approximately 50% of the infected population, hampering their quality of life. The persistence of HAND is promoted by several factors, including longer life expectancies, the residual levels of virus in the central nervous system (CNS) and the continued presence of HIV-1 regulatory proteins such as the transactivator of transcription (Tat) in the brain. Tat is a secreted viral protein that crosses the blood–brain barrier into the CNS, where it has the ability to directly act on neurons and non-neuronal cells alike. These actions result in the release of soluble factors involved in inflammation, oxidative stress and excitotoxicity, ultimately resulting in neuronal damage. The percentage of methamphetamine (MA) abusers is high among the HIV-1-positive population compared to the general population. On the other hand, MA abuse is correlated with increased viral replication, enhanced Tat-mediated neurotoxicity and neurocognitive impairments. Although several strategies have been investigated to reduce HAND and MA use, no clinically approved treatment is currently available. Here, we review the latest findings of the effects of Tat and MA in HAND and discuss a few promising potential therapeutic developments.</p>
</abstract>
<kwd-group>
<kwd>methamphetamine</kwd>
<kwd>HAND</kwd>
<kwd>HIV-1 Tat</kwd>
<kwd>antiretroviral therapy</kwd>
<kwd>neurotoxicity</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">National Institute of Allergy and Infectious Diseases<named-content content-type="fundref-id">10.13039/100000060</named-content></funding-source>
<award-id rid="cn001">AI097012-01A1, R21AI116226-01</award-id>
</award-group>
<award-group>
<funding-source id="cn002">National Institute on Drug Abuse<named-content content-type="fundref-id">10.13039/100000026</named-content></funding-source>
<award-id rid="cn002">5R01DA036164</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="359"></ref-count>
<page-count count="24"></page-count>
<word-count count="21995"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>The human immunodeficiency virus 1 (HIV-1) affects 35.3 million individuals worldwide (UNAIDS). The entry of the virus in the central nervous system (CNS) early during infection, and the relatively low penetration of current antiretroviral therapies (ART) in the brain, results in neurological complications collectively called HIV-associated neurocognitive disorders (HAND; <xref ref-type="bibr" rid="B68">Davis et al., 1992</xref>; reviewed in <xref ref-type="bibr" rid="B107">Gray et al., 1993</xref>; reviewed in <xref ref-type="bibr" rid="B225">Owen and Khoo, 2004</xref>; reviewed in <xref ref-type="bibr" rid="B202">Miller et al., 2008</xref>; <xref ref-type="bibr" rid="B323">Valcour et al., 2012</xref>; reviewed in <xref ref-type="bibr" rid="B295">Spudich, 2013</xref>). HAND can be subdivided into asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and severe forms of HIV-associated encephalitis/dementia (HAD). Patients affected with ANI and MND score poorly in neuropsychological testing, but their everyday functioning is only minimally impacted. In contrast, HAD patients experience severe neurological failure that severely hampers their daily lives. Characteristic HAD symptoms include inflammation of the brain, decline in cognitive functions (memory, concentration, attention, and executive control), reduced motor function (loss of dexterity and coordination) and the mimicking of other dementia symptoms, such as in Alzheimer’s and Parkinson’s diseases. In addition, HAD patients present comorbid behavioral changes such as unipolar depression (apathy and loss of motivation), fatigue and social withdrawal (reviewed in <xref ref-type="bibr" rid="B15">Antinori et al., 2007</xref>). ART has considerably decreased the early occurrence of HAD, but the diagnosis of moderate neurocognitive impairments continues to increase (reviewed in <xref ref-type="bibr" rid="B59">Cisneros and Ghorpade, 2012</xref>). This increase is primarily attributed to longer life spans, the long-term toxicity of ART, and the development of resistance to therapy (reviewed in <xref ref-type="bibr" rid="B227">Pardo et al., 2001</xref>; reviewed in <xref ref-type="bibr" rid="B183">Lv et al., 2015</xref>; reviewed in <xref ref-type="bibr" rid="B321">Underwood et al., 2015</xref>).</p>
<p>The best accepted model to explain how HIV-1 gains access to the CNS is the “Trojan horse” hypothesis, in which infected monocytes and macrophages cross the blood–brain barrier (BBB) and subsequently infect non-neuronal cells including perivascular macrophages and glial cells (reviewed in <xref ref-type="bibr" rid="B110">Haase, 1986</xref>). Macrophages and microglia are the main supporters of viral replication in the brain (reviewed in <xref ref-type="bibr" rid="B20">Bagashev and Sawaya, 2013</xref>), whereas astrocytes are susceptible to HIV-1 infection but alone are not thought to support productive infection (reviewed in <xref ref-type="bibr" rid="B20">Bagashev and Sawaya, 2013</xref>). Pericytes have also been suggested as cells that may become infected by HIV-1, although at low levels, and be modified as a result of the presence of HIV-1 in the brain, thereby further contributing to BBB disruption (<xref ref-type="bibr" rid="B212">Nakagawa et al., 2012</xref>). Even though HIV-1 does not infect neurons, a major aspect of HAND is neuronal damage and apoptosis (reviewed in <xref ref-type="bibr" rid="B162">Kovalevich and Langford, 2012</xref>). Two mechanistic models of toxicity have been proposed: direct and indirect (or “bystander”; reviewed in <xref ref-type="bibr" rid="B177">Lindl et al., 2010</xref>). The direct model suggests that viral proteins released from infected cells cause neuronal death through a direct interaction with neurons. The indirect model proposes the death of neurons through the activity of soluble factors released as a result of inflammatory responses to viral particles or changes in the brain environment by non-neuronal cells. Regardless of the means, among the consequences of HIV infection is synaptodendritic injury to neurons that closely correlates to the occurrence and severity of neurocognitive disorders (reviewed in <xref ref-type="bibr" rid="B78">Ellis et al., 2007</xref>).</p>
<p>This synaptodendritic injury may be driven by viral replication in non-neuronal cells and is defined by structural and chemical changes occurring at neuronal synapses, resulting in a disturbance of communication between neurons responsible for behaviors such as memory, learning, and executive functions (reviewed in <xref ref-type="bibr" rid="B78">Ellis et al., 2007</xref>; reviewed in <xref ref-type="bibr" rid="B217">Nath and Steiner, 2014</xref>). Experimental studies in mice, monkeys or in human brain tissues confirm that exposure to HIV and the transactivator of transcription (Tat) protein induce alterations in neuronal morphology (reviewed in <xref ref-type="bibr" rid="B78">Ellis et al., 2007</xref>; <xref ref-type="bibr" rid="B29">Bertrand et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B217">Nath and Steiner, 2014</xref>). These morphological changes associated with synaptodendritic injury may involve mitochondrial dysfunction (<xref ref-type="bibr" rid="B108">Greenwood et al., 2007</xref>). Notably, synaptodendritic injury may be reversible depending on the degree of injury (an example of “brain plasticity”; reviewed in <xref ref-type="bibr" rid="B78">Ellis et al., 2007</xref>). Accordingly, the addition of neuroprotective and regenerative factors to ART has been proposed to reduce HAND progression (reviewed in <xref ref-type="bibr" rid="B78">Ellis et al., 2007</xref>).</p>
<p>Among the viral proteins that play a role in neuropathogenesis, Tat, is a significant contributor. Although the main function of Tat is to regulate HIV-1 transcription, it has also been implicated in the dysregulation of inflammatory processes, induction of oxidative stress, excessive activation of neurotransmitters, modulation of apoptotic pathways, and irregular neurogenesis (see “Tat Neurotoxicity”, below). Indeed, elevated levels of Tat mRNA are commonly found in post-mortem brain samples from individuals with HAD (<xref ref-type="bibr" rid="B335">Wesselingh et al., 1993</xref>; <xref ref-type="bibr" rid="B336">Wiley et al., 1996</xref>; <xref ref-type="bibr" rid="B131">Hudson et al., 2000</xref>).</p>
<p>Beyond this, drug abuse correlates with an increased risk of exposure to HIV-1. The world drug report of 2014 (UNAIDS) describes that the prevalence of HIV infection among injecting drug users is 22–50 times higher than in the general population, depending on the country. The abuse of drugs largely prevalent in the US and worldwide, particularly the strong psychostimulant methamphetamine (MA), is correlated with increased neurotoxicity and immune system impairments, with a consequential exacerbation of HAND (<xref ref-type="bibr" rid="B234">Potula and Persidsky, 2008</xref>). It has been demonstrated in human and animal studies that the neurotoxicity caused by MA and Tat (or HIV-1 infection), results in greater cognitive and locomotor impairments than with either MA or Tat (or HIV-1) alone (see “Tat and Methamphetamine Neurotoxicity”).</p>
<p>This review will focus on the effects of Tat, MA, and their concerted effects in the CNS. Given that no treatment is yet available against the neurotoxic activity of Tat (<xref ref-type="bibr" rid="B195">Mediouni et al., 2012</xref>), or the additive detrimental effects of both Tat and MA, we will conclude with a discussion of some promising candidates emerging in the literature.</p>
</sec>
<sec>
<title>Tat Neurotoxicity</title>
<p>The early HIV-1 gene product, Tat, is an 86–103 amino acid protein, divided in six functional regions (<xref ref-type="bibr" rid="B166">Kuppuswamy et al., 1989</xref>; Figure <xref ref-type="fig" rid="F1">1A</xref>). Tat binds through its basic domain to the 5′-terminal region of HIV mRNA’s stem-bulge-loop structure transactivation response element (TAR), and recruits the positive transcription elongation factor b (P-TEFb) to promote transcriptional elongation from the viral promoter (<xref ref-type="bibr" rid="B44">Cann et al., 1985</xref>). In addition to its key role in HIV-1 transcription amplification, Tat can be transported and secreted by HIV-1 infected cells, and can cross the BBB. Once in the brain, non-infected cells may uptake Tat passively or <italic>via</italic> interaction with membrane receptors (reviewed in <xref ref-type="bibr" rid="B173">Li et al., 2009</xref>). Immunostaining patterns suggest that Tat can be found in the cytoplasm of perivascular macrophages, microglia nodules and in glial cells, but also in the nuclei of some neurons and oligodendrocytes. These data suggest that Tat can be taken up by all CNS cells and potentially exert its effects distally from HIV-1 replication sites (<xref ref-type="bibr" rid="B70">Del Valle et al., 2000</xref>; <xref ref-type="bibr" rid="B131">Hudson et al., 2000</xref>; <xref ref-type="bibr" rid="B181">Liu et al., 2000</xref>). As noted above, the neurotoxic activity of Tat comes from both direct action on neurons and by altering the release of different soluble factors from surrounding non-neuronal cells resulting in neuronal or synaptodendritic injury. Brain histological changes similar to those observed in HAD patients have been observed in different mouse models expressing HIV-1 Tat (reviewed in <xref ref-type="bibr" rid="B245">Rappaport et al., 1999</xref>; <xref ref-type="bibr" rid="B36">Bruce-Keller et al., 2003</xref>; <xref ref-type="bibr" rid="B51">Chauhan et al., 2003</xref>; <xref ref-type="bibr" rid="B154">Kim et al., 2003</xref>). A positive correlation has also been shown between the levels of Tat mRNA transcripts and HIV- and simian human immunodeficiency virus (SIV)-induced encephalitis (<xref ref-type="bibr" rid="B131">Hudson et al., 2000</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p><bold>Tat HIV clades and HAND. (A)</bold> Conservation of the nucleotide sequences of Tat representative of the main HIV-1 clades (A–D and the circulating recombinant CRF_ AE/AG), brain derived isolates from non-demented HIV/AIDS individuals (ND sequences from <xref ref-type="bibr" rid="B33">Boven et al., 2007</xref>) and from individuals with HIV associated dementia [HAD sequences from <xref ref-type="bibr" rid="B33">Boven et al. (2007)</xref> and <xref ref-type="bibr" rid="B311">Thomas et al. (2007)</xref>]. Tat is encoded by two exons, divided into six functional regions. Region I (residues 1–21) is a proline-rich region, shown to protect Tat from degradation (<xref ref-type="bibr" rid="B42">Campbell and Loret, 2009</xref>; <xref ref-type="bibr" rid="B46">Caputo et al., 2009</xref>). Region II (residues 22–37) has seven conserved cysteines except for subtype C (which has <sup>31</sup>C→<sup>31</sup>S) and the recombinant CRF_AE and CRF_AG (with more cysteines). Any mutation of these cysteines (except <sup>31</sup>C) leads to loss of the transactivation activity (<xref ref-type="bibr" rid="B166">Kuppuswamy et al., 1989</xref>; <xref ref-type="bibr" rid="B138">Jeang et al., 1999</xref>). Region III (residues 38–48) has a conserved <sup>38</sup>F(x)2KxLGISY motif. Mutation of <sup>41</sup>K results in loss of transactivation (<xref ref-type="bibr" rid="B166">Kuppuswamy et al., 1989</xref>; <xref ref-type="bibr" rid="B228">Peloponese et al., 2000</xref>). <sup>38</sup>F is conserved in Tat sequences and shown to be involved in binding to tubulin, resulting in apoptosis (<xref ref-type="bibr" rid="B54">Chen et al., 2002</xref>). Region I, II, and III constitute the minimal activation domain, which binds to cyclin T1. Region IV (residues 49–59) is rich in basic residues with the conserved sequence <sup>49</sup>RKKRRQRRRPP. This domain is responsible for Tat’s interaction with TAR and is also a nuclear and nucleolar signal. Mutations in this domain results in loss of transactivation (<xref ref-type="bibr" rid="B116">Hauber et al., 1989</xref>) and delocalization of Tat from the nucleolus (<xref ref-type="bibr" rid="B208">Mousseau et al., 2012</xref>). The regions II as well as IV and Tat peptides covering the 31–61 amino acid region (in gray) were demonstrated to be neurotoxic (<xref ref-type="bibr" rid="B186">Mabrouk et al., 1991</xref>; <xref ref-type="bibr" rid="B263">Sabatier et al., 1991</xref>; <xref ref-type="bibr" rid="B230">Philippon et al., 1994</xref>; <xref ref-type="bibr" rid="B333">Weeks et al., 1995</xref>; <xref ref-type="bibr" rid="B327">Vives et al., 1997</xref>; <xref ref-type="bibr" rid="B142">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="B140">Jia et al., 2001</xref>; <xref ref-type="bibr" rid="B316">Turchan et al., 2001</xref>; <xref ref-type="bibr" rid="B275">Self et al., 2004</xref>; <xref ref-type="bibr" rid="B8">Aksenov et al., 2006</xref>; <xref ref-type="bibr" rid="B66">Daily et al., 2006</xref>; <xref ref-type="bibr" rid="B172">Li et al., 2008</xref>; <xref ref-type="bibr" rid="B203">Mishra et al., 2008</xref>). Region V (residues 60–72) is the glutamine-rich region and was shown to be involved in apoptosis of lymphocytes T (<xref ref-type="bibr" rid="B43">Campbell et al., 2004</xref>). Regions I to V are encoded by exon I. Region VI is encoded by the second exon and contain a conserved RGD motif, found only in subtypes B and D. Predicted stop codon is indicated by an asterisk (*). % P: percentage of HIV-1 infected individuals in 2004–2007 with the indicated type of clade (<xref ref-type="bibr" rid="B122">Hemelaar et al., 2011</xref>). <bold>(B)</bold> Number of publications comparing the activity of HIV-1 clade B to other clades in the indicated neurotoxic activities.</p>
</caption>
<graphic xlink:href="fmicb-06-01164-g0001"></graphic>
</fig>
<p>The majority of the studies investigating neurotoxicity mediated by Tat demonstrated that the neurotoxic domain comprised part of the cysteine-rich/ZnF domain, the core and the basic domain of the protein (Figure <xref ref-type="fig" rid="F1">1A</xref>). Studies on HIV-1 clade B demonstrated the strong contribution of the highly conserved cysteine-rich/ZnF domain to neurotoxicity (<xref ref-type="bibr" rid="B6">Aksenov et al., 2009</xref>). In fact, studies carried out using other clades reported lesser neurotoxicity, which was attributed to differences in the sequence of the cysteine-rich/ZnF domain (<xref ref-type="bibr" rid="B203">Mishra et al., 2008</xref>). A summary of these findings is shown in Figure <xref ref-type="fig" rid="F1">1B</xref>. Interestingly, Tat from HIV-1 isolates found in patients with HAD exhibited higher neurotoxic potential than Tat isolated from non-HAD patients (Figure <xref ref-type="fig" rid="F1">1B</xref>). This suggests a relationship between characteristics of the brain environment and the selection of neurotoxic isolates, and validates the relevance of using Tat from virus present in HAD-positive individuals to study Tat activity, rather than laboratory adapted viruses. Regrettably, most of the studies on Tat to date do not address potential differences between the neurotoxic activity of Tat expressed upon transfection of eukaryotic cells and recombinant Tat produced in bacteria. Of the few studies that have offered such comparisons, either no differences were observed (<xref ref-type="bibr" rid="B348">Zauli et al., 2000</xref>; <xref ref-type="bibr" rid="B157">Koller et al., 2001</xref>), or higher toxicity was detected with transfected Tat when equivalent concentrations of both were examined (<xref ref-type="bibr" rid="B172">Li et al., 2008</xref>). These results could be explained by differences on the folding of Tat protein <italic>in vitro</italic>, and <italic>in vivo</italic>, or by differences of post-transcriptional modifications of Tat between eukaryotic and prokaryotic cells. There is also the possibility that the recombinant protein suffers some degradation when added to cell cultures, resulting in reduced activity.</p>
<sec>
<title>Tat and Neurotransmitters Modulation</title>
<p>The effects of Tat on neurotransmission have been largely studied on the glutamatergic (GLUTergic) and dopaminergic (DAergic) systems. Glutamate is an excitatory neurotransmitter essential for learning, memory, and synaptic plasticity (reviewed in <xref ref-type="bibr" rid="B242">Rahn et al., 2012</xref>), and has been shown to regulate drug reward (<xref ref-type="bibr" rid="B43">Campbell et al., 2004</xref>; <xref ref-type="bibr" rid="B203">Mishra et al., 2008</xref>). However, excessive glutamate causes “glutamate excitotoxicity” leading to neuron death (reviewed in <xref ref-type="bibr" rid="B242">Rahn et al., 2012</xref>). Tat protein impairs glutamate reuptake by astrocytes (<xref ref-type="bibr" rid="B355">Zhou et al., 2004</xref>) and increases microglial glutamate release (<xref ref-type="bibr" rid="B109">Gupta et al., 2010</xref>), elevating extracellular glutamate levels. The down-regulation of the excitatory amino acid transporter-2 (EAAT-2) involved in the reuptake of glutamate and the stimulation of the glutamate release from microglial cells, was also reported in the presence of Tat (<xref ref-type="bibr" rid="B261">Rumbaugh et al., 2007</xref>). More directly, Tat further promotes glutamate excitotoxicity by directly binding to or phosphorylating the glutamate <italic>N</italic>-methyl-D-aspartate (NMDA) receptor (<xref ref-type="bibr" rid="B119">Haughey et al., 2001</xref>; <xref ref-type="bibr" rid="B236">Prendergast et al., 2002</xref>; <xref ref-type="bibr" rid="B293">Song et al., 2003</xref>). The Cys<sup>30–31</sup> motif in the clade B Tat protein interacts with the extracellular domain of the NR1 subunit of the NMDA receptor (<xref ref-type="bibr" rid="B172">Li et al., 2008</xref>). The mutation of Cys<sup>31</sup> into Ser<sup>31</sup> in HIV-1 Tat expressed by HIV-1 clade C and/or polymorphisms of the NMDA receptor subunits could explain the lesser neurotoxic activity of clade C Tat (<xref ref-type="bibr" rid="B203">Mishra et al., 2008</xref>; <xref ref-type="bibr" rid="B244">Rao et al., 2008</xref>; <xref ref-type="bibr" rid="B156">King et al., 2010</xref>; <xref ref-type="bibr" rid="B81">Eugenin et al., 2011</xref>). Interestingly, a recent study showed that Tat potentiates NMDA-evoked increases in intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]i) <italic>via</italic> the low-density lipoprotein receptor-related protein (LRP) and activation of Src tyrosine kinase, and mediated by a GTPase RhoA and Rho-associated protein kinase (ROCK; <xref ref-type="bibr" rid="B163">Krogh et al., 2015</xref>). However, potentiation is rapidly followed by a gradual adaptation and decrease of [Ca<sup>2+</sup>]i, resulting in neuronal protection from excessive calcium influx (<xref ref-type="bibr" rid="B164">Krogh et al., 2014</xref>, <xref ref-type="bibr" rid="B163">2015</xref>). This suggests that even if Tat activates the NMDA receptor at picomolar concentrations (<xref ref-type="bibr" rid="B172">Li et al., 2008</xref>), Tat-mediated neurotoxicity through NMDA may require a certain activation threshold. Consistent with this, Tat inhibits glutamate-induced variation in intracellular Ca<sup>2+</sup> in astrocytes (<xref ref-type="bibr" rid="B157">Koller et al., 2001</xref>), resulting in protection from death. Several studies using astrocyte cells to study the effects of Tat in HAND and/or the response to drugs of abuse may take advantage of this protection from death (<xref ref-type="bibr" rid="B51">Chauhan et al., 2003</xref>; <xref ref-type="bibr" rid="B154">Kim et al., 2003</xref>; <xref ref-type="bibr" rid="B311">Thomas et al., 2007</xref>; <xref ref-type="bibr" rid="B196">Mediouni et al., 2015</xref>).</p>
<p>The neurotransmitter dopamine (DA) plays important roles in motor control, motivation, reward, arousal, cognition, executive functions, and maternal behaviors (reviewed in <xref ref-type="bibr" rid="B223">Nutt et al., 2015</xref>). The impairment of DA neuronal functions correlates with early stage of HIV infection (<xref ref-type="bibr" rid="B28">Berger et al., 1994</xref>). Tat perturbs the normal signaling of DA transmission by inhibiting the activity of the DA transporter (DAT) through a concentration-dependent allosteric mechanism (<xref ref-type="bibr" rid="B50">Chan and Kantor, 2009</xref>; <xref ref-type="bibr" rid="B357">Zhu et al., 2009</xref>) without affecting DA release (reviewed in <xref ref-type="bibr" rid="B319">Turowski and Kenny, 2015</xref>). This prevents astrocytes from buffering DA and from triggering the release signal for neuroprotective molecules mediated through DAT (<xref ref-type="bibr" rid="B282">Silvers et al., 2007</xref>; <xref ref-type="bibr" rid="B357">Zhu et al., 2009</xref>, <xref ref-type="bibr" rid="B356">2011</xref>; <xref ref-type="bibr" rid="B229">Perry et al., 2010</xref>; <xref ref-type="bibr" rid="B204">Miyazaki et al., 2011</xref>; <xref ref-type="bibr" rid="B199">Midde et al., 2012</xref>, <xref ref-type="bibr" rid="B200">2013</xref>). Tat also inhibits the vesicular monoamine transporter (VMAT2) and the expression of tyrosine hydroxylase (TH, the rate limiting enzyme in DA biosynthesis), thus amplifying DA neurotoxicity (<xref ref-type="bibr" rid="B348">Zauli et al., 2000</xref>; reviewed in <xref ref-type="bibr" rid="B83">Everall et al., 2005</xref>; <xref ref-type="bibr" rid="B199">Midde et al., 2012</xref>, <xref ref-type="bibr" rid="B200">2013</xref>; <xref ref-type="bibr" rid="B305">Theodore et al., 2012</xref>). These findings, associated with disturbances in the DAergic system are observed both in humans and in animals models (reviewed in <xref ref-type="bibr" rid="B160">Koutsilieri et al., 2002a</xref>,<xref ref-type="bibr" rid="B161">b</xref>; <xref ref-type="bibr" rid="B139">Jenuwein et al., 2004</xref>) and may have implications in the development of symptoms commonly observed in both Parkinson’s disease and in HAND (reviewed in <xref ref-type="bibr" rid="B160">Koutsilieri et al., 2002a</xref>,<xref ref-type="bibr" rid="B161">b</xref>).</p>
</sec>
<sec>
<title>Tat and Oxidative Stress</title>
<p>Low- and short-term reactive oxygen species (ROS) such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and nitric oxide (NO) are important to cellular physiology as they participate in cell signaling in several biological processes (reviewed in <xref ref-type="bibr" rid="B65">D’Autreaux and Toledano, 2007</xref>; reviewed in <xref ref-type="bibr" rid="B79">Erusalimsky and Moncada, 2007</xref>). In the brain, ROS and NO interact in many ways to induce activation of brain cell glial subpopulations (<xref ref-type="bibr" rid="B266">Saha and Pahan, 2006a</xref>,<xref ref-type="bibr" rid="B267">b</xref>) and promote neuronal activity (<xref ref-type="bibr" rid="B18">Atkins and Sweatt, 1999</xref>). However, sustained high levels of ROS induce lipid peroxidation, protein oxidation and impairment of DNA synthesis and fidelity, events collectively called “oxidative stress” (reviewed in <xref ref-type="bibr" rid="B233">Pocernich et al., 2005</xref>; reviewed in <xref ref-type="bibr" rid="B273">Schieber and Chandel, 2014</xref>). Markers of oxidative stress are detected in brain and cerebrospinal fluid (CSF) of HAD patients (reviewed in <xref ref-type="bibr" rid="B233">Pocernich et al., 2005</xref>). Oxidative stress and neurodegeneration are secondary to glial activation and occur when ROS and NO approach inflammatory levels.</p>
<p>Tat has been shown to alter the production of ROS, in particular of reactive nitrogen species, leading to a loss of neuronal activity. Several studies <italic>in vivo</italic> and <italic>in vitro</italic> have shown an increase in the expression of intracellular NO synthase (NOS2) in brain cell subsets, resulting in an increase of NO following Tat exposure (<xref ref-type="bibr" rid="B230">Philippon et al., 1994</xref>; <xref ref-type="bibr" rid="B37">Bukrinsky et al., 1995</xref>; <xref ref-type="bibr" rid="B142">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="B180">Liu et al., 2002</xref>; <xref ref-type="bibr" rid="B155">Kim et al., 2015</xref>). Excess NO may induce glutamate release from astrocytes (<xref ref-type="bibr" rid="B21">Bal-Price et al., 2002</xref>), thereby further hyperactivating NMDA receptors on neurons that, in turn, triggers further ROS-associated neuronal death (<xref ref-type="bibr" rid="B45">Capone et al., 2013</xref>). Moreover, in astrocytes exposed to Tat, a NOS2-dependent mechanism up-regulates adhesion molecules that induce recruitment of monocytes and viral replication (<xref ref-type="bibr" rid="B292">Song et al., 2011</xref>), consistent with the observation that elevated NO levels are associated with increased HIV-1 replication (reviewed in <xref ref-type="bibr" rid="B314">Torre et al., 2002</xref>). In parallel, Tat can induce the expression of factors that regulate its own activity over the HIV LTR, such as Nrf2 (nuclear erythroid 2 related factor 2). Nrf2 is a critical regulator of genes involved in the antioxidant response. Although the induction of Nrf2 by Tat is not enough to protect cells from oxidative stress in MAGI cell systems (<xref ref-type="bibr" rid="B349">Zhang et al., 2009</xref>), the ROS-induced expression in astrocytes has been reported to show a strong neuroprotective effect (<xref ref-type="bibr" rid="B27">Bell et al., 2011</xref>).</p>
<p>Other markers of oxidative stress such as protein carbonyl formation and lipid peroxidation <italic>in vitro</italic> and <italic>in vivo</italic>, as well as perturbation of the cellular antioxidant response have also been linked to Tat expression (<xref ref-type="bibr" rid="B89">Flores et al., 1993</xref>; <xref ref-type="bibr" rid="B201">Milani et al., 1996</xref>; <xref ref-type="bibr" rid="B32">Borgatti et al., 1998</xref>; <xref ref-type="bibr" rid="B118">Haughey et al., 1999</xref>, <xref ref-type="bibr" rid="B117">2004</xref>; <xref ref-type="bibr" rid="B58">Choi et al., 2000</xref>; <xref ref-type="bibr" rid="B9">Aksenov et al., 2001</xref>; <xref ref-type="bibr" rid="B253">Richard et al., 2001</xref>; <xref ref-type="bibr" rid="B232">Pocernich et al., 2004</xref>; <xref ref-type="bibr" rid="B4">Agrawal et al., 2012</xref>; <xref ref-type="bibr" rid="B155">Kim et al., 2015</xref>).</p>
</sec>
<sec>
<title>Tat and Blood–Brain Barrier Disruption</title>
<p>The BBB is composed of brain endothelial cells connected by tight junctions and is supported by astrocytes. Tat and specific Tat peptides can passively cross the BBB in both directions (<xref ref-type="bibr" rid="B23">Banks et al., 2005</xref>). Tat can also use different mechanisms to decrease the expression of tight junction proteins and basement membrane extracellular matrix proteins by promoting the expression of inflammatory molecules, oxidative stress and the expression of the matrix metalloproteinase 9 (MMP-9, a zinc dependent endopeptidase; reviewed in <xref ref-type="bibr" rid="B345">Yong et al., 1998</xref>; <xref ref-type="bibr" rid="B358">Zidovetzki et al., 1998</xref>; <xref ref-type="bibr" rid="B334">Weiss et al., 1999</xref>; <xref ref-type="bibr" rid="B237">Pu et al., 2007</xref>; <xref ref-type="bibr" rid="B143">Ju et al., 2009</xref>; <xref ref-type="bibr" rid="B22">Banerjee et al., 2010</xref>; <xref ref-type="bibr" rid="B292">Song et al., 2011</xref>; <xref ref-type="bibr" rid="B343">Xu et al., 2012</xref>; <xref ref-type="bibr" rid="B130">Huang et al., 2014</xref>). Consistent with these effects, agonists of the peroxisome proliferator activated receptors (PPAR), a group of a nuclear receptor proteins mediating expression of anti-inflammatory and anti-oxidative genes, reduce Tat mediated BBB disruption in mice (<xref ref-type="bibr" rid="B130">Huang et al., 2014</xref>).</p>
<p>The level of BBB damage may vary depending on the Tat sequence variant found in different clades of the virus. Tat from the HIV-1 B subtype and Tat from isolates recovered from patients diagnosed with advanced HAD proved the most potent in disrupting the BBB (Figure <xref ref-type="fig" rid="F1">1B</xref>).</p>
<p>Of the molecules present on cells of the BBB that change upon exposure of Tat protein, P-glycoprotein (P-gp) is critical, since it is a pump involved in the transport of small molecule compounds out of the brain. Interestingly, the efflux function, expression and promoter activity of P-gp are up-regulated by Tat (<xref ref-type="bibr" rid="B353">Zhong et al., 2010</xref>). This may help explain why HIV-infected individuals maintained on suppressive therapy present low levels of ART in the brain (<xref ref-type="bibr" rid="B101">Gimenez et al., 2004</xref>; reviewed in <xref ref-type="bibr" rid="B202">Miller et al., 2008</xref>), with up-regulated P-gp removing ART from the CNS. A better understanding of the mechanism of action of Tat on P-gp may offer solutions to improve the efficiency of ART in the brain reservoir of HIV, not only for the enhancement of ART crossing the BBB, but also for improving the anti-viral performance of immune cells that express this protein (reviewed in <xref ref-type="bibr" rid="B225">Owen and Khoo, 2004</xref>).</p>
</sec>
<sec>
<title>Tat, Glial Cells, and Neuroinflammation</title>
<p>Markers of gliosis have been found <italic>in vitro</italic> after treatment of cells with either Tat or its neurotoxic domain. The same is true <italic>in vivo</italic> in the brain and CSF of HAD-affected individuals (<xref ref-type="bibr" rid="B95">Gallo et al., 1989</xref>; <xref ref-type="bibr" rid="B320">Tyor et al., 1992</xref>; <xref ref-type="bibr" rid="B103">Glass et al., 1993</xref>; <xref ref-type="bibr" rid="B335">Wesselingh et al., 1993</xref>; <xref ref-type="bibr" rid="B230">Philippon et al., 1994</xref>; <xref ref-type="bibr" rid="B142">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="B280">Shi et al., 1998</xref>; <xref ref-type="bibr" rid="B36">Bruce-Keller et al., 2003</xref>; <xref ref-type="bibr" rid="B154">Kim et al., 2003</xref>; <xref ref-type="bibr" rid="B317">Turchan-Cholewo et al., 2009a</xref>,<xref ref-type="bibr" rid="B318">b</xref>; <xref ref-type="bibr" rid="B238">Puccini et al., 2015</xref>). Indeed, Tat induces the expression of important pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) (<xref ref-type="bibr" rid="B12">Ambrosino et al., 1997</xref>; <xref ref-type="bibr" rid="B56">Chen et al., 1997</xref>; <xref ref-type="bibr" rid="B358">Zidovetzki et al., 1998</xref>; <xref ref-type="bibr" rid="B215">Nath et al., 1999</xref>; <xref ref-type="bibr" rid="B39">Buscemi et al., 2007</xref>; reviewed in <xref ref-type="bibr" rid="B171">Li et al., 2010</xref>; <xref ref-type="bibr" rid="B337">Williams et al., 2010</xref>; <xref ref-type="bibr" rid="B344">Yang et al., 2010</xref>; <xref ref-type="bibr" rid="B352">Zhao et al., 2014</xref>; <xref ref-type="bibr" rid="B196">Mediouni et al., 2015</xref>), which make strong contributions to the development of an inflammatory neuropathology. For instance, TNF-α is associated with increased HIV-1 replication, NMDA receptor neurotoxicity and BBB disruption (<xref ref-type="bibr" rid="B339">Wright et al., 1988</xref>; <xref ref-type="bibr" rid="B197">Merrill et al., 1989</xref>; <xref ref-type="bibr" rid="B298">Stone, 1993</xref>; <xref ref-type="bibr" rid="B86">Fine et al., 1996</xref>; <xref ref-type="bibr" rid="B124">Heyes et al., 1996</xref>; <xref ref-type="bibr" rid="B222">Nuovo and Alfieri, 1996</xref>; <xref ref-type="bibr" rid="B31">Bezzi et al., 2001</xref>; <xref ref-type="bibr" rid="B287">Smith et al., 2001</xref>; reviewed in <xref ref-type="bibr" rid="B34">Brabers and Nottet, 2006</xref>; <xref ref-type="bibr" rid="B39">Buscemi et al., 2007</xref>; <xref ref-type="bibr" rid="B332">Wang et al., 2008</xref>; <xref ref-type="bibr" rid="B354">Zhong et al., 2008</xref>; <xref ref-type="bibr" rid="B143">Ju et al., 2009</xref>; <xref ref-type="bibr" rid="B153">Kiebala et al., 2010</xref>; <xref ref-type="bibr" rid="B152">Kiebala and Maggirwar, 2011</xref>). Likewise, IL-1β up-regulation, which leads to the transcription of several pro-inflammatory cytokines and chemokines, has been correlated with the severe neurologic symptoms of HAD patients (<xref ref-type="bibr" rid="B95">Gallo et al., 1989</xref>; reviewed in <xref ref-type="bibr" rid="B11">Allan et al., 2005</xref>; reviewed in <xref ref-type="bibr" rid="B210">Moynagh, 2005</xref>; reviewed in <xref ref-type="bibr" rid="B34">Brabers and Nottet, 2006</xref>). In the pathway that leads to Tat up-regulation of these two pro-inflammatory cytokines, targeting of the protein-tyrosine phosphatase (PTP), or CD45, was shown to attenuate microglia activation, suggesting a promising drug target (<xref ref-type="bibr" rid="B141">Jin et al., 2012</xref>). Additionally, elevation of IL-6 levels was reportedly associated with increased BBB permeability (<xref ref-type="bibr" rid="B358">Zidovetzki et al., 1998</xref>) and HIV replication (reviewed in <xref ref-type="bibr" rid="B171">Li et al., 2010</xref>). Tat-induced expression of inflammatory cytokines was also shown to involve other potential targets, such as the Ankyrin-rich membrane spanning protein (ARMS/Kidins220) in microglia cells (<xref ref-type="bibr" rid="B286">Singh et al., 2015</xref>) and the regulator of microglial phagocytosis (Leucine-rich repeat kinase 2; <xref ref-type="bibr" rid="B191">Marker et al., 2012</xref>).</p>
<p>In addition to the effect on cytokines, Tat modulates chemokine pathways in microglia, inducing neuroinflammation and changes in BBB permeability. Tat may bind to chemokine receptors through its cysteine/ZnF domain (a chemokine like sequence), thereby inhibiting the expression of CX3CR1 by suppressing a NF-kB-YY1 pathway, or inducing the expression of the potent chemoattractant chemokine MCP-1 (<xref ref-type="bibr" rid="B92">Fuentes et al., 1995</xref>; <xref ref-type="bibr" rid="B10">Albini et al., 1998</xref>; <xref ref-type="bibr" rid="B334">Weiss et al., 1999</xref>; <xref ref-type="bibr" rid="B80">Eugenin et al., 2003</xref>; <xref ref-type="bibr" rid="B279">Sheng et al., 2003</xref>; <xref ref-type="bibr" rid="B30">Bethel-Brown et al., 2011</xref>; <xref ref-type="bibr" rid="B74">Duan et al., 2014</xref>; <xref ref-type="bibr" rid="B304">Tewari et al., 2015</xref>). However, the induction MCP-1 by Tat may result in a complicated mode of action, since it has also been shown that MCP-1 protects both neurons and astrocytes from NMDA or Tat-induced apoptosis (<xref ref-type="bibr" rid="B80">Eugenin et al., 2003</xref>).</p>
</sec>
<sec>
<title>Tat and Apoptotic Pathways</title>
<p>As Tat influences processes of excitotoxicity, neuroinflammation and oxidative stress, it also modulates intrinsic cellular apoptotic pathways to variably promote both cellular death or protection. Apoptosis induced by Tat may be triggered by different mechanisms such as the disturbance of microtubule functions, changes of mitochondrial activity, reduction of the activity of the tumor suppressor p53 (involved in neuronal differentiation and survival), induction of reticulum stress, or triggering of the complex LRP/postsynaptic density protein-95/NMDA receptor/neuronal nitric oxide synthase (nNOS) at the neuronal membrane (reviewed in <xref ref-type="bibr" rid="B260">Roshal et al., 2001</xref>; <xref ref-type="bibr" rid="B54">Chen et al., 2002</xref>; <xref ref-type="bibr" rid="B43">Campbell et al., 2004</xref>; <xref ref-type="bibr" rid="B235">Pourroy et al., 2004</xref>; <xref ref-type="bibr" rid="B71">de Mareuil et al., 2005</xref>; <xref ref-type="bibr" rid="B82">Eugenin et al., 2007</xref>; <xref ref-type="bibr" rid="B220">Norman et al., 2007</xref>; <xref ref-type="bibr" rid="B67">Darbinian et al., 2008</xref>; <xref ref-type="bibr" rid="B170">Lecoeur et al., 2012</xref>; <xref ref-type="bibr" rid="B178">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="B185">Ma et al., 2014b</xref>). On the other hand, infected cells from HIV infected patients Tat plays a critical role inducing pathways that inhibit autophagy, phagocytosis, or the expression of MHC molecules, as well as up-regulation of p73 (<xref ref-type="bibr" rid="B52">Chehimi et al., 1996</xref>; reviewed in <xref ref-type="bibr" rid="B133">Huigen et al., 2004</xref>; <xref ref-type="bibr" rid="B14">Amini et al., 2005</xref>; <xref ref-type="bibr" rid="B272">Saunders et al., 2005</xref>; reviewed in <xref ref-type="bibr" rid="B171">Li et al., 2010</xref>; <xref ref-type="bibr" rid="B326">Van Grol et al., 2010</xref>; <xref ref-type="bibr" rid="B132">Hui et al., 2012</xref>; <xref ref-type="bibr" rid="B69">Debaisieux et al., 2015</xref>). Thus, it is conceivable that Tat may cause the death of cells such as neurons and supportive glial subsets, while perversely preserving host infected cells, thereby contributing to the status of the brain as a reservoir at the cost of neurodegeneration.</p>
</sec>
</sec>
<sec>
<title>Methamphetamine Neurotoxicity</title>
<p>Methamphetamine belongs to the amphetamine-type stimulant family. Used clinically at low doses to improve behavioral and cognitive functions after brain injury (<xref ref-type="bibr" rid="B246">Rau et al., 2012</xref>), MA is a strong psychostimulant that is widely abused as a “street drug.” Easily synthesized, relatively long lasting, and generally inexpensive in comparison to cocaine and heroin, MA is the second most commonly abused drug in the world (Figure <xref ref-type="fig" rid="F2">2A</xref>). Although MA seizure has increased dramatically in the last few years (Figure <xref ref-type="fig" rid="F2">2B</xref>), these factors have contributed to the increase of drug-associated health problems and social burden.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p><bold>Worldwide distribution of methamphetamine (MA) use and HIV infection. (A)</bold> Worldwide estimation of drug use in 2012 (data from the world drug report 2014). ATS: amphetamine-type stimulants. <bold>(B)</bold> Total amount of seized drugs reported worldwide 2008–2012 (data from UNODC global synthetic drugs assessment 2014). <bold>(C)</bold> Superimposition of maps of the prevalence of intravenous drug use (IDU, map from the world drug report 2014) in 2012 with the prevalence of HIV infection among IDU in 2012 (numbers in white, data from the world drug report 2014), completed with the world distribution of HIV clades (data from <xref ref-type="bibr" rid="B50">Chan and Kantor, 2009</xref>) and the ranking of ATS use in 2012 (numbers in red, data from the world drug report 2014). Red arrow corresponds to an increase of more than 10% in MA/amphetamine drug use in 2011–2012 in the indicated country (data from the drug world report 2014).</p>
</caption>
<graphic xlink:href="fmicb-06-01164-g0002"></graphic>
</fig>
<p>Methamphetamine induces acute euphoria, the perception of limitless energy and high libido. Physiologically, it induces potentially lethal hyperthermia, due to both CNS and peripheral effects (<xref ref-type="bibr" rid="B271">Sanchez-Alavez et al., 2014</xref>). Chronic MA abuse leads to neuropsychiatric complications including memory impairment, attention deficit and psychomotor decay associated with neurotoxicity and neurological dysfunction, as well as significant dysregulation of neurotransmitters levels. Importantly, MA use correlates with enhanced risk-taking behaviors that may place drug abusers at a higher risk of exposure to infections such as Hepatitis C and HIV, each further contributing to CNS dysfunction. The impressive epidemiological overlap between intravenous drug use (IDU) and the population that is HIV-positive worldwide confirms this trend (Figure <xref ref-type="fig" rid="F2">2C</xref>).</p>
<sec>
<title>Methamphetamine and Neurotransmitter Modulation</title>
<p>Although MA modulates a broad assortment of neuro-transmitters, MA-induced toxicity is largely attributed to hyperactivation of the DAergic system. MA increases extracellular DA levels, resulting in long-term degeneration of DAergic neurons, a mechanism also responsible for the motor impairments associated with Parkinson’s disease (reviewed in <xref ref-type="bibr" rid="B254">Riddle et al., 2006</xref>). MA exposure also promotes cognitive deficits related to DAergic neurodegeneration (reviewed in <xref ref-type="bibr" rid="B254">Riddle et al., 2006</xref>). Considerable neurochemical evidence of this neurotoxicity includes the demonstrated decrease of DAT and the activity of TH, a decrease of degradation of DA by monoamine oxidase (MAO), a reduction of activity and protein levels of VMAT2, and an increase of the reverse transport of DA <italic>via</italic> the DAT into the extracellular space (<xref ref-type="bibr" rid="B99">Gibb and Kogan, 1979</xref>; <xref ref-type="bibr" rid="B347">Zaczek et al., 1991</xref>; <xref ref-type="bibr" rid="B102">Giros et al., 1996</xref>; reviewed in <xref ref-type="bibr" rid="B254">Riddle et al., 2006</xref>; <xref ref-type="bibr" rid="B84">Eyerman and Yamamoto, 2007</xref>; <xref ref-type="bibr" rid="B342">Xie and Miller, 2009</xref>; reviewed in <xref ref-type="bibr" rid="B283">Silverstein et al., 2011</xref>; reviewed in <xref ref-type="bibr" rid="B61">Coller and Hutchinson, 2012</xref>). MA acts through the DA receptors (D1 and D2) and the TAAR1 receptor, but recent studies have also posited a role for other DA receptors specially the D3 involved in addiction, hyperthermia and modulation of the immune system (<xref ref-type="bibr" rid="B249">Ricci and Amenta, 1994</xref>; <xref ref-type="bibr" rid="B251">Ricci et al., 1997</xref>, <xref ref-type="bibr" rid="B250">1998</xref>; <xref ref-type="bibr" rid="B13">Amenta et al., 1999</xref>; <xref ref-type="bibr" rid="B252">Ricci et al., 1999</xref>; <xref ref-type="bibr" rid="B105">Granado et al., 2011a</xref>, <xref ref-type="bibr" rid="B16">Ares-Santos et al., 2012</xref>; reviewed in <xref ref-type="bibr" rid="B346">Yu et al., 2015</xref>).</p>
<p>Following the increase of extracellular DA, MA causes a rise in striatal glutamate release (<xref ref-type="bibr" rid="B214">Nash and Yamamoto, 1992</xref>; <xref ref-type="bibr" rid="B296">Stephans and Yamamoto, 1994</xref>; <xref ref-type="bibr" rid="B190">Mark et al., 2004</xref>). Glutamate receptors, the EAAT-2 and VGLUT (the vesicular glutamate transporters, which are in charge of transporting glutamate into synaptic vesicles), are also involved in mediating different behaviors attributed to MA, such as reward, hyperlocomotor activity and, to some extent, hyperthermia (<xref ref-type="bibr" rid="B104">Golembiowska et al., 2003</xref>; <xref ref-type="bibr" rid="B2">Achat-Mendes et al., 2012a</xref>,<xref ref-type="bibr" rid="B3">b</xref>; reviewed in <xref ref-type="bibr" rid="B59">Cisneros and Ghorpade, 2012</xref>; <xref ref-type="bibr" rid="B64">Crawford et al., 2013</xref>; <xref ref-type="bibr" rid="B123">Herrold et al., 2013</xref>; <xref ref-type="bibr" rid="B125">He et al., 2014</xref>; <xref ref-type="bibr" rid="B129">Hiyoshi et al., 2014</xref>; <xref ref-type="bibr" rid="B300">Suryavanshi et al., 2014</xref>).</p>
<p>Independent from the DAergic system, MA also directly modulates the presynaptic release of glutamate in rat cultured hippocampal primary neurons (<xref ref-type="bibr" rid="B350">Zhang et al., 2014</xref>). Furthermore, serotonergic, γ-amino-butyric acid-ergic (GABAergic) and cholinergic systems are also altered by MA, highlighting the widespread damage caused by this drug (<xref ref-type="bibr" rid="B111">Halpin et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B221">Northrop and Yamamoto, 2015</xref>; reviewed in <xref ref-type="bibr" rid="B346">Yu et al., 2015</xref>).</p>
</sec>
<sec>
<title>Methamphetamine and Oxidative Stress</title>
<p>Several <italic>in vivo</italic> and <italic>in vitro</italic> studies showed the increase of cytoplasmic and mitochondrial oxidative stress markers following acute or chronic exposition to MA (reviewed in <xref ref-type="bibr" rid="B283">Silverstein et al., 2011</xref>; <xref ref-type="bibr" rid="B270">Sanchez-Alavez et al., 2013</xref>; <xref ref-type="bibr" rid="B111">Halpin et al., 2014</xref>; <xref ref-type="bibr" rid="B213">Nam et al., 2014</xref>; <xref ref-type="bibr" rid="B271">Sanchez-Alavez et al., 2014</xref>; <xref ref-type="bibr" rid="B291">Solhi et al., 2014</xref>; <xref ref-type="bibr" rid="B329">Walker et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B346">Yu et al., 2015</xref>). Importantly, several neurotoxicity hallmarks induced by MA are absent in animals that express the human superoxide dismutase 1 (SOD 1) gene, or that can otherwise quickly detoxify free radicals induced by MA (<xref ref-type="bibr" rid="B40">Cadet et al., 1994</xref>; <xref ref-type="bibr" rid="B128">Hirata et al., 1995</xref>, <xref ref-type="bibr" rid="B127">1996</xref>, <xref ref-type="bibr" rid="B126">1998</xref>; <xref ref-type="bibr" rid="B72">Deng and Cadet, 2000</xref>; <xref ref-type="bibr" rid="B73">Deng et al., 2001</xref>). In addition, antioxidant treatments have shown neuroprotective effects against MA-induced brain damage, suggesting a significant role for oxidative stress in MA toxicity (reviewed in <xref ref-type="bibr" rid="B55">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="B170">Lecoeur et al., 2012</xref>; <xref ref-type="bibr" rid="B24">Barayuga et al., 2013</xref>; <xref ref-type="bibr" rid="B158">Koriem et al., 2013</xref>; reviewed in <xref ref-type="bibr" rid="B175">Liddie et al., 2013</xref>; <xref ref-type="bibr" rid="B281">Shin et al., 2014</xref>). Antioxidants are also able to prevent and reverse MA-induced hyperthermia, and MA-associated mitochondrial changes in animal models, suggesting that the thermal dysregulation in drug abuse, which is also reported as a trigger of neurotoxicity, involves the capacity of MA to induce ROS (<xref ref-type="bibr" rid="B270">Sanchez-Alavez et al., 2013</xref>, <xref ref-type="bibr" rid="B271">2014</xref>).</p>
<p>The effects of MA are associated with cellular energy consumption and increased metabolism, potentially leading to mitochondrial dysfunction. Mitochondria functions are affected by the inhibition of ATP and the complex II of the electron transport chain (<xref ref-type="bibr" rid="B38">Burrows et al., 2000</xref>; <xref ref-type="bibr" rid="B35">Brown et al., 2005</xref>), mediated both by glutamate and NO (<xref ref-type="bibr" rid="B35">Brown et al., 2005</xref>). Moreover, ROS and quinone, a product of DA oxidation, are both known to inhibit mitochondrial enzymes associated with energy production (<xref ref-type="bibr" rid="B224">O’Shea et al., 2014</xref>). Therefore, the oxidative stress that results from MA abuse may have dramatic consequences for mitochondria metabolic efficiency.</p>
<p>Interestingly, unlike Tat, MA-induced astrogliosis was associated with the decrease of Nrf2 (<xref ref-type="bibr" rid="B106">Granado et al., 2011b</xref>), suggesting that astrocytes may have a low antioxidant capacity when exposed to MA.</p>
</sec>
<sec>
<title>Methamphetamine and Blood–Brain Barrier Disruption</title>
<p>Several preclinical and clinical studies reported BBB dysfunction by MA through different mechanisms (reviewed in <xref ref-type="bibr" rid="B159">Kousik et al., 2012</xref>; <xref ref-type="bibr" rid="B194">Matsumoto et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B221">Northrop and Yamamoto, 2015</xref>; reviewed in <xref ref-type="bibr" rid="B319">Turowski and Kenny, 2015</xref>). MA-induced oxidative stress, hyperthermia, glutamate release and induction of inflammation combine to decrease tight junctions and transendothelial electric resistance <italic>via</italic> oxidative stress, down-regulate MMP expression mediated by hyperthermia, activate glutamate receptors, and increase the release of inflammatory cytokines as well as the expression of heat shock proteins (<xref ref-type="bibr" rid="B243">Ramirez et al., 2009</xref>; reviewed in <xref ref-type="bibr" rid="B283">Silverstein et al., 2011</xref>; reviewed in <xref ref-type="bibr" rid="B159">Kousik et al., 2012</xref>; <xref ref-type="bibr" rid="B277">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="B192">Martins et al., 2013</xref>; <xref ref-type="bibr" rid="B322">Urrutia et al., 2013</xref>; reviewed in <xref ref-type="bibr" rid="B221">Northrop and Yamamoto, 2015</xref>). In addition, MA exposure has been correlated with a lack of the glucose-induced energy required for tight junction assembly and in the attenuation of brain capillary endothelial cell growth (<xref ref-type="bibr" rid="B1">Abdul Muneer et al., 2011</xref>; <xref ref-type="bibr" rid="B87">Fisher et al., 2015</xref>). Taken together, these mechanisms account for collective insults to the BBB that precedes neurological symptoms associated with chronic MA abuse.</p>
</sec>
<sec>
<title>Methamphetamine, Glial Cells, and Neuroinflammation</title>
<p>Modifications to the inflammatory status of CNS glial cells caused by MA exposure have strong implications that vary from biochemical alterations to behavioral changes. For instance, the release of cytokines by activated glial cells following MA exposure is correlated with behavioral effects such as high motor activity, MA self-administration and relapse, as well as hyperthermia (<xref ref-type="bibr" rid="B33">Boven et al., 2007</xref>; reviewed in <xref ref-type="bibr" rid="B25">Beardsley and Hauser, 2014</xref>; reviewed in <xref ref-type="bibr" rid="B182">Loftis and Janowsky, 2014</xref>; reviewed in <xref ref-type="bibr" rid="B268">Salamanca et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B346">Yu et al., 2015</xref>). MA-induced DA and glutamate release can induce the activation of pattern recognition receptors (PRRs) in microglia that were shown to activate glial cells (<xref ref-type="bibr" rid="B165">Kuhn et al., 2006</xref>; reviewed in <xref ref-type="bibr" rid="B25">Beardsley and Hauser, 2014</xref>; <xref ref-type="bibr" rid="B111">Halpin et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B182">Loftis and Janowsky, 2014</xref>).</p>
<p>Sigma receptors on glia and neurons have been recently implicated in MA-induced neuroinflammation. The sigma receptor is a chaperone protein at the endoplasmic reticulum that controls calcium signaling through the inositol triphosphate receptor. Various sigma receptor antagonists with different characteristics and potency have been characterized, and proven effective against neuroinflammatory activity (<xref ref-type="bibr" rid="B150">Kaushal et al., 2013</xref>, <xref ref-type="bibr" rid="B147">2014</xref>; <xref ref-type="bibr" rid="B351">Zhang et al., 2015</xref>).</p>
<p>It has been suggested that voltage-gated potassium channels (Kv) are involved in neuronal damage as well as microglial function. Indeed, Kv1.3 is a major K<sup>+</sup> channel expressed in microglia that has been previously involved in MA-induced microglia damage. MA significantly increases outward K<sup>+</sup> currents and Kv1.3 antagonists increase microglial viability, while also decreasing the expression of neurotoxins and pro-inflammatory cytokines from these cells (<xref ref-type="bibr" rid="B331">Wang et al., 2014</xref>).</p>
<p>Interestingly, the pattern of microgliosis in individuals with a history of MA addiction has been shown to persist for at least 2 years into abstinence (<xref ref-type="bibr" rid="B274">Sekine et al., 2008</xref>). Likewise, astrocytes remain reactive up to 30 days following MA exposure. It is possible this is initially beneficial, turning maladaptive over time. In the short term, these effects may serve as a protection mechanism against MA-induced neurotoxicity (<xref ref-type="bibr" rid="B121">Hebert and O’Callaghan, 2000</xref>; <xref ref-type="bibr" rid="B91">Friend and Keefe, 2013</xref>; <xref ref-type="bibr" rid="B257">Robson et al., 2014</xref>). The release of neurotrophic factors, anti-inflammatory cytokines, and radical scavengers by glial cells to protect neurons from MA, have also been reported (reviewed in <xref ref-type="bibr" rid="B25">Beardsley and Hauser, 2014</xref>).</p>
</sec>
<sec>
<title>Methamphetamine and Apoptotic Pathways</title>
<p>The interaction between the excitotoxicity, oxidative stress, neuroinflammation and BBB disruption results in significant neuronal death in DA-rich regions (reviewed in <xref ref-type="bibr" rid="B61">Coller and Hutchinson, 2012</xref>; reviewed in <xref ref-type="bibr" rid="B182">Loftis and Janowsky, 2014</xref>; reviewed in <xref ref-type="bibr" rid="B268">Salamanca et al., 2014</xref>; reviewed in <xref ref-type="bibr" rid="B346">Yu et al., 2015</xref>). The mechanisms of apoptosis can be either caspase-dependent or -independent (<xref ref-type="bibr" rid="B134">Jayanthi et al., 2004</xref>). Even though MA-mediated neuronal apoptosis is very well documented, the apoptosis of other cells in the brain is less clearly established (<xref ref-type="bibr" rid="B73">Deng et al., 2001</xref>; <xref ref-type="bibr" rid="B134">Jayanthi et al., 2004</xref>; <xref ref-type="bibr" rid="B111">Halpin et al., 2014</xref>). MA induces the death of glial and oligodendrocytes through caspase-dependent pathways (<xref ref-type="bibr" rid="B97">Genc et al., 2003</xref>; <xref ref-type="bibr" rid="B144">Jumnongprakhon et al., 2014</xref>). Melatonin has been shown to rescue glial cells from death (<xref ref-type="bibr" rid="B144">Jumnongprakhon et al., 2014</xref>), an effect that might be anticipated because melatonin serves several immune-related functions such as the modulation of immune cell numbers, inhibition of pro-inflammatory cytokines, increased neurogenesis and a reduction of adhesion molecules (reviewed in <xref ref-type="bibr" rid="B187">Maldonado et al., 2009</xref>). As such, melatonin was suggested as a potential candidate to treat mental disorders and to possess potential in MA recovery therapies (reviewed in <xref ref-type="bibr" rid="B187">Maldonado et al., 2009</xref>).</p>
<p>On the other hand, MA was also associated with the autophagy process to protect neurons and endothelial cells (<xref ref-type="bibr" rid="B48">Castino et al., 2008</xref>; <xref ref-type="bibr" rid="B90">Fornai et al., 2008</xref>; <xref ref-type="bibr" rid="B176">Lin et al., 2012</xref>; <xref ref-type="bibr" rid="B184">Ma et al., 2014a</xref>). Interestingly, caffeine increases MA induced toxicity in neuroblastoma cell lines by inhibiting this autophagy process (<xref ref-type="bibr" rid="B284">Sinchai et al., 2011</xref>; <xref ref-type="bibr" rid="B231">Pitaksalee et al., 2015</xref>).</p>
</sec>
</sec>
<sec>
<title>Tat and Methamphetamine Neurotoxicity</title>
<p>It is not surprising that a positive correlation exists between worldwide MA drug statistics (World drug report 2014) and the prevalence of HIV among intravenous drug users (Figure <xref ref-type="fig" rid="F2">2C</xref>). Interestingly, there is an increased tendency to MA/amphetamine consumption in countries that are predominantly affected with HIV-1 B subtype (Figure <xref ref-type="fig" rid="F2">2C</xref>), reported to be more neurotoxic (Figure <xref ref-type="fig" rid="F1">1B</xref>). Below we review some of studies that show Tat neurotoxicity enhanced by MA co-incubation.</p>
<sec>
<title>Tat/Methamphetamine and HIV Replication</title>
<p>One important activity of MA in HIV disease progression is the ability to enhance viral replication. MA was shown to activate the promoter of HIV-1 in microglia cells, which Tat synergistically amplifies (<xref ref-type="bibr" rid="B338">Wires et al., 2012</xref>).</p>
<p>Methamphetamine dysregulation of the DA system augments viral production in different immune cells by promoting HIV entry and HIV transcription (<xref ref-type="bibr" rid="B258">Rohr et al., 1999a</xref>,<xref ref-type="bibr" rid="B259">b</xref>; <xref ref-type="bibr" rid="B248">Reynolds et al., 2007</xref>; <xref ref-type="bibr" rid="B174">Liang et al., 2008</xref>; <xref ref-type="bibr" rid="B315">Toussi et al., 2009</xref>; <xref ref-type="bibr" rid="B189">Marcondes et al., 2010</xref>; <xref ref-type="bibr" rid="B211">Nair and Saiyed, 2011</xref>; reviewed in <xref ref-type="bibr" rid="B240">Purohit et al., 2011</xref>). A review by <xref ref-type="bibr" rid="B240">Purohit et al. (2011)</xref> nicely illustrates the effects of DA in HIV transcription caused by oxidative stress and NF-κB activation in the presence of drugs of abuse in the brain (reviewed in <xref ref-type="bibr" rid="B240">Purohit et al., 2011</xref>). Inhibition of phagocytosis, disruption of pH and the reduced expression of Toll-like receptor 9 have each been proposed as mechanisms to explain the MA promotion of spreading HIV infection (<xref ref-type="bibr" rid="B303">Talloczy et al., 2008</xref>; <xref ref-type="bibr" rid="B49">Cen et al., 2013</xref>). In turn, the MA-induced elevation in DA levels seems to induce the migration of activated monocytes into the brain in the context of HIV (reviewed in <xref ref-type="bibr" rid="B96">Gaskill et al., 2013</xref>; <xref ref-type="bibr" rid="B60">Coley et al., 2015</xref>). This finding may be also correlated to the ability of MA in non-human primate to up-regulate C-C chemokine receptor type 5 (CCR5), the co-receptor for viral entry, in microglia cells, and in brain-derived macrophages which otherwise do not exhibit a classical inflammatory phenotype based on surface markers (<xref ref-type="bibr" rid="B189">Marcondes et al., 2010</xref>).</p>
<p>An interesting pathway with ties to the neuroinflammatory process triggered by MA that modulates infection is the Wnt/β-catenin signaling cascade, which regulates the survival process of neurons and astrocytes. In fact, astrocytes are the primary source of Wnt ligands, triggering the Wnt signaling cascade that mediates anti-inflammatory responses, neuroprotection and neurogenesis (<xref ref-type="bibr" rid="B278">Sharma et al., 2011</xref>). It has been reported that the Wnt/β-catenin/transcription factor 4 signaling pathway inhibits HIV replication in astrocytes. Co-incubation of primary human astrocytes with Tat and MA leads to an increased down-regulation of the Wnt signaling by more than 50% compared to the activity of MA or Tat alone. Given the additive effect of MA and Tat, it was suggested that the toxins may be engaging distinct pathways (<xref ref-type="bibr" rid="B278">Sharma et al., 2011</xref>).</p>
</sec>
<sec>
<title>Tat/Methamphetamine and Neurotransmitters Modulation</title>
<p>The effects of Tat and MA on neurotransmission have been described primarily in the context of the DA and GLUTergic systems. Cooperative effects of Tat and MA have been shown to enhance the DA mediated amplification of viral replication in correlation with the enhanced motor-stimulant response to a recurrent exposure to MA, a demonstration of behavioral sensitization (<xref ref-type="bibr" rid="B179">Liu et al., 2009</xref>). Moreover, Tat and MA showed <italic>in vivo</italic> a synergetic effect on the death of striatal DA terminals (<xref ref-type="bibr" rid="B188">Maragos et al., 2002</xref>; <xref ref-type="bibr" rid="B47">Cass et al., 2003</xref>; <xref ref-type="bibr" rid="B307">Theodore et al., 2006b</xref>,<xref ref-type="bibr" rid="B309">d</xref>; reviewed in <xref ref-type="bibr" rid="B310">Theodore et al., 2007</xref>).</p>
<p>Pre-pulse inhibition (PPI) is a neural mechanism in which a weaker pre-stimulus (pre-pulse) reduces the reaction to a following strong startling stimulus (pulse), and is used to measure adaptive inhibition mechanisms. This is thought to be a measure of sensorimotor gating and deficits have been reported in schizophrenia (<xref ref-type="bibr" rid="B29">Bertrand et al., 2014</xref>).</p>
<p>Patients with HAND demonstrate deficits in PPI responses not observed in HIV-positive participants without neurocognitive impairment (<xref ref-type="bibr" rid="B108">Greenwood et al., 2007</xref>). Similarly, intra-hippocampal infusion of Tat protein disrupts acoustic startle response and PPI in rats (<xref ref-type="bibr" rid="B217">Nath and Steiner, 2014</xref>). Among adult HIV-1 transgenic rats (that express seven of the nine clade B HIV-1 genes), Tat has a synergistic role in the increase of the MA-mediated disruption of PPI, an effect attributed to its ability to decrease TH while increasing MAO (<xref ref-type="bibr" rid="B207">Moran et al., 2012</xref>). Together, these findings suggest disruptions of DAergic signaling with behavioral and cognitive consequences.</p>
<p>In the GLUTergic system, the combination of MA and Tat was shown to be additive in enhancing the disruption of EAAT-2 in astrocytic cells. This leads to elevated glutamate levels in the synaptic clefts and a synergistic increase in midbrain neuronal death <italic>in vitro</italic>, in a process that requires both D1 and NMDA-receptors (<xref ref-type="bibr" rid="B7">Aksenov et al., 2012</xref>; reviewed in <xref ref-type="bibr" rid="B59">Cisneros and Ghorpade, 2012</xref>).</p>
</sec>
<sec>
<title>Tat/Methamphetamine and Oxidative Stress</title>
<p>Co-incubation of Tat and MA in cell culture <italic>in vitro</italic> has an additive effect promoting oxidative stress (<xref ref-type="bibr" rid="B167">Langford et al., 2004</xref>). Likewise, the combination <italic>in vivo</italic> results in a synergic/additive activation of redox system-regulated transcription factors, the increased expression of the intracellular adhesion molecule-1 (ICAM-1) gene, and of cytokines (TNF-α and IL-1β) in some brain regions (<xref ref-type="bibr" rid="B88">Flora et al., 2003</xref>). Tat and MA also have an additive effect in decreasing antioxidant enzyme levels (<xref ref-type="bibr" rid="B22">Banerjee et al., 2010</xref>). Other studies have shown that the combination of the HIV-1 envelope glycoprotein 120 (gp120) with Tat/MA also has the capacity of synergistically reducing the expression of tight junction proteins through a mechanism that seems to be dependent on oxidative stress, resulting in an impairment of the BBB (<xref ref-type="bibr" rid="B22">Banerjee et al., 2010</xref>). This report also demonstrates the possible synergy between the viral proteins in the induction of oxidative stress (<xref ref-type="bibr" rid="B22">Banerjee et al., 2010</xref>). On the other hand, a recent study has shown no significant concerted effects between HIV and substance of abuse in the increase of oxidative stress markers detected in the CSF of HIV-positive subjects, with or without substance use disorders (<xref ref-type="bibr" rid="B226">Panee et al., 2015</xref>). The differences between these studies may be due to different levels of Tat and/or MA used in the <italic>in vitro</italic> experiments and models, particularly in comparison to how much Tat is present in patients and their rate of MA usage. Tat in the serum of HIV-infected patients was detected at about 40 ng/ml (<xref ref-type="bibr" rid="B341">Xiao et al., 2000</xref>), and the concentration of MA in postmortem brains of chronic MA abusers is reportedly around 0.8–1 mM (<xref ref-type="bibr" rid="B303">Talloczy et al., 2008</xref>). However, relatively little work has been done on this topic, and the magnitude of the progression of HIV infection, the frequency of drug use, the composition of ART and the sensitivity of the assays may all influence the outcome of these studies.</p>
</sec>
<sec>
<title>Tat/Methamphetamine and Blood–Brain Barrier Disruption</title>
<p>Tat and MA synergistically and additively alter the BBB through the increase of cell adhesion molecules (ICAM-1), the decrease of the tight junction proteins and induction of MMP (<xref ref-type="bibr" rid="B88">Flora et al., 2003</xref>; <xref ref-type="bibr" rid="B63">Conant et al., 2004</xref>; <xref ref-type="bibr" rid="B22">Banerjee et al., 2010</xref>). Moreover, <xref ref-type="bibr" rid="B145">Kass et al. (2010)</xref> reported that MA-induced hyperthermia was enhanced in HIV transgenic rats (<xref ref-type="bibr" rid="B145">Kass et al., 2010</xref>), consistent with hyperthermia-induced BBB permeability (reviewed in <xref ref-type="bibr" rid="B221">Northrop and Yamamoto, 2015</xref>). It has been proposed that low non-toxic doses of Tat and MA could potentially be helpful in temporarily reducing the BBB permeability to enhance the access of antiretrovirals to the CNS (reviewed in <xref ref-type="bibr" rid="B319">Turowski and Kenny, 2015</xref>).</p>
</sec>
<sec>
<title>Tat/Methamphetamine, Glial Cells, and Neuroinflammation</title>
<p>As previously mentioned, <xref ref-type="bibr" rid="B88">Flora et al. (2003)</xref> showed that co-administration of Tat and MA resulted in the higher expression of the pro-inflammatory cytokines TNF-α and IL-1β, as well as the adhesion molecule ICAM-1 in several mouse brain regions (<xref ref-type="bibr" rid="B88">Flora et al., 2003</xref>). <xref ref-type="bibr" rid="B308">Theodore et al. (2006c)</xref> confirmed the involvement of TNF-α in depletion of DA levels, using a double KO for TNF-αR1 and TNF-αR2. The induction of TNF-α was also associated with a greater loss of hippocampal neurons (<xref ref-type="bibr" rid="B308">Theodore et al., 2006c</xref>,<xref ref-type="bibr" rid="B309">d</xref>).</p>
<p>A cytokine array performed on rat striatal tissue treated with a combination of MA and Tat revealed synergistically higher levels of MCP-1, timp metallo-peptidase inhibitor 1 (TIMP-1), and IL-1α. This activity was absent in MCP-1 KO mice, highlighting the importance of MCP-1 in Tat/MA neurotoxicity (<xref ref-type="bibr" rid="B306">Theodore et al., 2006a</xref>). These findings strongly suggest a crucial role for cytokines in mediating the interactions between MA and Tat in HIV-associated neurotoxicity.</p>
<p><xref ref-type="bibr" rid="B278">Sharma et al. (2011)</xref> previously described the additive effect of Tat and MA in down-regulating the Wnt/β-catenin survival pathway (<xref ref-type="bibr" rid="B278">Sharma et al., 2011</xref>). In that study, the authors found that unlike Tat, MA also down-regulated NF-κB reporter activity, and as expected, decreased MCP-1 and IL-6 mRNAs. When Tat and MA were used in combination, the reduction of NF-κB reporter activity and MCP-1 mRNA persisted, but IL-6 expression was normalized. This seeming discrepancy could be explained by the fact that Tat can transactivate the IL-6 promoter by binding to IL-6 leader RNA (a stem loop structure located at the 5′-terminal region of the IL-6 mRNA) and by interacting and increasing the CAAT enhancer-binding protein (C/EBP) DNA binding activity (NF-IL-6) at the IL-6 promoter (reviewed in <xref ref-type="bibr" rid="B171">Li et al., 2010</xref>). Together, this suggests that the effect of both toxins together is not always positively correlated, as each toxin could trigger different pathways and produce unexpected phenotypes.</p>
</sec>
<sec>
<title>Tat/Methamphetamine and Apoptotic Pathways</title>
<p>The cooperation between Tat and MA in triggering BBB permeability, oxidative stress and increased viral replication may explain the severity of HAD symptoms in HIV-infected MA abusers, as compared to non-drug abusing patients (<xref ref-type="bibr" rid="B216">Nath et al., 2001</xref>; <xref ref-type="bibr" rid="B294">Sporer et al., 2005</xref>; reviewed in <xref ref-type="bibr" rid="B85">Ferris et al., 2008</xref>; reviewed in <xref ref-type="bibr" rid="B240">Purohit et al., 2011</xref>; reviewed in <xref ref-type="bibr" rid="B283">Silverstein et al., 2011</xref>; reviewed in <xref ref-type="bibr" rid="B299">Strazza et al., 2011</xref>; reviewed in <xref ref-type="bibr" rid="B239">Purohit et al., 2013</xref>; reviewed in <xref ref-type="bibr" rid="B120">Hauser and Knapp, 2014</xref>). This is confirmed in animal studies using the fully replicating virus in combination with MA, showing greater alteration of cognitive and locomotor behavior when compared with either treatment alone (<xref ref-type="bibr" rid="B179">Liu et al., 2009</xref>; <xref ref-type="bibr" rid="B145">Kass et al., 2010</xref>; reviewed in <xref ref-type="bibr" rid="B283">Silverstein et al., 2011</xref>; <xref ref-type="bibr" rid="B151">Kesby et al., 2015</xref>), an effect mediated by inflammation and oxidative stress processes (<xref ref-type="bibr" rid="B188">Maragos et al., 2002</xref>; <xref ref-type="bibr" rid="B306">Theodore et al., 2006a</xref>,<xref ref-type="bibr" rid="B307">b</xref>,<xref ref-type="bibr" rid="B308">c</xref>,<xref ref-type="bibr" rid="B309">d</xref>; <xref ref-type="bibr" rid="B22">Banerjee et al., 2010</xref>). The cognitive and locomotor decay may also be explained by the synergic activity of Tat and MA in triggering autophagy and apoptosis mechanisms. For instance, in presence of Tat and MA an increase of autophagosomes and/or multilamellar bodies was observed upon death of a neuroblastoma cell line (<xref ref-type="bibr" rid="B41">Cai and Cadet, 2008</xref>; <xref ref-type="bibr" rid="B241">Qi et al., 2011</xref>).</p>
<p>Melatonin has been shown to rescue glial cells from death and it was proposed to have potential in MA recovery therapies (reviewed in <xref ref-type="bibr" rid="B187">Maldonado et al., 2009</xref>; <xref ref-type="bibr" rid="B144">Jumnongprakhon et al., 2014</xref>). Tat was shown to up-regulate melatonin (<xref ref-type="bibr" rid="B147">Kaushal et al., 2014</xref>), with potentially resulting effects that remain to be assessed.</p>
</sec>
<sec>
<title>Caveats</title>
<p>Throughout this review, we have discussed different mechanisms by which Tat and MA may mediate neurocognitive and locomotor disorders (summarized in Figure <xref ref-type="fig" rid="F3">3</xref>). Nevertheless, these may represent just the tip of the proverbial iceberg, as Tat is known to have more than 775 interactions with cellular proteins, and thus may interact with many more aspects of cell regulation (<xref ref-type="bibr" rid="B275">Self et al., 2004</xref>). On the other hand, the extent of MA-induced cellular damage is also not fully understood (reviewed in <xref ref-type="bibr" rid="B268">Salamanca et al., 2014</xref>). It should be noted that other factors such as gender, nutrition, immunological strength and genetic variation could significantly change the neurologic outcomes of HAND in MA abusers.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p><bold>Summary of the different effects of Tat, methamphetamine (MA) or Tat and MA in combination.</bold> Synergic activity is shown in italic and additive effects in light gray. Light gray squares correspond to the main activity of each toxin.</p>
</caption>
<graphic xlink:href="fmicb-06-01164-g0003"></graphic>
</fig>
</sec>
</sec>
<sec>
<title>Neurotoxicity by Methamphetamine Use and HIV-1 Infection: Potential Therapeutics</title>
<p>According to the CDC, as of 2010, the lifetime treatment cost of an HIV infected patient in the United States was an estimated $379,668. Moreover, the economical cost of substance abuse in the United States in terms of health care, job loss, corruption, imprisonment, and drug enforcement is more than $180 billion dollars a year (2008, NIDA). Unfortunately, the negative impact of HIV infection and drug abuse in our society is anticipated to deepen as the combined incidence of HAND, MA use, and HIV-1 infected MA abusers increases.</p>
<p>Under suppressive ART, HIV-1 patients are living longer, even as current evidence suggests their quality of life will degrade over time. Viral and human genetic variations, presence of latent cells and viral sanctuaries reduce the efficacy of ART (<xref ref-type="bibr" rid="B8">Aksenov et al., 2006</xref>). In addition, cofactors such as drug abuse significantly deepen HIV-induced neurological impairments.</p>
<p>As such, improving ART penetration across the BBB remains an important goal. The use of nano-ART (“cell-mediated medication delivery”; reviewed in <xref ref-type="bibr" rid="B98">Gendelman and Gelbard, 2014</xref>) or the use of intranasal delivery (reviewed in <xref ref-type="bibr" rid="B114">Hanson and Frey, 2007</xref>), have shown improved efficiency in that regard. The addition to ART of adjunctive therapies targeting the excitotoxicity, inflammatory or anti-oxidant systems is also being explored. Individually targeting Tat or MA is also another viable alternative. There are currently several ongoing clinical trials testing these approaches with MA-abusing HIV-1 patients to assess the inhibition of neurocognitive degradation or the decrease of MA use.</p>
<sec>
<title>Current Clinical Trials in HIV Infected Methamphetamine Users: Adjunctive Therapies</title>
<p><italic>Minocycline</italic>, a tetracycline antibiotic currently used to treat bacterial infections, is a potentially exciting therapeutic agent to treat brain disorders including HAND (<xref ref-type="bibr" rid="B53">Chen et al., 2000</xref>; <xref ref-type="bibr" rid="B75">Du et al., 2001</xref>; <xref ref-type="bibr" rid="B269">Sanchez Mejia et al., 2001</xref>; <xref ref-type="bibr" rid="B17">Arvin et al., 2002</xref>; <xref ref-type="bibr" rid="B325">Van Den Bosch et al., 2002</xref>; <xref ref-type="bibr" rid="B340">Wu et al., 2002</xref>; <xref ref-type="bibr" rid="B198">Metz et al., 2004</xref>). Minocycline possesses several therapeutic indications including antioxidant, anti-inflammatory, anti-viral, and anti-addictive proprieties, and it crosses the BBB. Using cultured primary macrophages and lymphocytes <italic>in vitro</italic>, minocycline has been shown to prevent NMDA-induced microglial proliferation and activation (<xref ref-type="bibr" rid="B313">Tikka and Koistinaho, 2001</xref>; <xref ref-type="bibr" rid="B312">Tikka et al., 2001</xref>) as well as HIV and SIV replication (<xref ref-type="bibr" rid="B359">Zink et al., 2005</xref>). Tested <italic>in vivo</italic>, minocycline prevents inflammation and HIV replication in central and peripheral systems (<xref ref-type="bibr" rid="B359">Zink et al., 2005</xref>; <xref ref-type="bibr" rid="B285">Singh et al., 2014</xref>). At the behavioral level, mouse studies have demonstrated that minocycline decreases the rewarding proprieties of dextroamphetamine (a stereoisomer of amphetamine), MA and ethanol (<xref ref-type="bibr" rid="B5">Agrawal et al., 2011</xref>; <xref ref-type="bibr" rid="B290">Sofuoglu et al., 2011</xref>; <xref ref-type="bibr" rid="B94">Fujita et al., 2012</xref>). Moreover, minocycline improves cognitive deficits associated with exposure to phencyclidine (NMDA receptor antagonist) or MA (<xref ref-type="bibr" rid="B93">Fujita et al., 2008</xref>; <xref ref-type="bibr" rid="B205">Mizoguchi et al., 2008</xref>).</p>
<p>Minocycline has been tested in three clinical trials (NCT00855062; NCT01064752; NCT00361257) related to HIV-1-associated cognitive impairments. In the only results available to date, the phase II clinical trial with minocycline (NCT00361257) showed that it was safe and well-tolerated by individuals with HAND. However, no cognitive improvement was observed (<xref ref-type="bibr" rid="B264">Sacktor et al., 2011</xref>). Intake of minocycline only resulted in a decrease in lipid markers of oxidative stress (<xref ref-type="bibr" rid="B265">Sacktor et al., 2014</xref>), a disappointing result given the promise of preclinical studies.</p>
<p><italic>Ibudilast</italic> (AV-411 or MN-166) is a non-specific phosphodiesterase inhibitor, used in Japan to treat ischemic stroke and bronchial asthma (<xref ref-type="bibr" rid="B100">Gibson et al., 2006</xref>). Ibudilast inhibits the activation of glial cells and the expression of macrophage migration inhibitor factors (<xref ref-type="bibr" rid="B302">Suzumura et al., 1999</xref>, <xref ref-type="bibr" rid="B301">2003</xref>; <xref ref-type="bibr" rid="B57">Cho et al., 2010</xref>). It was shown to attenuate microglia activation by inhibiting the expression of pro-inflammatory cytokines, inhibiting markers of oxidative stress and increasing the secretion of anti-inflammatory mediators, which prevent neuronal death and white matter injury <italic>in vivo</italic> (<xref ref-type="bibr" rid="B328">Wakita et al., 2003</xref>; <xref ref-type="bibr" rid="B206">Mizuno et al., 2004</xref>).</p>
<p>Interestingly, ibudilast inhibits Tat mediated TNF-α expression by microglial cells (<xref ref-type="bibr" rid="B153">Kiebala et al., 2010</xref>; <xref ref-type="bibr" rid="B152">Kiebala and Maggirwar, 2011</xref>). It also inhibits Tat induced HIV-neuronal loss <italic>in vitro</italic> in the presence or absence of drugs such as morphine (<xref ref-type="bibr" rid="B152">Kiebala and Maggirwar, 2011</xref>; <xref ref-type="bibr" rid="B76">El-Hage et al., 2014</xref>). Moreover, ibudilast was reported to significantly inhibit HIV replication in microglia cells (<xref ref-type="bibr" rid="B76">El-Hage et al., 2014</xref>).</p>
<p>Ibudilast also effectively protects against the glial activation responsible for modulating MA-induced behaviors, such as hyperlocomotion activity and MA self-administration, as well as MA relapse caused by stress or re-exposure to MA (reviewed in <xref ref-type="bibr" rid="B46">Caputo et al., 2009</xref>; <xref ref-type="bibr" rid="B26">Beardsley et al., 2010</xref>; <xref ref-type="bibr" rid="B289">Snider et al., 2012</xref>, <xref ref-type="bibr" rid="B288">2013</xref>). Ibudilast and an Ibudilast-analog that is ineffective at inhibiting phosphodiesterase, similarly suppressed MA self-administration in rats (<xref ref-type="bibr" rid="B57">Cho et al., 2010</xref>; <xref ref-type="bibr" rid="B288">Snider et al., 2013</xref>), raising questions over the mechanism though which ibudilast works.</p>
<p>Currently, there are 10 clinical trials testing ibudilast. Of these, NCT01217970 is a completed phase I clinical trial demonstrating the safety of the compound in combination with MA, whereas NCT01860807 is an ongoing phase II trial on HIV-1 patients.</p>
</sec>
<sec>
<title>Other Adjunctive Drugs</title>
<p>Additional FDA approved compounds, currently effective for others brain disorders have been used in clinical trials for reducing MA use in HIV-1 patients such as aripiprazole, mirtazapin, and naltrexone.</p>
<p><italic>Aripiprazole</italic>, which is a partial agonist at D2 receptors, is an antipsychotic used in the treatment of schizophrenia, bipolar disorder, depression and autism. It presented high toxicity when used in combination with ritonavir-boosted ART and cytochrome P450 inhibitor, reinforcing the need for caution when choosing the dosage and ART combination (<xref ref-type="bibr" rid="B19">Aung et al., 2010</xref>). In addition, depending on the dosage Aripiprazole has also been shown to increase MA-induced reward (<xref ref-type="bibr" rid="B218">Newton et al., 2008</xref>). In 2014, a phase II clinical trial (NCT00497055) was completed to test its efficacy to decrease the use of MA by HIV patients. However, the results are not yet available.</p>
<p><italic>Mirtazapine</italic>, an antidepressant inhibitor of serotonin receptors, was reported to participate in the reduction of progressive multifocal leukoencephalopathy in one HIV-1 infected male (reviewed in <xref ref-type="bibr" rid="B168">Lasso and Ceron, 2012</xref>) and to reduce depression (<xref ref-type="bibr" rid="B77">Elliott and Roy-Byrne, 2000</xref>). It was used in a phase II trial in a cohort of HIV-1 men, which were actively using MA. In this study (NCT00497081), mirtazapine reduced MA usage and sexual risk.</p>
<p><italic>Naltrexone</italic>, an opioid antagonist, was recently tested in a phase II trial (NCT01822132) in MA-using HIV patients to assess its ability to diminish MA-induced impulsive decision under observation with magnetic resonance imaging to determine functional correlate changes in brain. The results of this trial have not yet been made public.</p>
<p>Phase II clinical trials have been performed with this compound (NCT01449565; NCT00984360) for MA dependence on a cohort of men who have sex with men, due to the high percentage of this population in HIV infected MA abusers (NCT01449565), as well as on a cohort of individuals exhibiting the mutation A<sup>118</sup> to G<sup>118</sup> on the mu opioid receptor gene (NCT00984360). This mutation was shown to increase MA, alcohol and heroin addiction (<xref ref-type="bibr" rid="B166">Kuppuswamy et al., 1989</xref>; reviewed in <xref ref-type="bibr" rid="B138">Jeang et al., 1999</xref>; <xref ref-type="bibr" rid="B228">Peloponese et al., 2000</xref>; <xref ref-type="bibr" rid="B54">Chen et al., 2002</xref>; reviewed in <xref ref-type="bibr" rid="B42">Campbell and Loret, 2009</xref>). NCT00984360 was completed but the results are still not available, whereas, the NCT01449565 trial is still recruiting participants at the time of this review. In 2015, a study showed that naltrexone decreased the cue-induced craving and subjective responses to MA (<xref ref-type="bibr" rid="B247">Ray et al., 2015</xref>). This activity of the naltrexone had previously been observed with amphetamine and cocaine (<xref ref-type="bibr" rid="B137">Jayaram-Lindstrom et al., 2004</xref>, <xref ref-type="bibr" rid="B135">2008a</xref>,<xref ref-type="bibr" rid="B136">b</xref>; <xref ref-type="bibr" rid="B62">Comer et al., 2013</xref>).</p>
<p>In parallel, several trials based on the <italic>management</italic> of HIV/MA are still ongoing<sup><xref ref-type="fn" rid="fn01">1</xref></sup>.</p>
</sec>
<sec>
<title>Promising Candidates</title>
<p>BBB alteration, excitotoxicity, oxidative stress, neuro-inflammation and apoptosis all result from the disruption of different physiological pathways by Tat and/or MA. The review of <xref ref-type="bibr" rid="B262">Rumbaugh et al. (2008)</xref> describes different pathways involving Tat in HAND, which are mostly used in MA activities (reviewed in <xref ref-type="bibr" rid="B262">Rumbaugh et al., 2008</xref>). Therapeutically targeting cellular pathways requires using caution with dosages, as normally expressed human proteins are involved. Alternatively, one can physically target each toxin individually, which may be a less cytotoxic alternative.</p>
<sec>
<title>Tat</title>
<p>Triptolide and didehydro-Cortistatin A (dCA), target the N-terminus and the basic domain of Tat respectively. These are currently the most promising Tat-targeting compounds, with an activity in the nanomolar concentration range.</p>
<p>
<bold>
<italic>Triptolide</italic>
</bold>
</p>
<p>Triptolide, is a diterpenoid epoxide isolated from <italic>Tripterygium wilfordii</italic>, which inhibits HIV-1 transcription by accelerating Tat degradation. Triptolide was described to have anti-inflammatory, immunosuppressive and anti-tumor properties (<xref ref-type="bibr" rid="B330">Wan and Chen, 2014</xref>). It is currently in a phase III clinical trial (NCT02219672), being tested in combination with ART on HIV-1 infected Chinese individuals for its ability to reduce the HIV-1 reservoir size.</p>
<p>
<bold>
<italic>Didehydro-Cortistatin A</italic>
</bold>
</p>
<p>Didehydro-Cortistatin A, is an analog of a natural steroidal alkaloid isolated from a marine sponge, <italic>Corticium simplex</italic>. It inhibits Tat-mediated transactivation of the HIV integrated provirus by binding specifically to the TAR-binding domain of Tat (basic region; <xref ref-type="bibr" rid="B208">Mousseau et al., 2012</xref>; reviewed in <xref ref-type="bibr" rid="B209">Mousseau et al., 2015</xref>). dCA promotes sustained silencing of the HIV promoter without viral rebound even in the absence of ART <italic>in vitro</italic>. dCA was also shown to inhibit Tat induced neuroinflammation of astrocytes <italic>in vitro</italic>, as well as Tat-induced cocaine potentiation <italic>in vivo</italic> (<xref ref-type="bibr" rid="B196">Mediouni et al., 2015</xref>).</p>
<p>For currently ongoing clinical trials for Tat vaccines<sup><xref ref-type="fn" rid="fn02">2</xref></sup>.</p>
</sec>
<sec>
<title>Methamphetamine</title>
<p>
<bold>
<italic>Passive and active immunizations</italic>
</bold>
</p>
<p>Passive and active immunizations against drugs of abuse are expected to slow down entry of the drug of abuse inside the brain thus preventing drug-associated behaviors. MA vaccines are still in preclinical development and promote low and variable level of antibodies production with moderate affinity for MA (<xref ref-type="bibr" rid="B116">Hauber et al., 1989</xref>; <xref ref-type="bibr" rid="B186">Mabrouk et al., 1991</xref>; <xref ref-type="bibr" rid="B263">Sabatier et al., 1991</xref>; <xref ref-type="bibr" rid="B208">Mousseau et al., 2012</xref>; <xref ref-type="bibr" rid="B112">Hambuchen et al., 2015</xref>). Research based on conjugate vaccine and adjuvant optimization should enhance the efficiency of these vaccines. Passive immunization with the human-mouse chimeric monoclonal antibody, mAb7F9, is already in more advanced stages of development (<xref ref-type="bibr" rid="B112">Hambuchen et al., 2015</xref>). Mab7F9 was reported to specifically bind to MA in the nanomolar range and mediate MA clearance (<xref ref-type="bibr" rid="B169">Laurenzana et al., 2014</xref>; <xref ref-type="bibr" rid="B297">Stevens et al., 2014</xref>). mAb7F9 attenuated MA induced hyper-locomotion even after irregular treatment and challenge with higher MA doses (<xref ref-type="bibr" rid="B113">Hambuchen et al., 2014</xref>; <xref ref-type="bibr" rid="B169">Laurenzana et al., 2014</xref>). It also partially reduced addiction-related behavior (<xref ref-type="bibr" rid="B115">Harris et al., 2015</xref>). Combination of MA hapten-conjugate vaccine to this antibody for 4 months reduced the presence of MA in the brain (<xref ref-type="bibr" rid="B112">Hambuchen et al., 2015</xref>). In 2014, this mAb was the first MA mAb to be used in a phase I clinical study in MA abusers (NCT01603147). The study was completed and confirmed the safety of the antibody. One potential caveat of this approach is that patients could be expected to increase their drug intake to overcome the effects of the antibody.</p>
<p>
<bold>
<italic>Sigma receptors</italic>
</bold>
</p>
<p>Methamphetamine and cocaine have been shown to directly interact with sigma receptors at physiological relevant concent-rations (<xref ref-type="bibr" rid="B219">Nguyen et al., 2005</xref>; reviewed in <xref ref-type="bibr" rid="B255">Robson et al., 2012</xref>). Sigma receptors have been shown to be involved in MA induced neurotoxicity through a variety of mechanisms such as neuroinflammation, hyperthermia, apoptosis, modulation of neurotransmitters and oxidative stress (reviewed in <xref ref-type="bibr" rid="B146">Kaushal and Matsumoto, 2011</xref>). In addition, sigma receptors show no homology to other human proteins, supporting the development of sigma receptor antagonists therapeutics to treat MA abuse (reviewed in <xref ref-type="bibr" rid="B193">Matsumoto, 2009</xref>). Several antagonists with nanomolar affinity have been developed. For instance, pretreatment with CM156 prevents hyperthermia and hyper-locomotor effects of MA as well as monoamine depletion in mice (<xref ref-type="bibr" rid="B149">Kaushal et al., 2011b</xref>), whereas AZ66 has been shown to prevent both MA-induced locomotor stimulation and the behavioral sensitization resulting from repeated MA administration in mice (<xref ref-type="bibr" rid="B276">Seminerio et al., 2012</xref>). Recently, SN79, which has been shown to have good “drugable” proprieties (<xref ref-type="bibr" rid="B148">Kaushal et al., 2011a</xref>), has mitigated MA-induced oxidative stress (<xref ref-type="bibr" rid="B147">Kaushal et al., 2014</xref>), apoptosis (<xref ref-type="bibr" rid="B148">Kaushal et al., 2011a</xref>), neuroinflammation (astrogliosis and microgliosis; <xref ref-type="bibr" rid="B256">Robson et al., 2013</xref>, <xref ref-type="bibr" rid="B257">2014</xref>), hyperthermia (<xref ref-type="bibr" rid="B150">Kaushal et al., 2013</xref>, <xref ref-type="bibr" rid="B147">2014</xref>), and neurotransmitters modulation (<xref ref-type="bibr" rid="B150">Kaushal et al., 2013</xref>). Moreover, SN79 also reverses cocaine-induced convulsions, locomotor activity and prevents sensitization to cocaine (<xref ref-type="bibr" rid="B148">Kaushal et al., 2011a</xref>). However, at higher doses, SN79 induces sedation and motor incoordination (<xref ref-type="bibr" rid="B148">Kaushal et al., 2011a</xref>). Currently, none of the sigma receptors antagonists are clinically tested in HIV-infected MA abusers or MA abusers cohorts.</p>
</sec>
<sec>
<title>Caveats</title>
<p>Finding the ideal therapy to treat HAND on the increasingly aging population of HIV-infected individuals, drug abusers in particular, is a significant challenge, especially with restricted animal models that fully reflect both HAND and drug abuse toxicity. The ideal therapy should block the pleiotropic activities of the toxic agent(s) without cell-associated toxicity, penetrate the brain or retain the toxic agent in the blood stream (e.g., antibodies), have low posology, present a high threshold for resistance development, and importantly, be inexpensive. Personalized therapeutic strategies may also be envisaged, given the human genetic variation (e.g., the mu opioid mutation A<sup>118</sup> to G<sup>118</sup>, the HIV-1 co-receptor CCR5 Δ32 deletion), drug of abuse-induced epigenetic variations and HIV-1 genome variation (<xref ref-type="bibr" rid="B166">Kuppuswamy et al., 1989</xref>; reviewed in <xref ref-type="bibr" rid="B138">Jeang et al., 1999</xref>; <xref ref-type="bibr" rid="B228">Peloponese et al., 2000</xref>; <xref ref-type="bibr" rid="B54">Chen et al., 2002</xref>; <xref ref-type="bibr" rid="B66">Daily et al., 2006</xref>; <xref ref-type="bibr" rid="B172">Li et al., 2008</xref>; reviewed in <xref ref-type="bibr" rid="B42">Campbell and Loret, 2009</xref>). However, the cost of these strategies may be a hurdle. The combination of potent specific compounds (and/or immunizations) to ART could constitute a first step in the treatment of HAND (see Figure <xref ref-type="fig" rid="F4">4</xref>, for an overview of pathways and potential therapeutic tools).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p><bold>Potential approaches for the treatment of Tat/methamphetamine toxicity.</bold> The optimization of ART blood–brain barrier penetration may be achieved though a better route of administration, using carriers, or by including adjunctive therapy.</p>
</caption>
<graphic xlink:href="fmicb-06-01164-g0004"></graphic>
</fig>
</sec>
</sec>
</sec>
<sec>
<title>Conclusion</title>
<p>Although the biological effects of MA abuse and Tat protein have been extensively studied in the past, the result of their interaction is still not fully understood.</p>
<p>Methamphetamine abusers exhibit drug-related risk behaviors, such as needle sharing and unsafe sexual practices that increase the risk of acquiring an infectious disease. MA was shown to enhance HIV-1 replication, which may explain the rapid progression to AIDS of HIV infected MA users. On the other hand, Tat increases drug reward, which may partially explain the higher frequency of drug users in the HIV population.</p>
<p>Tat and MA act on homologous pathways, synergistically or additively, disturbing the same biological processes, including neurotransmitter pathways, inflammation, oxidative stress, and apoptosis. The outcome of this cross-interaction results in varying degrees of neurocognitive and locomotor disorders, that depend on patient complexity (reviewed in <xref ref-type="bibr" rid="B324">Valderas et al., 2009</xref>), HIV clade and drug use frequency. Compounds that target cellular pathways used for either Tat or MA-mediated cellular and behavioral activities, have the potential to reduce damage from both agents. Addition of these specific adjunctive compounds to ART is the most accepted treatment approach for HIV infected MA users. In addition, efforts on drug and HIV education and prevention, should be continuously provided.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>SM and SV are supported by NIH grants #NIAID RO1 AI097012-01A1and R21AI116226-01. MM is supported by NIDA 5R01DA036164. MM would like to thank Floriska Chizer for administrative assistance.</p>
</ack>
<fn-group>
<fn id="fn01">
<label>1</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=hiv+methamphetamine&amp;Search+Search">https://clinicaltrials.gov/ct2/results?term=hiv+methamphetamine&amp;Search+Search</ext-link>
</p>
</fn>
<fn id="fn02">
<label>2</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=tat+vaccine&amp;Search=Search">https://clinicaltrials.gov/ct2/results?term=tat+vaccine&amp;Search=Search</ext-link>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul Muneer</surname><given-names>P. M.</given-names></name><name><surname>Alikunju</surname><given-names>S.</given-names></name><name><surname>Szlachetka</surname><given-names>A. M.</given-names></name><name><surname>Murrin</surname><given-names>L. C.</given-names></name><name><surname>Haorah</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction</article-title>. <source/>Mol. Neurodegener
<volume>6</volume>, <fpage>23</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1326-6-23</pub-id><pub-id pub-id-type="pmid">21426580</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achat-Mendes</surname><given-names>C.</given-names></name><name><surname>Lynch</surname><given-names>L. J.</given-names></name><name><surname>Sullivan</surname><given-names>K. A.</given-names></name><name><surname>Vallender</surname><given-names>E. J.</given-names></name><name><surname>Miller</surname><given-names>G. M.</given-names></name></person-group> (<year>2012a</year>). <article-title>Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>101</volume>, <fpage>201</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2011.10.025</pub-id><pub-id pub-id-type="pmid">22079347</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achat-Mendes</surname><given-names>C.</given-names></name><name><surname>Platt</surname><given-names>D. M.</given-names></name><name><surname>Spealman</surname><given-names>R. D.</given-names></name></person-group> (<year>2012b</year>). <article-title>Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>343</volume>, <fpage>214</fpage>–<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.112.196295</pub-id><pub-id pub-id-type="pmid">22815535</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>L.</given-names></name><name><surname>Louboutin</surname><given-names>J. P.</given-names></name><name><surname>Reyes</surname><given-names>B. A.</given-names></name><name><surname>Van Bockstaele</surname><given-names>E. J.</given-names></name><name><surname>Strayer</surname><given-names>D. S.</given-names></name></person-group> (<year>2012</year>). <article-title>HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes</article-title>. <source/>Neurobiol. Dis.
<volume>45</volume>, <fpage>657</fpage>–<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.10.005</pub-id><pub-id pub-id-type="pmid">22036626</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>R. G.</given-names></name><name><surname>Hewetson</surname><given-names>A.</given-names></name><name><surname>George</surname><given-names>C. M.</given-names></name><name><surname>Syapin</surname><given-names>P. J.</given-names></name><name><surname>Bergeson</surname><given-names>S. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Minocycline reduces ethanol drinking</article-title>. <source/>Brain Behav. Immun.
<volume>25</volume>(<issue>Suppl. 1</issue>), <fpage>S165</fpage>–<lpage>S169</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2011.03.002</pub-id><pub-id pub-id-type="pmid">21397005</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksenov</surname><given-names>M. Y.</given-names></name><name><surname>Aksenova</surname><given-names>M. V.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Attenuated neurotoxicity of the transactivation-defective HIV-1 Tat protein in hippocampal cell cultures</article-title>. <source/>Exp. Neurol.
<volume>219</volume>, <fpage>586</fpage>–<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2009.07.005</pub-id><pub-id pub-id-type="pmid">19615365</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksenov</surname><given-names>M. Y.</given-names></name><name><surname>Aksenova</surname><given-names>M. V.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2012</year>). <article-title>D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>7</volume>, <fpage>599</fpage>–<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9362-3</pub-id><pub-id pub-id-type="pmid">22552781</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksenov</surname><given-names>M. Y.</given-names></name><name><surname>Aksenova</surname><given-names>M. V.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Ray</surname><given-names>P. D.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor</article-title>. <source/>Neurotoxicology
<volume>27</volume>, <fpage>217</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2005.10.003</pub-id><pub-id pub-id-type="pmid">16386305</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksenov</surname><given-names>M. Y.</given-names></name><name><surname>Hasselrot</surname><given-names>U.</given-names></name><name><surname>Bansal</surname><given-names>A. K.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Anderson</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum</article-title>. <source/>Neurosci. Lett.
<volume>305</volume>, <fpage>5</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3940(01)01786-4</pub-id><pub-id pub-id-type="pmid">11356294</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albini</surname><given-names>A.</given-names></name><name><surname>Ferrini</surname><given-names>S.</given-names></name><name><surname>Benelli</surname><given-names>R.</given-names></name><name><surname>Sforzini</surname><given-names>S.</given-names></name><name><surname>Giunciuglio</surname><given-names>D.</given-names></name><name><surname>Aluigi</surname><given-names>M. G.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>HIV-1 Tat protein mimicry of chemokines</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>95</volume>, <fpage>13153</fpage>–<lpage>13158</lpage>.<pub-id pub-id-type="pmid">9789057</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>S. M.</given-names></name><name><surname>Tyrrell</surname><given-names>P. J.</given-names></name><name><surname>Rothwell</surname><given-names>N. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Interleukin-1 and neuronal injury</article-title>. <source/>Nat. Rev. Immunol.
<volume>5</volume>, <fpage>629</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1038/nri1664</pub-id><pub-id pub-id-type="pmid">16034365</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosino</surname><given-names>C.</given-names></name><name><surname>Ruocco</surname><given-names>M. R.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Mallardo</surname><given-names>M.</given-names></name><name><surname>Baudi</surname><given-names>F.</given-names></name><name><surname>Trematerra</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>1997</year>). <article-title>HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors</article-title>. <source/>J. Biol. Chem.
<volume>272</volume>, <fpage>14883</fpage>–<lpage>14892</lpage>.<pub-id pub-id-type="pmid">9169458</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amenta</surname><given-names>F.</given-names></name><name><surname>Bronzetti</surname><given-names>E.</given-names></name><name><surname>Felici</surname><given-names>L.</given-names></name><name><surname>Ricci</surname><given-names>A.</given-names></name><name><surname>Tayebati</surname><given-names>S. K.</given-names></name></person-group> (<year>1999</year>). <article-title>Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study</article-title>. <source/>J. Auton Pharmacol.
<volume>19</volume>, <fpage>151</fpage>–<lpage>159</lpage>.<pub-id pub-id-type="pmid">10511471</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>S.</given-names></name><name><surname>Mameli</surname><given-names>G.</given-names></name><name><surname>Del Valle</surname><given-names>L.</given-names></name><name><surname>Skowronska</surname><given-names>A.</given-names></name><name><surname>Reiss</surname><given-names>K.</given-names></name><name><surname>Gelman</surname><given-names>B. B.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28</article-title>. <source/>Mol. Cell. Biol.
<volume>25</volume>, <fpage>8126</fpage>–<lpage>8138</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.25.18.8126-8138.2005</pub-id><pub-id pub-id-type="pmid">16135803</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antinori</surname><given-names>A.</given-names></name><name><surname>Arendt</surname><given-names>G.</given-names></name><name><surname>Becker</surname><given-names>J. T.</given-names></name><name><surname>Brew</surname><given-names>B. J.</given-names></name><name><surname>Byrd</surname><given-names>D. A.</given-names></name><name><surname>Cherner</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Updated research nosology for HIV-associated neurocognitive disorders</article-title>. <source/>Neurology
<volume>69</volume>, <fpage>1789</fpage>–<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000287431.88658.8b</pub-id><pub-id pub-id-type="pmid">17914061</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ares-Santos</surname><given-names>S.</given-names></name><name><surname>Granado</surname><given-names>N.</given-names></name><name><surname>Oliva</surname><given-names>I.</given-names></name><name><surname>O’Shea</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>E. D.</given-names></name><name><surname>Colado</surname><given-names>M. I.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine</article-title>. <source/>Neurobiol. Dis.
<volume>45</volume>, <fpage>810</fpage>–<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.11.005</pub-id><pub-id pub-id-type="pmid">22115942</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvin</surname><given-names>K. L.</given-names></name><name><surname>Han</surname><given-names>B. H.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>S. Z.</given-names></name><name><surname>Paul</surname><given-names>S. M.</given-names></name><name><surname>Holtzman</surname><given-names>D. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury</article-title>. <source/>Ann. Neurol.
<volume>52</volume>, <fpage>54</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1002/ana.10242</pub-id><pub-id pub-id-type="pmid">12112047</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>C. M.</given-names></name><name><surname>Sweatt</surname><given-names>J. D.</given-names></name></person-group> (<year>1999</year>). <article-title>Reactive oxygen species mediate activity-dependent neuron-glia signaling in output fibers of the hippocampus</article-title>. <source/>J. Neurosci.
<volume>19</volume>, <fpage>7241</fpage>–<lpage>7248</lpage>.<pub-id pub-id-type="pmid">10460230</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aung</surname><given-names>G. L.</given-names></name><name><surname>O’brien</surname><given-names>J. G.</given-names></name><name><surname>Tien</surname><given-names>P. G.</given-names></name><name><surname>Kawamoto</surname><given-names>L. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir</article-title>. <source/>Ann. Pharmacother.
<volume>44</volume>, <fpage>1850</fpage>–<lpage>1854</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1P139</pub-id><pub-id pub-id-type="pmid">20978219</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagashev</surname><given-names>A.</given-names></name><name><surname>Sawaya</surname><given-names>B. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Roles and functions of HIV-1 Tat protein in the CNS: an overview</article-title>. <source/>Virol. J.
<volume>10</volume>, <fpage>358</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422x-10-358</pub-id><pub-id pub-id-type="pmid">24359561</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bal-Price</surname><given-names>A.</given-names></name><name><surname>Moneer</surname><given-names>Z.</given-names></name><name><surname>Brown</surname><given-names>G. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes</article-title>. <source/>Glia
<volume>40</volume>, <fpage>312</fpage>–<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1002/glia.10124</pub-id><pub-id pub-id-type="pmid">12420311</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Manda</surname><given-names>K. R.</given-names></name><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Ercal</surname><given-names>N.</given-names></name></person-group> (<year>2010</year>). <article-title>HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide</article-title>. <source/>Free Radic Biol. Med.
<volume>48</volume>, <fpage>1388</fpage>–<lpage>1398</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.02.023</pub-id><pub-id pub-id-type="pmid">20188164</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Robinson</surname><given-names>S. M.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Permeability of the blood-brain barrier to HIV-1 Tat</article-title>. <source/>Exp. Neurol.
<volume>193</volume>, <fpage>218</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2004.11.019</pub-id><pub-id pub-id-type="pmid">15817280</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barayuga</surname><given-names>S. M.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Andres</surname><given-names>M. A.</given-names></name><name><surname>Panee</surname><given-names>J.</given-names></name><name><surname>Bellinger</surname><given-names>F. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Methamphetamine decreases levels of glutathione peroxidases 1 and 4 in SH-SY5Y neuronal cells: protective effects of selenium</article-title>. <source/>Neurotoxicology
<volume>37</volume>, <fpage>240</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2013.05.009</pub-id><pub-id pub-id-type="pmid">23721877</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beardsley</surname><given-names>P. M.</given-names></name><name><surname>Hauser</surname><given-names>K. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Glial modulators as potential treatments of psychostimulant abuse</article-title>. <source/>Adv. Pharmacol.
<volume>69</volume>, <fpage>1</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-420118-7.00001-9</pub-id><pub-id pub-id-type="pmid">24484974</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beardsley</surname><given-names>P. M.</given-names></name><name><surname>Shelton</surname><given-names>K. L.</given-names></name><name><surname>Hendrick</surname><given-names>E.</given-names></name><name><surname>Johnson</surname><given-names>K. W.</given-names></name></person-group> (<year>2010</year>). <article-title>The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse</article-title>. <source/>Eur. J. Pharmacol.
<volume>637</volume>, <fpage>102</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.04.010</pub-id><pub-id pub-id-type="pmid">20399770</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>K. F.</given-names></name><name><surname>Al-Mubarak</surname><given-names>B.</given-names></name><name><surname>Fowler</surname><given-names>J. H.</given-names></name><name><surname>Baxter</surname><given-names>P. S.</given-names></name><name><surname>Gupta</surname><given-names>K.</given-names></name><name><surname>Tsujita</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>108</volume>, <fpage>E1</fpage>–<lpage>E2</lpage><comment>; author reply E3–E4.</comment>
<pub-id pub-id-type="doi">10.1073/pnas.1015229108</pub-id><pub-id pub-id-type="pmid">21177433</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>J. R.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Fernandez</surname><given-names>J. B.</given-names></name><name><surname>Levin</surname><given-names>B.</given-names></name></person-group> (<year>1994</year>). <article-title>Cerebrospinal fluid dopamine in HIV-1 infection</article-title>. <source/>AIDS
<volume>8</volume>, <fpage>67</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">8011238</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>S. J.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Aksenova</surname><given-names>M. V.</given-names></name><name><surname>Espensen-Sturges</surname><given-names>T. D.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens</article-title>. <source/>J. Neurochem.
<volume>128</volume>, <fpage>140</fpage>–<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12375</pub-id><pub-id pub-id-type="pmid">23875777</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bethel-Brown</surname><given-names>C.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Callen</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>Y. H.</given-names></name><name><surname>Dash</surname><given-names>P. K.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>HIV-1 Tat-mediated induction of platelet-derived growth factor in astrocytes: role of early growth response gene 1</article-title>. <source/>J. Immunol.
<volume>186</volume>, <fpage>4119</fpage>–<lpage>4129</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1002235</pub-id><pub-id pub-id-type="pmid">21368226</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezzi</surname><given-names>P.</given-names></name><name><surname>Domercq</surname><given-names>M.</given-names></name><name><surname>Brambilla</surname><given-names>L.</given-names></name><name><surname>Galli</surname><given-names>R.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity</article-title>. <source/>Nat. Neurosci.
<volume>4</volume>, <fpage>702</fpage>–<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1038/89490</pub-id><pub-id pub-id-type="pmid">11426226</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgatti</surname><given-names>P.</given-names></name><name><surname>Zauli</surname><given-names>G.</given-names></name><name><surname>Cantley</surname><given-names>L. C.</given-names></name><name><surname>Capitani</surname><given-names>S.</given-names></name></person-group> (<year>1998</year>). <article-title>Extracellular HIV-1 Tat protein induces a rapid and selective activation of protein kinase C (PKC)-alpha, and -epsilon and -zeta isoforms in PC12 cells</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>242</volume>, <fpage>332</fpage>–<lpage>337</lpage>.<pub-id pub-id-type="pmid">9446795</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boven</surname><given-names>L. A.</given-names></name><name><surname>Noorbakhsh</surname><given-names>F.</given-names></name><name><surname>Bouma</surname><given-names>G.</given-names></name><name><surname>Van Der Zee</surname><given-names>R.</given-names></name><name><surname>Vargas</surname><given-names>D. L.</given-names></name><name><surname>Pardo</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation</article-title>. <source/>J. Neurovirol.
<volume>13</volume>, <fpage>173</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1080/13550280701258399</pub-id><pub-id pub-id-type="pmid">17505986</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabers</surname><given-names>N. A.</given-names></name><name><surname>Nottet</surname><given-names>H. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia</article-title>. <source/>Eur. J. Clin. Invest.
<volume>36</volume>, <fpage>447</fpage>–<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2362.2006.01657.x</pub-id><pub-id pub-id-type="pmid">16796601</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J. M.</given-names></name><name><surname>Quinton</surname><given-names>M. S.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite</article-title>. <source/>J. Neurochem.
<volume>95</volume>, <fpage>429</fpage>–<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03379.x</pub-id><pub-id pub-id-type="pmid">16086684</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce-Keller</surname><given-names>A. J.</given-names></name><name><surname>Chauhan</surname><given-names>A.</given-names></name><name><surname>Dimayuga</surname><given-names>F. O.</given-names></name><name><surname>Gee</surname><given-names>J.</given-names></name><name><surname>Keller</surname><given-names>J. N.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain</article-title>. <source/>J. Neurosci.
<volume>23</volume>, <fpage>8417</fpage>–<lpage>8422</lpage>.<pub-id pub-id-type="pmid">12968004</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukrinsky</surname><given-names>M. I.</given-names></name><name><surname>Nottet</surname><given-names>H. S.</given-names></name><name><surname>Schmidtmayerova</surname><given-names>H.</given-names></name><name><surname>Dubrovsky</surname><given-names>L.</given-names></name><name><surname>Flanagan</surname><given-names>C. R.</given-names></name><name><surname>Mullins</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>1995</year>). <article-title>Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease</article-title>. <source/>J. Exp. Med.
<volume>181</volume>, <fpage>735</fpage>–<lpage>745</lpage>.<pub-id pub-id-type="pmid">7530762</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrows</surname><given-names>K. B.</given-names></name><name><surname>Gudelsky</surname><given-names>G.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>2000</year>). <article-title>Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration</article-title>. <source/>Eur. J. Pharmacol.
<volume>398</volume>, <fpage>11</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(00)00264-8</pub-id><pub-id pub-id-type="pmid">10856443</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buscemi</surname><given-names>L.</given-names></name><name><surname>Ramonet</surname><given-names>D.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity</article-title>. <source/>Neurobiol. Dis.
<volume>26</volume>, <fpage>661</fpage>–<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2007.03.004</pub-id><pub-id pub-id-type="pmid">17451964</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadet</surname><given-names>J. L.</given-names></name><name><surname>Sheng</surname><given-names>P.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Rothman</surname><given-names>R.</given-names></name><name><surname>Carlson</surname><given-names>E.</given-names></name><name><surname>Epstein</surname><given-names>C.</given-names></name></person-group> (<year>1994</year>). <article-title>Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice</article-title>. <source/>J. Neurochem.
<volume>62</volume>, <fpage>380</fpage>–<lpage>383</lpage>.<pub-id pub-id-type="pmid">7505315</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>N. S.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>2008</year>). <article-title>The combination of methamphetamine and of the HIV protein, Tat, induces death of the human neuroblastoma cell line, SH-SY5Y</article-title>. <source/>Synapse
<volume>62</volume>, <fpage>551</fpage>–<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1002/syn.20512</pub-id><pub-id pub-id-type="pmid">18435425</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>G. R.</given-names></name><name><surname>Loret</surname><given-names>E. P.</given-names></name></person-group> (<year>2009</year>). <article-title>What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?</article-title>
<source/>Retrovirology
<volume>6</volume>, <fpage>50</fpage>. <pub-id pub-id-type="doi">10.1186/1742-4690-6-50</pub-id><pub-id pub-id-type="pmid">19467159</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>G. R.</given-names></name><name><surname>Pasquier</surname><given-names>E.</given-names></name><name><surname>Watkins</surname><given-names>J.</given-names></name><name><surname>Bourgarel-Rey</surname><given-names>V.</given-names></name><name><surname>Peyrot</surname><given-names>V.</given-names></name><name><surname>Esquieu</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>48197</fpage>–<lpage>48204</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M406195200</pub-id><pub-id pub-id-type="pmid">15331610</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cann</surname><given-names>A. J.</given-names></name><name><surname>Rosenblatt</surname><given-names>J. D.</given-names></name><name><surname>Wachsman</surname><given-names>W.</given-names></name><name><surname>Shah</surname><given-names>N. P.</given-names></name><name><surname>Chen</surname><given-names>I. S.</given-names></name></person-group> (<year>1985</year>). <article-title>Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation</article-title>. <source/>Nature
<volume>318</volume>, <fpage>571</fpage>–<lpage>574</lpage>.<pub-id pub-id-type="pmid">2999613</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capone</surname><given-names>C.</given-names></name><name><surname>Cervelli</surname><given-names>M.</given-names></name><name><surname>Angelucci</surname><given-names>E.</given-names></name><name><surname>Colasanti</surname><given-names>M.</given-names></name><name><surname>Macone</surname><given-names>A.</given-names></name><name><surname>Mariottini</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>A role for spermine oxidase as a mediator of reactive oxygen species production in HIV-Tat-induced neuronal toxicity</article-title>. <source/>Free Radic Biol. Med.
<volume>63</volume>, <fpage>99</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.05.007</pub-id><pub-id pub-id-type="pmid">23665428</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caputo</surname><given-names>A.</given-names></name><name><surname>Gavioli</surname><given-names>R.</given-names></name><name><surname>Bellino</surname><given-names>S.</given-names></name><name><surname>Longo</surname><given-names>O.</given-names></name><name><surname>Tripiciano</surname><given-names>A.</given-names></name><name><surname>Francavilla</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development</article-title>. <source/>Int. Rev. Immunol.
<volume>28</volume>, <fpage>285</fpage>–<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1080/08830180903013026</pub-id><pub-id pub-id-type="pmid">19811313</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Harned</surname><given-names>M. E.</given-names></name><name><surname>Peters</surname><given-names>L. E.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2003</year>). <article-title>HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat</article-title>. <source/>Brain Res.
<volume>984</volume>, <fpage>133</fpage>–<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(03)03122-6</pub-id><pub-id pub-id-type="pmid">12932847</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castino</surname><given-names>R.</given-names></name><name><surname>Lazzeri</surname><given-names>G.</given-names></name><name><surname>Lenzi</surname><given-names>P.</given-names></name><name><surname>Bellio</surname><given-names>N.</given-names></name><name><surname>Follo</surname><given-names>C.</given-names></name><name><surname>Ferrucci</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine</article-title>. <source/>J. Neurochem.
<volume>106</volume>, <fpage>1426</fpage>–<lpage>1439</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05488.x</pub-id><pub-id pub-id-type="pmid">18489716</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cen</surname><given-names>P.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Su</surname><given-names>Q. J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J. L.</given-names></name><name><surname>Lin</surname><given-names>X. Q.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Methamphetamine inhibits Toll-like receptor 9-mediated anti-HIV activity in macrophages</article-title>. <source/>AIDS Res. Hum. Retrovir.
<volume>29</volume>, <fpage>1129</fpage>–<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2012.0264</pub-id><pub-id pub-id-type="pmid">23751096</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>P. A.</given-names></name><name><surname>Kantor</surname><given-names>R.</given-names></name></person-group> (<year>2009</year>). <article-title>Transmitted drug resistance in nonsubtype B HIV-1 infection</article-title>. <source/>HIV Ther.
<volume>3</volume>, <fpage>447</fpage>–<lpage>465</lpage>. <pub-id pub-id-type="doi">10.2217/hiv.09.30</pub-id><pub-id pub-id-type="pmid">20161523</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>A.</given-names></name><name><surname>Turchan</surname><given-names>J.</given-names></name><name><surname>Pocernich</surname><given-names>C.</given-names></name><name><surname>Bruce-Keller</surname><given-names>A.</given-names></name><name><surname>Roth</surname><given-names>S.</given-names></name><name><surname>Butterfield</surname><given-names>D. A.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>13512</fpage>–<lpage>13519</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M209381200</pub-id><pub-id pub-id-type="pmid">12551932</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chehimi</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Chouaib</surname><given-names>S.</given-names></name><name><surname>Zyad</surname><given-names>A.</given-names></name><name><surname>Nagashunmugam</surname><given-names>T.</given-names></name><name><surname>Wojcik</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>1996</year>). <article-title>Differential production of interleukin 10 during human immunodeficiency virus infection</article-title>. <source/>AIDS Res. Hum. Retrovir.
<volume>12</volume>, <fpage>1141</fpage>–<lpage>1149</lpage>.<pub-id pub-id-type="pmid">8844018</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. H.</given-names></name><name><surname>Howng</surname><given-names>S. L.</given-names></name><name><surname>Hwang</surname><given-names>S. L.</given-names></name><name><surname>Chou</surname><given-names>C. K.</given-names></name><name><surname>Liao</surname><given-names>C. H.</given-names></name><name><surname>Hong</surname><given-names>Y. R.</given-names></name></person-group> (<year>2000</year>). <article-title>Differential expression of four human dynamin-like protein variants in brain tumors</article-title>. <source/>DNA Cell Biol.
<volume>19</volume>, <fpage>189</fpage>–<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1089/104454900314573</pub-id><pub-id pub-id-type="pmid">10749171</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2002</year>). <article-title>HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim</article-title>. <source/>EMBO J.
<volume>21</volume>, <fpage>6801</fpage>–<lpage>6810</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/cdf683</pub-id><pub-id pub-id-type="pmid">12486001</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence</article-title>. <source/>Curr. Drug Abuse Rev.
<volume>3</volume>, <fpage>222</fpage>–<lpage>238</lpage>. <pub-id pub-id-type="doi">10.2174/1874473711003040222</pub-id><pub-id pub-id-type="pmid">21208168</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Mayne</surname><given-names>M.</given-names></name><name><surname>Power</surname><given-names>C.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>1997</year>). <article-title>The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases</article-title>. <source/>J. Biol. Chem.
<volume>272</volume>, <fpage>22385</fpage>–<lpage>22388</lpage>.<pub-id pub-id-type="pmid">9278385</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y.</given-names></name><name><surname>Crichlow</surname><given-names>G. V.</given-names></name><name><surname>Vermeire</surname><given-names>J. J.</given-names></name><name><surname>Leng</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Hodsdon</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>107</volume>, <fpage>11313</fpage>–<lpage>11318</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1002716107</pub-id><pub-id pub-id-type="pmid">20534506</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>R. M.</given-names></name><name><surname>Kundu</surname><given-names>R. K.</given-names></name><name><surname>Sangiorgi</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Maxson</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice</article-title>. <source/>J. Biol. Chem.
<volume>275</volume>, <fpage>3693</fpage>–<lpage>3698</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.275.5.3693</pub-id><pub-id pub-id-type="pmid">10652368</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisneros</surname><given-names>I. E.</given-names></name><name><surname>Ghorpade</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS</article-title>. <source/>Curr. HIV Res.
<volume>10</volume>, <fpage>392</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.2174/157016212802138832</pub-id><pub-id pub-id-type="pmid">22591363</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coley</surname><given-names>J. S.</given-names></name><name><surname>Calderon</surname><given-names>T. M.</given-names></name><name><surname>Gaskill</surname><given-names>P. J.</given-names></name><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>Berman</surname><given-names>J. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis</article-title>. <source/>PLoS ONE
<volume>10</volume>:<fpage>e0117450</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0117450</pub-id><pub-id pub-id-type="pmid">25647501</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coller</surname><given-names>J. K.</given-names></name><name><surname>Hutchinson</surname><given-names>M. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence</article-title>. <source/>Pharmacol. Ther.
<volume>134</volume>, <fpage>219</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.01.008</pub-id><pub-id pub-id-type="pmid">22316499</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comer</surname><given-names>S. D.</given-names></name><name><surname>Mogali</surname><given-names>S.</given-names></name><name><surname>Saccone</surname><given-names>P. A.</given-names></name><name><surname>Askalsky</surname><given-names>P.</given-names></name><name><surname>Martinez</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>E. A.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers</article-title>. <source/>Neuropsychopharmacology
<volume>38</volume>, <fpage>2427</fpage>–<lpage>2438</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2013.143</pub-id><pub-id pub-id-type="pmid">23736314</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conant</surname><given-names>K.</given-names></name><name><surname>St Hillaire</surname><given-names>C.</given-names></name><name><surname>Anderson</surname><given-names>C.</given-names></name><name><surname>Galey</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases</article-title>. <source/>J. Neurovirol.
<volume>10</volume>, <fpage>21</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1080/13550280490261699</pub-id><pub-id pub-id-type="pmid">14982725</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>J. T.</given-names></name><name><surname>Roberts</surname><given-names>D. C.</given-names></name><name><surname>Beveridge</surname><given-names>T. J.</given-names></name></person-group> (<year>2013</year>). <article-title>The group II metabotropic glutamate receptor agonist, LY379268, decreases methamphetamine self-administration in rats</article-title>. <source/>Drug Alcohol. Depend.
<volume>132</volume>, <fpage>414</fpage>–<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2013.07.024</pub-id><pub-id pub-id-type="pmid">23953655</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Autreaux</surname><given-names>B.</given-names></name><name><surname>Toledano</surname><given-names>M. B.</given-names></name></person-group> (<year>2007</year>). <article-title>ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>8</volume>, <fpage>813</fpage>–<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2256</pub-id><pub-id pub-id-type="pmid">17848967</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daily</surname><given-names>A.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Hersh</surname><given-names>L. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Tat peptides inhibit neprilysin</article-title>. <source/>J. Neurovirol.
<volume>12</volume>, <fpage>153</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1080/13550280600760677</pub-id><pub-id pub-id-type="pmid">16877296</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darbinian</surname><given-names>N.</given-names></name><name><surname>Darbinyan</surname><given-names>A.</given-names></name><name><surname>Czernik</surname><given-names>M.</given-names></name><name><surname>Peruzzi</surname><given-names>F.</given-names></name><name><surname>Khalili</surname><given-names>K.</given-names></name><name><surname>Reiss</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>HIV-1 Tat inhibits NGF-induced Egr-1 transcriptional activity and consequent p35 expression in neural cells</article-title>. <source/>J. Cell. Physiol.
<volume>216</volume>, <fpage>128</fpage>–<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.21382</pub-id><pub-id pub-id-type="pmid">18247371</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>L. E.</given-names></name><name><surname>Hjelle</surname><given-names>B. L.</given-names></name><name><surname>Miller</surname><given-names>V. E.</given-names></name><name><surname>Palmer</surname><given-names>D. L.</given-names></name><name><surname>Llewellyn</surname><given-names>A. L.</given-names></name><name><surname>Merlin</surname><given-names>T. L.</given-names></name><etal></etal></person-group> (<year>1992</year>). <article-title>Early viral brain invasion in iatrogenic human immunodeficiency virus infection</article-title>. <source/>Neurology
<volume>42</volume>, <fpage>1736</fpage>–<lpage>1739</lpage>.<pub-id pub-id-type="pmid">1513462</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debaisieux</surname><given-names>S.</given-names></name><name><surname>Lachambre</surname><given-names>S.</given-names></name><name><surname>Gross</surname><given-names>A.</given-names></name><name><surname>Mettling</surname><given-names>C.</given-names></name><name><surname>Besteiro</surname><given-names>S.</given-names></name><name><surname>Yezid</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>HIV-1 Tat inhibits phagocytosis by preventing the recruitment of Cdc42 to the phagocytic cup</article-title>. <source/>Nat. Commun.
<volume>6</volume>, <fpage>6211</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7211</pub-id><pub-id pub-id-type="pmid">25648615</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Valle</surname><given-names>L.</given-names></name><name><surname>Croul</surname><given-names>S.</given-names></name><name><surname>Morgello</surname><given-names>S.</given-names></name><name><surname>Amini</surname><given-names>S.</given-names></name><name><surname>Rappaport</surname><given-names>J.</given-names></name><name><surname>Khalili</surname><given-names>K.</given-names></name></person-group> (<year>2000</year>). <article-title>Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy</article-title>. <source/>J. Neurovirol.
<volume>6</volume>, <fpage>221</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.3109/13550280009015824</pub-id><pub-id pub-id-type="pmid">10878711</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Mareuil</surname><given-names>J.</given-names></name><name><surname>Carre</surname><given-names>M.</given-names></name><name><surname>Barbier</surname><given-names>P.</given-names></name><name><surname>Campbell</surname><given-names>G. R.</given-names></name><name><surname>Lancelot</surname><given-names>S.</given-names></name><name><surname>Opi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>HIV-1 Tat protein enhances microtubule polymerization</article-title>. <source/>Retrovirology
<volume>2</volume>, <fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/1742-4690-2-5</pub-id><pub-id pub-id-type="pmid">15691386</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>2000</year>). <article-title>Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice</article-title>. <source/>Brain Res. Mol. Brain Res.
<volume>83</volume>, <fpage>121</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-328X(00)00169-8</pub-id><pub-id pub-id-type="pmid">11072101</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chou</surname><given-names>J.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>2001</year>). <article-title>Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method</article-title>. <source/>Brain Res. Mol. Brain Res.
<volume>93</volume>, <fpage>64</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-328X(01)00184-X</pub-id><pub-id pub-id-type="pmid">11532339</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>M.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Liao</surname><given-names>K.</given-names></name><name><surname>Seth</surname><given-names>P.</given-names></name><name><surname>Buch</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>HIV-1 Tat disrupts CX3CL1-CX3CR1 axis in microglia via the NF-kappaBYY1 pathway</article-title>. <source/>Curr. HIV Res.
<volume>12</volume>, <fpage>189</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.2174/1570162X12666140526123119</pub-id><pub-id pub-id-type="pmid">24862326</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Dodel</surname><given-names>R. C.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Bales</surname><given-names>K. R.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>98</volume>, <fpage>14669</fpage>–<lpage>14674</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.251341998</pub-id><pub-id pub-id-type="pmid">11724929</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Hage</surname><given-names>N.</given-names></name><name><surname>Rodriguez</surname><given-names>M.</given-names></name><name><surname>Podhaizer</surname><given-names>E. M.</given-names></name><name><surname>Zou</surname><given-names>S.</given-names></name><name><surname>Dever</surname><given-names>S. M.</given-names></name><name><surname>Snider</surname><given-names>S. E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine</article-title>. <source/>AIDS
<volume>28</volume>, <fpage>1409</fpage>–<lpage>1419</lpage>. <pub-id pub-id-type="doi">10.1097/qad.0000000000000291</pub-id><pub-id pub-id-type="pmid">24732776</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>A. J.</given-names></name><name><surname>Roy-Byrne</surname><given-names>P. P.</given-names></name></person-group> (<year>2000</year>). <article-title>Mirtazapine for depression in patients with human immunodeficiency virus</article-title>. <source/>J. Clin. Psychopharmacol.
<volume>20</volume>, <fpage>265</fpage>–<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1097/00004714-200004000-00023</pub-id><pub-id pub-id-type="pmid">10770469</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>R.</given-names></name><name><surname>Langford</surname><given-names>D.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group> (<year>2007</year>). <article-title>HIV and antiretroviral therapy in the brain: neuronal injury and repair</article-title>. <source/>Nat. Rev. Neurosci.
<volume>8</volume>, <fpage>33</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2040</pub-id><pub-id pub-id-type="pmid">17180161</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erusalimsky</surname><given-names>J. D.</given-names></name><name><surname>Moncada</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Nitric oxide and mitochondrial signaling: from physiology to pathophysiology</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>27</volume>, <fpage>2524</fpage>–<lpage>2531</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.107.151167</pub-id><pub-id pub-id-type="pmid">17885213</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>D’aversa</surname><given-names>T. G.</given-names></name><name><surname>Lopez</surname><given-names>L.</given-names></name><name><surname>Calderon</surname><given-names>T. M.</given-names></name><name><surname>Berman</surname><given-names>J. W.</given-names></name></person-group> (<year>2003</year>). <article-title>MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis</article-title>. <source/>J. Neurochem.
<volume>85</volume>, <fpage>1299</fpage>–<lpage>1311</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01775.x</pub-id><pub-id pub-id-type="pmid">12753088</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>King</surname><given-names>J. E.</given-names></name><name><surname>Hazleton</surname><given-names>J. E.</given-names></name><name><surname>Major</surname><given-names>E. O.</given-names></name><name><surname>Bennett</surname><given-names>M. V.</given-names></name><name><surname>Zukin</surname><given-names>R. S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Differences in NMDA receptor expression during human development determine the response of neurons to HIV-tat-mediated neurotoxicity</article-title>. <source/>Neurotox. Res.
<volume>19</volume>, <fpage>138</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-010-9150-x</pub-id><pub-id pub-id-type="pmid">20094923</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>King</surname><given-names>J. E.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Calderon</surname><given-names>T. M.</given-names></name><name><surname>Zukin</surname><given-names>R. S.</given-names></name><name><surname>Bennett</surname><given-names>M. V.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>104</volume>, <fpage>3438</fpage>–<lpage>3443</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0611699104</pub-id><pub-id pub-id-type="pmid">17360663</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everall</surname><given-names>I. P.</given-names></name><name><surname>Hansen</surname><given-names>L. A.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group> (<year>2005</year>). <article-title>The shifting patterns of HIV encephalitis neuropathology</article-title>. <source/>Neurotox. Res.
<volume>8</volume>, <fpage>51</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/BF03033819</pub-id><pub-id pub-id-type="pmid">16260385</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyerman</surname><given-names>D. J.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>2007</year>). <article-title>A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine</article-title>. <source/>J. Neurochem.
<volume>103</volume>, <fpage>1219</fpage>–<lpage>1227</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04837.x</pub-id><pub-id pub-id-type="pmid">17683483</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>M. J.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>32</volume>, <fpage>883</fpage>–<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2008.01.004</pub-id><pub-id pub-id-type="pmid">18430470</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>S. M.</given-names></name><name><surname>Angel</surname><given-names>R. A.</given-names></name><name><surname>Perry</surname><given-names>S. W.</given-names></name><name><surname>Epstein</surname><given-names>L. G.</given-names></name><name><surname>Rothstein</surname><given-names>J. D.</given-names></name><name><surname>Dewhurst</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>1996</year>). <article-title>Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia</article-title>. <source/>J. Biol. Chem.
<volume>271</volume>, <fpage>15303</fpage>–<lpage>15306</lpage>.<pub-id pub-id-type="pmid">8663435</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>D.</given-names></name><name><surname>Gamieldien</surname><given-names>K.</given-names></name><name><surname>Mafunda</surname><given-names>P. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Methamphetamine is not toxic but disrupts the cell cycle of blood-brain barrier endothelial cells</article-title>. <source/>Neurotox. Res.
<volume>28</volume>, <fpage>8</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-015-9520-5</pub-id><pub-id pub-id-type="pmid">25666340</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flora</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>Y. W.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Hennig</surname><given-names>B.</given-names></name><name><surname>Maragos</surname><given-names>W.</given-names></name><name><surname>Toborek</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain</article-title>. <source/>Exp. Neurol.
<volume>179</volume>, <fpage>60</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.2002.8048</pub-id><pub-id pub-id-type="pmid">12504868</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>S. C.</given-names></name><name><surname>Marecki</surname><given-names>J. C.</given-names></name><name><surname>Harper</surname><given-names>K. P.</given-names></name><name><surname>Bose</surname><given-names>S. K.</given-names></name><name><surname>Nelson</surname><given-names>S. K.</given-names></name><name><surname>Mccord</surname><given-names>J. M.</given-names></name></person-group> (<year>1993</year>). <article-title>Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>90</volume>, <fpage>7632</fpage>–<lpage>7636</lpage>.<pub-id pub-id-type="pmid">8395050</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornai</surname><given-names>F.</given-names></name><name><surname>Longone</surname><given-names>P.</given-names></name><name><surname>Ferrucci</surname><given-names>M.</given-names></name><name><surname>Lenzi</surname><given-names>P.</given-names></name><name><surname>Isidoro</surname><given-names>C.</given-names></name><name><surname>Ruggieri</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium</article-title>. <source/>Autophagy
<volume>4</volume>, <fpage>527</fpage>–<lpage>530</lpage>. <pub-id pub-id-type="doi">10.4161/auto.5923</pub-id><pub-id pub-id-type="pmid">18367867</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friend</surname><given-names>D. M.</given-names></name><name><surname>Keefe</surname><given-names>K. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Glial reactivity in resistance to methamphetamine-induced neurotoxicity</article-title>. <source/>J. Neurochem.
<volume>125</volume>, <fpage>566</fpage>–<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12201</pub-id><pub-id pub-id-type="pmid">23414433</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>M. E.</given-names></name><name><surname>Durham</surname><given-names>S. K.</given-names></name><name><surname>Swerdel</surname><given-names>M. R.</given-names></name><name><surname>Lewin</surname><given-names>A. C.</given-names></name><name><surname>Barton</surname><given-names>D. S.</given-names></name><name><surname>Megill</surname><given-names>J. R.</given-names></name><etal></etal></person-group> (<year>1995</year>). <article-title>Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1</article-title>. <source/>J. Immunol.
<volume>155</volume>, <fpage>5769</fpage>–<lpage>5776</lpage>.<pub-id pub-id-type="pmid">7499865</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Ishima</surname><given-names>T.</given-names></name><name><surname>Kunitachi</surname><given-names>S.</given-names></name><name><surname>Hagiwara</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Iyo</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline</article-title>. <source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
<volume>32</volume>, <fpage>336</fpage>–<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.08.031</pub-id><pub-id pub-id-type="pmid">17884273</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Kunitachi</surname><given-names>S.</given-names></name><name><surname>Iyo</surname><given-names>M.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>101</volume>, <fpage>303</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2012.01.005</pub-id><pub-id pub-id-type="pmid">22260872</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>P.</given-names></name><name><surname>Frei</surname><given-names>K.</given-names></name><name><surname>Rordorf</surname><given-names>C.</given-names></name><name><surname>Lazdins</surname><given-names>J.</given-names></name><name><surname>Tavolato</surname><given-names>B.</given-names></name><name><surname>Fontana</surname><given-names>A.</given-names></name></person-group> (<year>1989</year>). <article-title>Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid</article-title>. <source/>J. Neuroimmunol.
<volume>23</volume>, <fpage>109</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">2656753</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaskill</surname><given-names>P. J.</given-names></name><name><surname>Calderon</surname><given-names>T. M.</given-names></name><name><surname>Coley</surname><given-names>J. S.</given-names></name><name><surname>Berman</surname><given-names>J. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>8</volume>, <fpage>621</fpage>–<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-013-9443-y</pub-id><pub-id pub-id-type="pmid">23456305</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genc</surname><given-names>K.</given-names></name><name><surname>Genc</surname><given-names>S.</given-names></name><name><surname>Kizildag</surname><given-names>S.</given-names></name><name><surname>Sonmez</surname><given-names>U.</given-names></name><name><surname>Yilmaz</surname><given-names>O.</given-names></name><name><surname>Tugyan</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Methamphetamine induces oligodendroglial cell death in vitro</article-title>. <source/>Brain Res.
<volume>982</volume>, <fpage>125</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(03)02890-7</pub-id><pub-id pub-id-type="pmid">12915247</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendelman</surname><given-names>H. E.</given-names></name><name><surname>Gelbard</surname><given-names>H. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders</article-title>. <source/>Curr. Opin. HIV AIDS
<volume>9</volume>, <fpage>585</fpage>–<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1097/coh.0000000000000111</pub-id><pub-id pub-id-type="pmid">25226025</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>J. W.</given-names></name><name><surname>Kogan</surname><given-names>F. J.</given-names></name></person-group> (<year>1979</year>). <article-title>Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity</article-title>. <source/>Naunyn Schmiedebergs Arch. Pharmacol.
<volume>310</volume>, <fpage>185</fpage>–<lpage>187</lpage>.<pub-id pub-id-type="pmid">43481</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>L. C.</given-names></name><name><surname>Hastings</surname><given-names>S. F.</given-names></name><name><surname>Mcphee</surname><given-names>I.</given-names></name><name><surname>Clayton</surname><given-names>R. A.</given-names></name><name><surname>Darroch</surname><given-names>C. E.</given-names></name><name><surname>Mackenzie</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family</article-title>. <source/>Eur. J. Pharmacol.
<volume>538</volume>, <fpage>39</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2006.02.053</pub-id><pub-id pub-id-type="pmid">16674936</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimenez</surname><given-names>F.</given-names></name><name><surname>Fernandez</surname><given-names>C.</given-names></name><name><surname>Mabondzo</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins</article-title>. <source/>J. Acquir. Immune Defic. Syndr.
<volume>36</volume>, <fpage>649</fpage>–<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1097/00126334-200406010-00001</pub-id><pub-id pub-id-type="pmid">15167283</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giros</surname><given-names>B.</given-names></name><name><surname>Jaber</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>S. R.</given-names></name><name><surname>Wightman</surname><given-names>R. M.</given-names></name><name><surname>Caron</surname><given-names>M. G.</given-names></name></person-group> (<year>1996</year>). <article-title>Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter</article-title>. <source/>Nature
<volume>379</volume>, <fpage>606</fpage>–<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1038/379606a0</pub-id><pub-id pub-id-type="pmid">8628395</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>J. D.</given-names></name><name><surname>Wesselingh</surname><given-names>S. L.</given-names></name><name><surname>Selnes</surname><given-names>O. A.</given-names></name><name><surname>Mcarthur</surname><given-names>J. C.</given-names></name></person-group> (<year>1993</year>). <article-title>Clinical-neuropathologic correlation in HIV-associated dementia</article-title>. <source/>Neurology
<volume>43</volume>, <fpage>2230</fpage>–<lpage>2237</lpage>.<pub-id pub-id-type="pmid">8232935</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golembiowska</surname><given-names>K.</given-names></name><name><surname>Konieczny</surname><given-names>J.</given-names></name><name><surname>Wolfarth</surname><given-names>S.</given-names></name><name><surname>Ossowska</surname><given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats</article-title>. <source/>Neuropharmacology
<volume>45</volume>, <fpage>484</fpage>–<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1016/S0028-3908(03)00209-0</pub-id><pub-id pub-id-type="pmid">12907309</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granado</surname><given-names>N.</given-names></name><name><surname>Ares-Santos</surname><given-names>S.</given-names></name><name><surname>Oliva</surname><given-names>I.</given-names></name><name><surname>O’Shea</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>E. D.</given-names></name><name><surname>Colado</surname><given-names>M. I.</given-names></name><etal></etal></person-group> (<year>2011a</year>). <article-title>Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA</article-title>. <source/>Neurobiol. Dis.
<volume>42</volume>, <fpage>391</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.01.033</pub-id><pub-id pub-id-type="pmid">21303698</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granado</surname><given-names>N.</given-names></name><name><surname>Lastres-Becker</surname><given-names>I.</given-names></name><name><surname>Ares-Santos</surname><given-names>S.</given-names></name><name><surname>Oliva</surname><given-names>I.</given-names></name><name><surname>Martin</surname><given-names>E.</given-names></name><name><surname>Cuadrado</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2011b</year>). <article-title>Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum</article-title>. <source/>Glia
<volume>59</volume>, <fpage>1850</fpage>–<lpage>1863</lpage>. <pub-id pub-id-type="doi">10.1002/glia.21229</pub-id><pub-id pub-id-type="pmid">21882243</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>F.</given-names></name><name><surname>Hurtrel</surname><given-names>M.</given-names></name><name><surname>Hurtrel</surname><given-names>B.</given-names></name></person-group> (<year>1993</year>). <article-title>Early central nervous system changes in human immunodeficiency virus (HIV)-infection</article-title>. <source/>Neuropathol. Appl. Neurobiol.
<volume>19</volume>, <fpage>3</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">8474597</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>S. M.</given-names></name><name><surname>Mizielinska</surname><given-names>S. M.</given-names></name><name><surname>Frenguelli</surname><given-names>B. G.</given-names></name><name><surname>Harvey</surname><given-names>J.</given-names></name><name><surname>Connolly</surname><given-names>C. N.</given-names></name></person-group> (<year>2007</year>). <article-title>Mitochondrial dysfunction and dendritic beading during neuronal toxicity</article-title>. <source/>J. Biol. Chem.
<volume>282</volume>, <fpage>26235</fpage>–<lpage>26244</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M704488200</pub-id><pub-id pub-id-type="pmid">17616519</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Knight</surname><given-names>A. G.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Knapp</surname><given-names>P. E.</given-names></name><name><surname>Hauser</surname><given-names>K. F.</given-names></name><name><surname>Keller</surname><given-names>J. N.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>HIV-Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antiporter</article-title>. <source/>Neurosci. Lett.
<volume>485</volume>, <fpage>233</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2010.09.019</pub-id><pub-id pub-id-type="pmid">20849923</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>A. T.</given-names></name></person-group> (<year>1986</year>). <article-title>The AIDS lentivirus connection</article-title>. <source/>Microb. Pathog.
<volume>1</volume>, <fpage>1</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">2854593</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpin</surname><given-names>L. E.</given-names></name><name><surname>Collins</surname><given-names>S. A.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>2014</year>). <article-title>Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine</article-title>. <source/>Life Sci.
<volume>97</volume>, <fpage>37</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2013.07.014</pub-id><pub-id pub-id-type="pmid">23892199</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambuchen</surname><given-names>M. D.</given-names></name><name><surname>Carroll</surname><given-names>F. I.</given-names></name><name><surname>Ruedi-Bettschen</surname><given-names>D.</given-names></name><name><surname>Hendrickson</surname><given-names>H.</given-names></name><name><surname>Hennings</surname><given-names>L.</given-names></name><name><surname>Blough</surname><given-names>B. E.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Combining active immunization with monoclonal antibody therapy to facilitate early initiation of a long-acting anti-methamphetamine antibody response</article-title>. <source/>J. Med. Chem.
<volume>58</volume>, <fpage>4665</fpage>–<lpage>4677</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00220</pub-id><pub-id pub-id-type="pmid">25973614</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambuchen</surname><given-names>M. D.</given-names></name><name><surname>Ruedi-Bettschen</surname><given-names>D.</given-names></name><name><surname>Williams</surname><given-names>D. K.</given-names></name><name><surname>Hendrickson</surname><given-names>H.</given-names></name><name><surname>Owens</surname><given-names>S. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period</article-title>. <source/>Vaccine
<volume>32</volume>, <fpage>6213</fpage>–<lpage>6219</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.09.025</pub-id><pub-id pub-id-type="pmid">25252196</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>L. R.</given-names></name><name><surname>Frey</surname><given-names>W. H.</given-names><suffix>II.</suffix></name></person-group> (<year>2007</year>). <article-title>Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>2</volume>, <fpage>81</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-006-9039-x</pub-id><pub-id pub-id-type="pmid">18040829</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>A. C.</given-names></name><name><surname>Lesage</surname><given-names>M. G.</given-names></name><name><surname>Shelley</surname><given-names>D.</given-names></name><name><surname>Perry</surname><given-names>J. L.</given-names></name><name><surname>Pentel</surname><given-names>P. R.</given-names></name><name><surname>Owens</surname><given-names>S. M.</given-names></name></person-group> (<year>2015</year>). <article-title>The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats</article-title>. <source/>PLoS ONE
<volume>10</volume>:<fpage>e0118787</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0118787</pub-id><pub-id pub-id-type="pmid">25742165</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauber</surname><given-names>J.</given-names></name><name><surname>Malim</surname><given-names>M. H.</given-names></name><name><surname>Cullen</surname><given-names>B. R.</given-names></name></person-group> (<year>1989</year>). <article-title>Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein</article-title>. <source/>J. Virol.
<volume>63</volume>, <fpage>1181</fpage>–<lpage>1187</lpage>.<pub-id pub-id-type="pmid">2536828</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haughey</surname><given-names>N. J.</given-names></name><name><surname>Cutler</surname><given-names>R. G.</given-names></name><name><surname>Tamara</surname><given-names>A.</given-names></name><name><surname>Mcarthur</surname><given-names>J. C.</given-names></name><name><surname>Vargas</surname><given-names>D. L.</given-names></name><name><surname>Pardo</surname><given-names>C. A.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia</article-title>. <source/>Ann. Neurol.
<volume>55</volume>, <fpage>257</fpage>–<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1002/ana.10828</pub-id><pub-id pub-id-type="pmid">14755730</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haughey</surname><given-names>N. J.</given-names></name><name><surname>Holden</surname><given-names>C. P.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name></person-group> (<year>1999</year>). <article-title>Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat</article-title>. <source/>J. Neurochem.
<volume>73</volume>, <fpage>1363</fpage>–<lpage>1374</lpage>.<pub-id pub-id-type="pmid">10501179</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haughey</surname><given-names>N. J.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Mattson</surname><given-names>M. P.</given-names></name><name><surname>Slevin</surname><given-names>J. T.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name></person-group> (<year>2001</year>). <article-title>HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity</article-title>. <source/>J. Neurochem.
<volume>78</volume>, <fpage>457</fpage>–<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00396.x</pub-id><pub-id pub-id-type="pmid">11483648</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>K. F.</given-names></name><name><surname>Knapp</surname><given-names>P. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors</article-title>. <source/>Int. Rev. Neurobiol.
<volume>118</volume>, <fpage>231</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-801284-0.00009-9</pub-id><pub-id pub-id-type="pmid">25175867</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>M. A.</given-names></name><name><surname>O’Callaghan</surname><given-names>J. P.</given-names></name></person-group> (<year>2000</year>). <article-title>Protein phosphorylation cascades associated with methamphetamine-induced glial activation</article-title>. <source/>Ann. N. Y. Acad. Sci.
<volume>914</volume>, <fpage>238</fpage>–<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05200.x</pub-id><pub-id pub-id-type="pmid">11085325</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemelaar</surname><given-names>J.</given-names></name><name><surname>Gouws</surname><given-names>E.</given-names></name><name><surname>Ghys</surname><given-names>P. D.</given-names></name><name><surname>Osmanov</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Global trends in molecular epidemiology of HIV-1 during 2000–2007</article-title>. <source/>AIDS
<volume>25</volume>, <fpage>679</fpage>–<lpage>689</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328342ff93</pub-id><pub-id pub-id-type="pmid">21297424</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrold</surname><given-names>A. A.</given-names></name><name><surname>Voigt</surname><given-names>R. M.</given-names></name><name><surname>Napier</surname><given-names>T. C.</given-names></name></person-group> (<year>2013</year>). <article-title>mGluR5 is necessary for maintenance of methamphetamine-induced associative learning</article-title>. <source/>Eur. Neuropsychopharmacol.
<volume>23</volume>, <fpage>691</fpage>–<lpage>696</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.05.014</pub-id><pub-id pub-id-type="pmid">22732517</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyes</surname><given-names>M. P.</given-names></name><name><surname>Achim</surname><given-names>C. L.</given-names></name><name><surname>Wiley</surname><given-names>C. A.</given-names></name><name><surname>Major</surname><given-names>E. O.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Markey</surname><given-names>S. P.</given-names></name></person-group> (<year>1996</year>). <article-title>Human microglia convert l-tryptophan into the neurotoxin quinolinic acid</article-title>. <source/>Biochem. J.
<volume>320</volume>, <fpage>595</fpage>–<lpage>597</lpage>.<pub-id pub-id-type="pmid">8973572</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>R.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Inhibition of vesicular glutamate transporters contributes to attenuate methamphetamine-induced conditioned place preference in rats</article-title>. <source/>Behav. Brain Res.
<volume>267</volume>, <fpage>1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2014.02.047</pub-id><pub-id pub-id-type="pmid">24613241</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Asanuma</surname><given-names>M.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>1998</year>). <article-title>Superoxide radicals are mediators of the effects of methamphetamine on Zif268 (Egr-1, NGFI-A) in the brain: evidence from using CuZn superoxide dismutase transgenic mice</article-title>. <source/>Brain Res. Mol. Brain Res.
<volume>58</volume>, <fpage>209</fpage>–<lpage>216</lpage>.<pub-id pub-id-type="pmid">9685645</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Ladenheim</surname><given-names>B.</given-names></name><name><surname>Carlson</surname><given-names>E.</given-names></name><name><surname>Epstein</surname><given-names>C.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>1996</year>). <article-title>Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice</article-title>. <source/>Brain Res.
<volume>714</volume>, <fpage>95</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">8861613</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Ladenheim</surname><given-names>B.</given-names></name><name><surname>Rothman</surname><given-names>R. B.</given-names></name><name><surname>Epstein</surname><given-names>C.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>1995</year>). <article-title>Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals</article-title>. <source/>Brain Res.
<volume>677</volume>, <fpage>345</fpage>–<lpage>347</lpage>.<pub-id pub-id-type="pmid">7552263</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiyoshi</surname><given-names>T.</given-names></name><name><surname>Marumo</surname><given-names>T.</given-names></name><name><surname>Hikichi</surname><given-names>H.</given-names></name><name><surname>Tomishima</surname><given-names>Y.</given-names></name><name><surname>Urabe</surname><given-names>H.</given-names></name><name><surname>Tamita</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>351</volume>, <fpage>642</fpage>–<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.114.218651</pub-id><pub-id pub-id-type="pmid">25277141</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Park</surname><given-names>M.</given-names></name><name><surname>Toborek</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice</article-title>. <source/>J. Cereb. Blood Flow Metab.
<volume>34</volume>, <fpage>646</fpage>–<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2013.240</pub-id><pub-id pub-id-type="pmid">24424383</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Raghavan</surname><given-names>R.</given-names></name><name><surname>Narayan</surname><given-names>O.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues</article-title>. <source/>J. Neurovirol.
<volume>6</volume>, <fpage>145</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.3109/13550280009013158</pub-id><pub-id pub-id-type="pmid">10822328</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Haughey</surname><given-names>N. J.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Role of endolysosomes in HIV-1 Tat-induced neurotoxicity</article-title>. <source/>ASN Neuro
<volume>4</volume>, <fpage>243</fpage>–<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1042/an20120017</pub-id><pub-id pub-id-type="pmid">22591512</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huigen</surname><given-names>M. C.</given-names></name><name><surname>Kamp</surname><given-names>W.</given-names></name><name><surname>Nottet</surname><given-names>H. S.</given-names></name></person-group> (<year>2004</year>). <article-title>Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection</article-title>. <source/>Eur. J. Clin. Invest.
<volume>34</volume>, <fpage>57</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2362.2004.01282.x</pub-id><pub-id pub-id-type="pmid">14984439</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayanthi</surname><given-names>S.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Noailles</surname><given-names>P. A.</given-names></name><name><surname>Ladenheim</surname><given-names>B.</given-names></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades</article-title>. <source/>FASEB J.
<volume>18</volume>, <fpage>238</fpage>–<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1096/fj.03-0295com</pub-id><pub-id pub-id-type="pmid">14769818</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaram-Lindstrom</surname><given-names>N.</given-names></name><name><surname>Hammarberg</surname><given-names>A.</given-names></name><name><surname>Beck</surname><given-names>O.</given-names></name><name><surname>Franck</surname><given-names>J.</given-names></name></person-group> (<year>2008a</year>). <article-title>Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial</article-title>. <source/>Am. J. Psychiatry
<volume>165</volume>, <fpage>1442</fpage>–<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2008.08020304</pub-id><pub-id pub-id-type="pmid">18765480</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaram-Lindstrom</surname><given-names>N.</given-names></name><name><surname>Konstenius</surname><given-names>M.</given-names></name><name><surname>Eksborg</surname><given-names>S.</given-names></name><name><surname>Beck</surname><given-names>O.</given-names></name><name><surname>Hammarberg</surname><given-names>A.</given-names></name><name><surname>Franck</surname><given-names>J.</given-names></name></person-group> (<year>2008b</year>). <article-title>Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence</article-title>. <source/>Neuropsychopharmacology
<volume>33</volume>, <fpage>1856</fpage>–<lpage>1863</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301572</pub-id><pub-id pub-id-type="pmid">17957221</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaram-Lindstrom</surname><given-names>N.</given-names></name><name><surname>Wennberg</surname><given-names>P.</given-names></name><name><surname>Hurd</surname><given-names>Y. L.</given-names></name><name><surname>Franck</surname><given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Effects of naltrexone on the subjective response to amphetamine in healthy volunteers</article-title>. <source/>J. Clin. Psychopharmacol.
<volume>24</volume>, <fpage>665</fpage>–<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1097/01.jcp.0000144893.29987.e5</pub-id><pub-id pub-id-type="pmid">15538132</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeang</surname><given-names>K. T.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Rich</surname><given-names>E. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Multifaceted activities of the HIV-1 transactivator of transcription, Tat</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>28837</fpage>–<lpage>28840</lpage>.<pub-id pub-id-type="pmid">10506122</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenuwein</surname><given-names>M.</given-names></name><name><surname>Scheller</surname><given-names>C.</given-names></name><name><surname>Neuen-Jacob</surname><given-names>E.</given-names></name><name><surname>Sopper</surname><given-names>S.</given-names></name><name><surname>Tatschner</surname><given-names>T.</given-names></name><name><surname>Ter Meulen</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys</article-title>. <source/>J. Neurovirol.
<volume>10</volume>, <fpage>163</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1080/13550280490448016</pub-id><pub-id pub-id-type="pmid">15204921</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Lohr</surname><given-names>M.</given-names></name><name><surname>Jezequel</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>D.</given-names></name><name><surname>Shaikh</surname><given-names>S.</given-names></name><name><surname>Selwood</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>283</volume>, <fpage>469</fpage>–<lpage>479</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.2001.4790</pub-id><pub-id pub-id-type="pmid">11327725</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Fang</surname><given-names>M.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>Multiple signaling pathways are involved in the interleukine-4 regulated expression of DC-SIGN in THP-1 cell line</article-title>. <source/>J. Biomed. Biotechnol.
<volume>2012</volume>, <fpage>357060</fpage>. <pub-id pub-id-type="doi">10.1155/2012/357060</pub-id><pub-id pub-id-type="pmid">22675249</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Olafson</surname><given-names>K.</given-names></name><name><surname>Del Bigio</surname><given-names>M. R.</given-names></name><name><surname>Peeling</surname><given-names>J.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>57</volume>, <fpage>563</fpage>–<lpage>570</lpage>.<pub-id pub-id-type="pmid">9630236</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>S. M.</given-names></name><name><surname>Song</surname><given-names>H. Y.</given-names></name><name><surname>Lee</surname><given-names>J. A.</given-names></name><name><surname>Lee</surname><given-names>S. J.</given-names></name><name><surname>Choi</surname><given-names>S. Y.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Extracellular HIV-1 Tat up-regulates expression of matrix metalloproteinase-9 via a MAPK-NF-kappaB dependent pathway in human astrocytes</article-title>. <source/>Exp. Mol. Med.
<volume>41</volume>, <fpage>86</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.3858/emm.2009.41.2.011</pub-id><pub-id pub-id-type="pmid">19287189</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumnongprakhon</surname><given-names>P.</given-names></name><name><surname>Govitrapong</surname><given-names>P.</given-names></name><name><surname>Tocharus</surname><given-names>C.</given-names></name><name><surname>Tungkum</surname><given-names>W.</given-names></name><name><surname>Tocharus</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Protective effect of melatonin on methamphetamine-induced apoptosis in glioma cell line</article-title>. <source/>Neurotox. Res.
<volume>25</volume>, <fpage>286</fpage>–<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-013-9419-y</pub-id><pub-id pub-id-type="pmid">23975636</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kass</surname><given-names>M. D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Vigorito</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>S. L.</given-names></name></person-group> (<year>2010</year>). <article-title>Methamphetamine-induced behavioral and physiological effects in adolescent and adult HIV-1 transgenic rats</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>5</volume>, <fpage>566</fpage>–<lpage>573</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-010-9221-z</pub-id><pub-id pub-id-type="pmid">20532992</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushal</surname><given-names>N.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Role of sigma receptors in methamphetamine-induced neurotoxicity</article-title>. <source/>Curr. Neuropharmacol.
<volume>9</volume>, <fpage>54</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.2174/157015911795016930</pub-id><pub-id pub-id-type="pmid">21886562</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushal</surname><given-names>N.</given-names></name><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Rosen</surname><given-names>A.</given-names></name><name><surname>Mccurdy</surname><given-names>C. R.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro</article-title>. <source/>Eur. J. Pharmacol.
<volume>724</volume>, <fpage>193</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2013.12.039</pub-id><pub-id pub-id-type="pmid">24380829</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushal</surname><given-names>N.</given-names></name><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Vinnakota</surname><given-names>H.</given-names></name><name><surname>Narayanan</surname><given-names>S.</given-names></name><name><surname>Avery</surname><given-names>B. A.</given-names></name><name><surname>Mccurdy</surname><given-names>C. R.</given-names></name><etal></etal></person-group> (<year>2011a</year>). <article-title>Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents</article-title>. <source/>AAPS J.
<volume>13</volume>, <fpage>336</fpage>–<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-011-9274-9</pub-id><pub-id pub-id-type="pmid">21494909</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushal</surname><given-names>N.</given-names></name><name><surname>Seminerio</surname><given-names>M. J.</given-names></name><name><surname>Shaikh</surname><given-names>J.</given-names></name><name><surname>Medina</surname><given-names>M. A.</given-names></name><name><surname>Mesangeau</surname><given-names>C.</given-names></name><name><surname>Wilson</surname><given-names>L. L.</given-names></name><etal></etal></person-group> (<year>2011b</year>). <article-title>CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice</article-title>. <source/>Neuropharmacology
<volume>61</volume>, <fpage>992</fpage>–<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.06.028</pub-id><pub-id pub-id-type="pmid">21762711</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushal</surname><given-names>N.</given-names></name><name><surname>Seminerio</surname><given-names>M. J.</given-names></name><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Mccurdy</surname><given-names>C. R.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Pharmacological evaluation of SN79, a sigma (sigma) receptor ligand, against methamphetamine-induced neurotoxicity in vivo</article-title>. <source/>Eur. Neuropsychopharmacol.
<volume>23</volume>, <fpage>960</fpage>–<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.08.005</pub-id><pub-id pub-id-type="pmid">22921523</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesby</surname><given-names>J. P.</given-names></name><name><surname>Heaton</surname><given-names>R. K.</given-names></name><name><surname>Young</surname><given-names>J. W.</given-names></name><name><surname>Umlauf</surname><given-names>A.</given-names></name><name><surname>Woods</surname><given-names>S. P.</given-names></name><name><surname>Letendre</surname><given-names>S. L.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Methamphetamine exposure combined with HIV-1 disease or gp120 expression: comparison of learning and executive functions in humans and mice</article-title>. <source/>Neuropsychopharmacology
<volume>40</volume>, <fpage>1899</fpage>–<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.39</pub-id><pub-id pub-id-type="pmid">25652249</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiebala</surname><given-names>M.</given-names></name><name><surname>Maggirwar</surname><given-names>S. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e18633</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018633</pub-id><pub-id pub-id-type="pmid">21494611</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiebala</surname><given-names>M.</given-names></name><name><surname>Polesskaya</surname><given-names>O.</given-names></name><name><surname>Yao</surname><given-names>Z.</given-names></name><name><surname>Perry</surname><given-names>S. W.</given-names></name><name><surname>Maggirwar</surname><given-names>S. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production</article-title>. <source/>PLoS ONE
<volume>5</volume>:<fpage>e11875</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0011875</pub-id><pub-id pub-id-type="pmid">20686703</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B. O.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ruan</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Z. C.</given-names></name><name><surname>Schantz</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>J. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline</article-title>. <source/>Am. J. Pathol.
<volume>162</volume>, <fpage>1693</fpage>–<lpage>1707</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9440(10)64304-0</pub-id><pub-id pub-id-type="pmid">12707054</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Smith</surname><given-names>A. J.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Shytle</surname><given-names>R. D.</given-names></name><name><surname>Giunta</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>MSM ameliorates HIV-1 Tat induced neuronal oxidative stress via rebalance of the glutathione cycle</article-title>. <source/>Am. J. Transl. Res.
<volume>7</volume>, <fpage>328</fpage>–<lpage>338</lpage>.<pub-id pub-id-type="pmid">25893035</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>J. E.</given-names></name><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>Hazleton</surname><given-names>J. E.</given-names></name><name><surname>Morgello</surname><given-names>S.</given-names></name><name><surname>Berman</surname><given-names>J. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Mechanisms of HIV-tat-induced phosphorylation of <italic>N</italic>-methyl-D-aspartate receptor subunit 2A in human primary neurons: implications for neuroAIDS pathogenesis</article-title>. <source/>Am. J. Pathol.
<volume>176</volume>, <fpage>2819</fpage>–<lpage>2830</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2010.090642</pub-id><pub-id pub-id-type="pmid">20448061</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koller</surname><given-names>H.</given-names></name><name><surname>Schaal</surname><given-names>H.</given-names></name><name><surname>Freund</surname><given-names>M.</given-names></name><name><surname>Garrido</surname><given-names>S. R.</given-names></name><name><surname>Von Giesen</surname><given-names>H. J.</given-names></name><name><surname>Ott</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>HIV-1 protein Tat reduces the glutamate-induced intracellular Ca2<sup>+</sup> increase in cultured cortical astrocytes</article-title>. <source/>Eur. J. Neurosci.
<volume>14</volume>, <fpage>1793</fpage>–<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1046/j.0953-816x.2001.01808.x</pub-id><pub-id pub-id-type="pmid">11860474</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koriem</surname><given-names>K. M.</given-names></name><name><surname>Abdelhamid</surname><given-names>A. Z.</given-names></name><name><surname>Younes</surname><given-names>H. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats</article-title>. <source/>Toxicol. Mech. Methods
<volume>23</volume>, <fpage>134</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.3109/15376516.2012.730561</pub-id><pub-id pub-id-type="pmid">22992185</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kousik</surname><given-names>S. M.</given-names></name><name><surname>Napier</surname><given-names>T. C.</given-names></name><name><surname>Carvey</surname><given-names>P. M.</given-names></name></person-group> (<year>2012</year>). <article-title>The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation</article-title>. <source/>Front. Pharmacol.
<volume>3</volume>:<fpage>121</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2012.00121</pub-id><pub-id pub-id-type="pmid">22754527</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsilieri</surname><given-names>E.</given-names></name><name><surname>Sopper</surname><given-names>S.</given-names></name><name><surname>Scheller</surname><given-names>C.</given-names></name><name><surname>Ter Meulen</surname><given-names>V.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name></person-group> (<year>2002a</year>). <article-title>Involvement of dopamine in the progression of AIDS Dementia Complex</article-title>. <source/>J. Neural. Transm.
<volume>109</volume>, <fpage>399</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1007/s007020200032</pub-id><pub-id pub-id-type="pmid">11956960</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsilieri</surname><given-names>E.</given-names></name><name><surname>Sopper</surname><given-names>S.</given-names></name><name><surname>Scheller</surname><given-names>C.</given-names></name><name><surname>Ter Meulen</surname><given-names>V.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name></person-group> (<year>2002b</year>). <article-title>Parkinsonism in HIV dementia</article-title>. <source/>J. Neural. Transm.
<volume>109</volume>, <fpage>767</fpage>–<lpage>775</lpage>. <pub-id pub-id-type="doi">10.1007/s007020200063</pub-id><pub-id pub-id-type="pmid">12111466</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovalevich</surname><given-names>J.</given-names></name><name><surname>Langford</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Neuronal toxicity in HIV CNS disease</article-title>. <source/>Future Virol.
<volume>7</volume>, <fpage>687</fpage>–<lpage>698</lpage>. <pub-id pub-id-type="doi">10.2217/fvl.12.57</pub-id><pub-id pub-id-type="pmid">23616788</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krogh</surname><given-names>K. A.</given-names></name><name><surname>Lyddon</surname><given-names>E.</given-names></name><name><surname>Thayer</surname><given-names>S. A.</given-names></name></person-group> (<year>2015</year>). <article-title>HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism</article-title>. <source/>J. Neurochem.
<volume>132</volume>, <fpage>354</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12936</pub-id><pub-id pub-id-type="pmid">25156524</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krogh</surname><given-names>K. A.</given-names></name><name><surname>Wydeven</surname><given-names>N.</given-names></name><name><surname>Wickman</surname><given-names>K.</given-names></name><name><surname>Thayer</surname><given-names>S. A.</given-names></name></person-group> (<year>2014</year>). <article-title>HIV-1 protein Tat produces biphasic changes in NMDA-evoked increases in intracellular Ca2<sup>+</sup> concentration via activation of Src kinase and nitric oxide signaling pathways</article-title>. <source/>J. Neurochem.
<volume>130</volume>, <fpage>642</fpage>–<lpage>656</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12724</pub-id><pub-id pub-id-type="pmid">24666322</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>D. M.</given-names></name><name><surname>Francescutti-Verbeem</surname><given-names>D. M.</given-names></name><name><surname>Thomas</surname><given-names>D. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage</article-title>. <source/>Ann. N. Y. Acad. Sci.
<volume>1074</volume>, <fpage>31</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1369.003</pub-id><pub-id pub-id-type="pmid">17105901</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuppuswamy</surname><given-names>M.</given-names></name><name><surname>Subramanian</surname><given-names>T.</given-names></name><name><surname>Srinivasan</surname><given-names>A.</given-names></name><name><surname>Chinnadurai</surname><given-names>G.</given-names></name></person-group> (<year>1989</year>). <article-title>Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis</article-title>. <source/>Nucleic Acids Res.
<volume>17</volume>, <fpage>3551</fpage>–<lpage>3561</lpage>.<pub-id pub-id-type="pmid">2542902</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>D.</given-names></name><name><surname>Grigorian</surname><given-names>A.</given-names></name><name><surname>Hurford</surname><given-names>R.</given-names></name><name><surname>Adame</surname><given-names>A.</given-names></name><name><surname>Crews</surname><given-names>L.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group> (<year>2004</year>). <article-title>The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons</article-title>. <source/>J. Neurovirol.
<volume>10</volume>, <fpage>327</fpage>–<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1080/13550280490520961</pub-id><pub-id pub-id-type="pmid">15765804</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasso</surname><given-names>M.</given-names></name><name><surname>Ceron</surname><given-names>I.</given-names></name></person-group> (<year>2012</year>). <article-title>Mirtazapine and antiretroviral therapy in the treatment of progressive multifocal leukoencephalopathy associated with HIV-1 infection: report of a case and review of literature</article-title>. <source/>Rev. Chilena Infectol.
<volume>29</volume>, <fpage>217</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.4067/s0716-10182012000200016</pub-id><pub-id pub-id-type="pmid">22689039</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurenzana</surname><given-names>E. M.</given-names></name><name><surname>Stevens</surname><given-names>M. W.</given-names></name><name><surname>Frank</surname><given-names>J. C.</given-names></name><name><surname>Hambuchen</surname><given-names>M. D.</given-names></name><name><surname>Hendrickson</surname><given-names>H. P.</given-names></name><name><surname>White</surname><given-names>S. J.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development</article-title>. <source/>Hum. Vaccin. Immunother.
<volume>10</volume>, <fpage>2638</fpage>–<lpage>2647</lpage>. <pub-id pub-id-type="doi">10.4161/hv.29707</pub-id><pub-id pub-id-type="pmid">25483484</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecoeur</surname><given-names>H.</given-names></name><name><surname>Borgne-Sanchez</surname><given-names>A.</given-names></name><name><surname>Chaloin</surname><given-names>O.</given-names></name><name><surname>El-Khoury</surname><given-names>R.</given-names></name><name><surname>Brabant</surname><given-names>M.</given-names></name><name><surname>Langonne</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase</article-title>. <source/>Cell Death Dis.
<volume>3</volume>, <fpage>e282</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2012.21</pub-id><pub-id pub-id-type="pmid">22419111</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J. C.</given-names></name><name><surname>Yim</surname><given-names>H. C.</given-names></name><name><surname>Lau</surname><given-names>A. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection</article-title>. <source/>AIDS
<volume>24</volume>, <fpage>1609</fpage>–<lpage>1623</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32833ac6a0</pub-id><pub-id pub-id-type="pmid">20588103</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Reid</surname><given-names>R.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Malpica-Llanos</surname><given-names>T.</given-names></name><name><surname>Darden</surname><given-names>T. A.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>NMDA receptor activation by HIV-Tat protein is clade dependent</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>12190</fpage>–<lpage>12198</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.3019-08.2008</pub-id><pub-id pub-id-type="pmid">19020013</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Role of Tat protein in HIV neuropathogenesis</article-title>. <source/>Neurotox. Res.
<volume>16</volume>, <fpage>205</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-009-9047-8</pub-id><pub-id pub-id-type="pmid">19526283</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>S. H.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Methamphetamine enhances HIV infection of macrophages</article-title>. <source/>Am. J. Pathol.
<volume>172</volume>, <fpage>1617</fpage>–<lpage>1624</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2008.070971</pub-id><pub-id pub-id-type="pmid">18458095</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liddie</surname><given-names>S.</given-names></name><name><surname>Balda</surname><given-names>M. A.</given-names></name><name><surname>Itzhak</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Nitric oxide (NO) signaling as a potential therapeutic modality against psychostimulants</article-title>. <source/>Curr. Pharm. Des.
<volume>19</volume>, <fpage>7092</fpage>–<lpage>7102</lpage>. <pub-id pub-id-type="doi">10.2174/138161281940131209144527</pub-id><pub-id pub-id-type="pmid">23574445</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Chandramani-Shivalingappa</surname><given-names>P.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Ghosh</surname><given-names>A.</given-names></name><name><surname>Anantharam</surname><given-names>V.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells</article-title>. <source/>Neuroscience
<volume>210</volume>, <fpage>308</fpage>–<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.03.004</pub-id><pub-id pub-id-type="pmid">22445524</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindl</surname><given-names>K. A.</given-names></name><name><surname>Marks</surname><given-names>D. R.</given-names></name><name><surname>Kolson</surname><given-names>D. L.</given-names></name><name><surname>Jordan-Sciutto</surname><given-names>K. L.</given-names></name></person-group> (<year>2010</year>). <article-title>HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>5</volume>, <fpage>294</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-010-9205-z</pub-id><pub-id pub-id-type="pmid">20396973</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Modulation of Eg5 activity contributes to mitotic spindle checkpoint activation and Tat-mediated apoptosis in CD4-positive T-lymphocytes</article-title>. <source/>J. Pathol.
<volume>233</volume>, <fpage>138</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1002/path.4333</pub-id><pub-id pub-id-type="pmid">24488929</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Vigorito</surname><given-names>M.</given-names></name><name><surname>Kass</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Chang</surname><given-names>S. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>4</volume>, <fpage>309</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-009-9160-8</pub-id><pub-id pub-id-type="pmid">19444617</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Jana</surname><given-names>M.</given-names></name><name><surname>Dasgupta</surname><given-names>S.</given-names></name><name><surname>Koka</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Wood</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>39312</fpage>–<lpage>39319</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M205107200</pub-id><pub-id pub-id-type="pmid">12167619</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Hingtgen</surname><given-names>C. M.</given-names></name><name><surname>Bu</surname><given-names>G.</given-names></name><name><surname>Laribee</surname><given-names>N.</given-names></name><name><surname>Tanzi</surname><given-names>R. E.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands</article-title>. <source/>Nat. Med.
<volume>6</volume>, <fpage>1380</fpage>–<lpage>1387</lpage>. <pub-id pub-id-type="doi">10.1038/82199</pub-id><pub-id pub-id-type="pmid">11100124</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loftis</surname><given-names>J. M.</given-names></name><name><surname>Janowsky</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Neuroimmune basis of methamphetamine toxicity</article-title>. <source/>Int. Rev. Neurobiol.
<volume>118</volume>, <fpage>165</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-801284-0.00007-5</pub-id><pub-id pub-id-type="pmid">25175865</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>HIV protease inhibitors: a review of molecular selectivity and toxicity</article-title>. <source/>HIV AIDS (Auckl)
<volume>7</volume>, <fpage>95</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.2147/hiv.s79956</pub-id><pub-id pub-id-type="pmid">25897264</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Ramakrishnan</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2014a</year>). <article-title>Methamphetamine induces autophagy as a pro-survival response against apoptotic endothelial cell death through the Kappa opioid receptor</article-title>. <source/>Cell Death Dis.
<volume>5</volume>, <fpage>e1099</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2014.64</pub-id><pub-id pub-id-type="pmid">24603327</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Niu</surname><given-names>F.</given-names></name><name><surname>Buch</surname><given-names>S.</given-names></name></person-group> (<year>2014b</year>). <article-title>HIV Tat-mediated induction of human brain microvascular endothelial cell apoptosis involves endoplasmic reticulum stress and mitochondrial dysfunction</article-title>. <source/>Mol. Neurobiol.
<pub-id pub-id-type="doi">10.1007/s12035-014-8991-3</pub-id>
<comment>[Epub ahead of print].</comment><pub-id pub-id-type="pmid">25409632</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabrouk</surname><given-names>K.</given-names></name><name><surname>Van Rietschoten</surname><given-names>J.</given-names></name><name><surname>Vives</surname><given-names>E.</given-names></name><name><surname>Darbon</surname><given-names>H.</given-names></name><name><surname>Rochat</surname><given-names>H.</given-names></name><name><surname>Sabatier</surname><given-names>J. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Lethal neurotoxicity in mice of the basic domains of HIV and SIV Rev proteins. Study of these regions by circular dichroism</article-title>. <source/>FEBS Lett.
<volume>289</volume>, <fpage>13</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">1894002</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>M. D.</given-names></name><name><surname>Reiter</surname><given-names>R. J.</given-names></name><name><surname>Perez-San-Gregorio</surname><given-names>M. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Melatonin as a potential therapeutic agent in psychiatric illness</article-title>. <source/>Hum. Psychopharmacol.
<volume>24</volume>, <fpage>391</fpage>–<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1002/hup.1032</pub-id><pub-id pub-id-type="pmid">19551767</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maragos</surname><given-names>W. F.</given-names></name><name><surname>Young</surname><given-names>K. L.</given-names></name><name><surname>Turchan</surname><given-names>J. T.</given-names></name><name><surname>Guseva</surname><given-names>M.</given-names></name><name><surname>Pauly</surname><given-names>J. R.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function</article-title>. <source/>J. Neurochem.
<volume>83</volume>, <fpage>955</fpage>–<lpage>963</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01212.x</pub-id><pub-id pub-id-type="pmid">12421368</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcondes</surname><given-names>M. C.</given-names></name><name><surname>Flynn</surname><given-names>C.</given-names></name><name><surname>Watry</surname><given-names>D. D.</given-names></name><name><surname>Zandonatti</surname><given-names>M.</given-names></name><name><surname>Fox</surname><given-names>H. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys</article-title>. <source/>Am. J. Pathol.
<volume>177</volume>, <fpage>355</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2010.090953</pub-id><pub-id pub-id-type="pmid">20489154</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>K. A.</given-names></name><name><surname>Soghomonian</surname><given-names>J. J.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>2004</year>). <article-title>High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity</article-title>. <source/>J. Neurosci.
<volume>24</volume>, <fpage>11449</fpage>–<lpage>11456</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.3597-04.2004</pub-id><pub-id pub-id-type="pmid">15601951</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marker</surname><given-names>D. F.</given-names></name><name><surname>Puccini</surname><given-names>J. M.</given-names></name><name><surname>Mockus</surname><given-names>T. E.</given-names></name><name><surname>Barbieri</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>S. M.</given-names></name><name><surname>Gelbard</surname><given-names>H. A.</given-names></name></person-group> (<year>2012</year>). <article-title>LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein</article-title>. <source/>J. Neuroinflamm.
<volume>9</volume>, <fpage>261</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-9-261</pub-id><pub-id pub-id-type="pmid">23190742</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>T.</given-names></name><name><surname>Burgoyne</surname><given-names>T.</given-names></name><name><surname>Kenny</surname><given-names>B. A.</given-names></name><name><surname>Hudson</surname><given-names>N.</given-names></name><name><surname>Futter</surname><given-names>C. E.</given-names></name><name><surname>Ambrosio</surname><given-names>A. F.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Methamphetamine-induced nitric oxide promotes vesicular transport in blood-brain barrier endothelial cells</article-title>. <source/>Neuropharmacology
<volume>65</volume>, <fpage>74</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.08.021</pub-id><pub-id pub-id-type="pmid">22960442</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Targeting sigma receptors: novel medication development for drug abuse and addiction</article-title>. <source/>Expert. Rev. Clin. Pharmacol.
<volume>2</volume>, <fpage>351</fpage>–<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1586/ecp.09.18</pub-id><pub-id pub-id-type="pmid">22112179</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name><name><surname>Nguyen</surname><given-names>L.</given-names></name><name><surname>Kaushal</surname><given-names>N.</given-names></name><name><surname>Robson</surname><given-names>M. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Sigma (sigma) receptors as potential therapeutic targets to mitigate psychostimulant effects</article-title>. <source/>Adv. Pharmacol.
<volume>69</volume>, <fpage>323</fpage>–<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-420118-7.00009-3</pub-id><pub-id pub-id-type="pmid">24484982</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mediouni</surname><given-names>S.</given-names></name><name><surname>Darque</surname><given-names>A.</given-names></name><name><surname>Baillat</surname><given-names>G.</given-names></name><name><surname>Ravaux</surname><given-names>I.</given-names></name><name><surname>Dhiver</surname><given-names>C.</given-names></name><name><surname>Tissot-Dupont</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein</article-title>. <source/>Infect. Disord. Drug. Targets
<volume>12</volume>, <fpage>81</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.2174/187152612798994939</pub-id><pub-id pub-id-type="pmid">22280310</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mediouni</surname><given-names>S.</given-names></name><name><surname>Jablonski</surname><given-names>J.</given-names></name><name><surname>Paris</surname><given-names>J. J.</given-names></name><name><surname>Clementz</surname><given-names>M. A.</given-names></name><name><surname>Thenin-Houssier</surname><given-names>S.</given-names></name><name><surname>Mclaughlin</surname><given-names>J. P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Didehydro-cortistatin a inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in tat transgenic mice</article-title>. <source/>Curr. HIV Res.
<volume>13</volume>, <fpage>64</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.2174/1570162X13666150121111548</pub-id><pub-id pub-id-type="pmid">25613133</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>J. E.</given-names></name><name><surname>Koyanagi</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>I. S.</given-names></name></person-group> (<year>1989</year>). <article-title>Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor</article-title>. <source/>J. Virol.
<volume>63</volume>, <fpage>4404</fpage>–<lpage>4408</lpage>.<pub-id pub-id-type="pmid">2789293</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>L. M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yeung</surname><given-names>M.</given-names></name><name><surname>Patry</surname><given-names>D. G.</given-names></name><name><surname>Bell</surname><given-names>R. B.</given-names></name><name><surname>Stoian</surname><given-names>C. A.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis</article-title>. <source/>Ann. Neurol.
<volume>55</volume>, <fpage>756</fpage>. <pub-id pub-id-type="doi">10.1002/ana.20111</pub-id><pub-id pub-id-type="pmid">15122721</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midde</surname><given-names>N. M.</given-names></name><name><surname>Gomez</surname><given-names>A. M.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>7</volume>, <fpage>629</fpage>–<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9369-9</pub-id><pub-id pub-id-type="pmid">22570010</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midde</surname><given-names>N. M.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Gomez</surname><given-names>A. M.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name><name><surname>Zhan</surname><given-names>C. G.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>8</volume>, <fpage>975</fpage>–<lpage>987</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-013-9464-6</pub-id><pub-id pub-id-type="pmid">23645138</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milani</surname><given-names>D.</given-names></name><name><surname>Mazzoni</surname><given-names>M.</given-names></name><name><surname>Borgatti</surname><given-names>P.</given-names></name><name><surname>Zauli</surname><given-names>G.</given-names></name><name><surname>Cantley</surname><given-names>L.</given-names></name><name><surname>Capitani</surname><given-names>S.</given-names></name></person-group> (<year>1996</year>). <article-title>Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells</article-title>. <source/>J. Biol. Chem.
<volume>271</volume>, <fpage>22961</fpage>–<lpage>22964</lpage>.<pub-id pub-id-type="pmid">8798481</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>D. S.</given-names></name><name><surname>Bauer</surname><given-names>B.</given-names></name><name><surname>Hartz</surname><given-names>A. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy</article-title>. <source/>Pharmacol. Rev.
<volume>60</volume>, <fpage>196</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1124/pr.107.07109</pub-id><pub-id pub-id-type="pmid">18560012</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>M.</given-names></name><name><surname>Vetrivel</surname><given-names>S.</given-names></name><name><surname>Siddappa</surname><given-names>N. B.</given-names></name><name><surname>Ranga</surname><given-names>U.</given-names></name><name><surname>Seth</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif</article-title>. <source/>Ann. Neurol.
<volume>63</volume>, <fpage>366</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21292</pub-id><pub-id pub-id-type="pmid">18074388</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>I.</given-names></name><name><surname>Asanuma</surname><given-names>M.</given-names></name><name><surname>Kikkawa</surname><given-names>Y.</given-names></name><name><surname>Takeshima</surname><given-names>M.</given-names></name><name><surname>Murakami</surname><given-names>S.</given-names></name><name><surname>Miyoshi</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity</article-title>. <source/>Glia
<volume>59</volume>, <fpage>435</fpage>–<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1002/glia.21112</pub-id><pub-id pub-id-type="pmid">21264950</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizoguchi</surname><given-names>H.</given-names></name><name><surname>Takuma</surname><given-names>K.</given-names></name><name><surname>Fukakusa</surname><given-names>A.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name><name><surname>Nakatani</surname><given-names>A.</given-names></name><name><surname>Ibi</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice</article-title>. <source/>Psychopharmacology (Berl.)
<volume>196</volume>, <fpage>233</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-007-0955-0</pub-id><pub-id pub-id-type="pmid">17909751</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>T.</given-names></name><name><surname>Kurotani</surname><given-names>T.</given-names></name><name><surname>Komatsu</surname><given-names>Y.</given-names></name><name><surname>Kawanokuchi</surname><given-names>J.</given-names></name><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Mitsuma</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia</article-title>. <source/>Neuropharmacology
<volume>46</volume>, <fpage>404</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2003.09.009</pub-id><pub-id pub-id-type="pmid">14975696</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>L. M.</given-names></name><name><surname>Aksenov</surname><given-names>M. Y.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name><name><surname>Webb</surname><given-names>K. M.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge</article-title>. <source/>Curr. HIV Res.
<volume>10</volume>, <fpage>415</fpage>–<lpage>424</lpage>. <pub-id pub-id-type="doi">10.2174/157016212802138788</pub-id><pub-id pub-id-type="pmid">22591365</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousseau</surname><given-names>G.</given-names></name><name><surname>Clementz</surname><given-names>M. A.</given-names></name><name><surname>Bakeman</surname><given-names>W. N.</given-names></name><name><surname>Nagarsheth</surname><given-names>N.</given-names></name><name><surname>Cameron</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription</article-title>. <source/>Cell Host Microbe
<volume>12</volume>, <fpage>97</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2012.05.016</pub-id><pub-id pub-id-type="pmid">22817991</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousseau</surname><given-names>G.</given-names></name><name><surname>Mediouni</surname><given-names>S.</given-names></name><name><surname>Valente</surname><given-names>S. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Targeting HIV transcription: the quest for a functional cure</article-title>. <source/>Curr. Top. Microbiol. Immunol.
<volume>389</volume>, <fpage>121</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1007/82_2015_435</pub-id><pub-id pub-id-type="pmid">25731772</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynagh</surname><given-names>P. N.</given-names></name></person-group> (<year>2005</year>). <article-title>The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain</article-title>. <source/>J. Anat.
<volume>207</volume>, <fpage>265</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-7580.2005.00445.x</pub-id><pub-id pub-id-type="pmid">16185251</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>M. P.</given-names></name><name><surname>Saiyed</surname><given-names>Z. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Effect of methamphetamine on expression of HIV coreceptors and CC-chemokines by dendritic cells</article-title>. <source/>Life Sci.
<volume>88</volume>, <fpage>987</fpage>–<lpage>994</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2010.09.019</pub-id><pub-id pub-id-type="pmid">20932494</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>S.</given-names></name><name><surname>Castro</surname><given-names>V.</given-names></name><name><surname>Toborek</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Infection of human pericytes by HIV-1 disrupts the integrity of the blood-brain barrier</article-title>. <source/>J. Cell Mol. Med.
<volume>16</volume>, <fpage>2950</fpage>–<lpage>2957</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2012.01622.x</pub-id><pub-id pub-id-type="pmid">22947176</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>E. J.</given-names></name><name><surname>Shin</surname><given-names>S. W.</given-names></name><name><surname>Lim</surname><given-names>Y. K.</given-names></name><name><surname>Jung</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>YY162 prevents ADHD-like behavioral side effects and cytotoxicity induced by Aroclor1254 via interactive signaling between antioxidant potential, BDNF/TrkB, DAT and NET</article-title>. <source/>Food Chem. Toxicol.
<volume>65</volume>, <fpage>280</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2013.12.046</pub-id><pub-id pub-id-type="pmid">24394491</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>J. F.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>1992</year>). <article-title>Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine</article-title>. <source/>Brain Res.
<volume>581</volume>, <fpage>237</fpage>–<lpage>243</lpage>.<pub-id pub-id-type="pmid">1356579</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Conant</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Scott</surname><given-names>C.</given-names></name><name><surname>Major</surname><given-names>E. O.</given-names></name></person-group> (<year>1999</year>). <article-title>Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>17098</fpage>–<lpage>17102</lpage>.<pub-id pub-id-type="pmid">10358063</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name><name><surname>Avison</surname><given-names>M. J.</given-names></name><name><surname>Schmitt</surname><given-names>F. A.</given-names></name><name><surname>Berger</surname><given-names>J. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Acceleration of HIV dementia with methamphetamine and cocaine</article-title>. <source/>J. Neurovirol.
<volume>7</volume>, <fpage>66</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1080/135502801300069737</pub-id><pub-id pub-id-type="pmid">11519485</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Synaptodendritic injury with HIV-Tat protein: what is the therapeutic target?</article-title>
<source/>Exp. Neurol.
<volume>251</volume>, <fpage>112</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2013.11.004</pub-id><pub-id pub-id-type="pmid">24246278</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>T. F.</given-names></name><name><surname>Reid</surname><given-names>M. S.</given-names></name><name><surname>De La Garza</surname><given-names>R.</given-names></name><name><surname>Mahoney</surname><given-names>J. J.</given-names></name><name><surname>Abad</surname><given-names>A.</given-names></name><name><surname>Condos</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>11</volume>, <fpage>1037</fpage>–<lpage>1045</lpage>. <pub-id pub-id-type="doi">10.1017/s1461145708009097</pub-id><pub-id pub-id-type="pmid">18664303</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>E. C.</given-names></name><name><surname>Mccracken</surname><given-names>K. A.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pouw</surname><given-names>B.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies</article-title>. <source/>Neuropharmacology
<volume>49</volume>, <fpage>638</fpage>–<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.04.016</pub-id><pub-id pub-id-type="pmid">15939443</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>J. P.</given-names></name><name><surname>Perry</surname><given-names>S. W.</given-names></name><name><surname>Kasischke</surname><given-names>K. A.</given-names></name><name><surname>Volsky</surname><given-names>D. J.</given-names></name><name><surname>Gelbard</surname><given-names>H. A.</given-names></name></person-group> (<year>2007</year>). <article-title>HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons</article-title>. <source/>J. Immunol.
<volume>178</volume>, <fpage>869</fpage>–<lpage>876</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.2.869</pub-id><pub-id pub-id-type="pmid">17202348</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northrop</surname><given-names>N. A.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Methamphetamine effects on blood-brain barrier structure and function</article-title>. <source/>Front. Neurosci
<volume>9</volume>:<fpage>69</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2015.00069</pub-id><pub-id pub-id-type="pmid">25788874</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuovo</surname><given-names>G. J.</given-names></name><name><surname>Alfieri</surname><given-names>M. L.</given-names></name></person-group> (<year>1996</year>). <article-title>AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines</article-title>. <source/>Mol. Med.
<volume>2</volume>, <fpage>358</fpage>–<lpage>366</lpage>.<pub-id pub-id-type="pmid">8784788</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>D. J.</given-names></name><name><surname>Lingford-Hughes</surname><given-names>A.</given-names></name><name><surname>Erritzoe</surname><given-names>D.</given-names></name><name><surname>Stokes</surname><given-names>P. R.</given-names></name></person-group> (<year>2015</year>). <article-title>The dopamine theory of addiction: 40 years of highs and lows</article-title>. <source/>Nat. Rev. Neurosci.
<volume>16</volume>, <fpage>305</fpage>–<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3939</pub-id><pub-id pub-id-type="pmid">25873042</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>E.</given-names></name><name><surname>Urrutia</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>A. R.</given-names></name><name><surname>Colado</surname><given-names>M. I.</given-names></name></person-group> (<year>2014</year>). <article-title>Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine</article-title>. <source/>Neuropharmacology
<volume>87</volume>, <fpage>125</fpage>–<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.02.015</pub-id><pub-id pub-id-type="pmid">24594477</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>A.</given-names></name><name><surname>Khoo</surname><given-names>S. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Intracellular pharmacokinetics of antiretroviral agents</article-title>. <source/>J. HIV Ther.
<volume>9</volume>, <fpage>97</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">15731742</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panee</surname><given-names>J.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Munsaka</surname><given-names>S.</given-names></name><name><surname>Berry</surname><given-names>M. J.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Independent and co-morbid HIV infection and Meth use disorders on oxidative stress markers in the cerebrospinal fluid and depressive symptoms</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>10</volume>, <fpage>111</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-014-9581-x</pub-id><pub-id pub-id-type="pmid">25575491</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>C. A.</given-names></name><name><surname>Mcarthur</surname><given-names>J. C.</given-names></name><name><surname>Griffin</surname><given-names>J. W.</given-names></name></person-group> (<year>2001</year>). <article-title>HIV neuropathy: insights in the pathology of HIV peripheral nerve disease</article-title>. <source/>J. Peripher. Nerv. Syst.
<volume>6</volume>, <fpage>21</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1046/j.1529-8027.2001.006001021.x</pub-id><pub-id pub-id-type="pmid">11293804</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peloponese</surname><given-names>J. M.</given-names><suffix>Jr.</suffix></name><name><surname>Gregoire</surname><given-names>C.</given-names></name><name><surname>Opi</surname><given-names>S.</given-names></name><name><surname>Esquieu</surname><given-names>D.</given-names></name><name><surname>Sturgis</surname><given-names>J.</given-names></name><name><surname>Lebrun</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein</article-title>. <source/>C. R. Acad. Sci.
<volume>323</volume>, <fpage>883</fpage>–<lpage>894</lpage>. <pub-id pub-id-type="doi">10.1016/S0764-4469(00)01228-2</pub-id><pub-id pub-id-type="pmid">11098404</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>S. W.</given-names></name><name><surname>Barbieri</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>N.</given-names></name><name><surname>Polesskaya</surname><given-names>O.</given-names></name><name><surname>Pudasaini</surname><given-names>S.</given-names></name><name><surname>Stout</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax</article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>14153</fpage>–<lpage>14164</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1042-10.2010</pub-id><pub-id pub-id-type="pmid">20962236</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippon</surname><given-names>V.</given-names></name><name><surname>Vellutini</surname><given-names>C.</given-names></name><name><surname>Gambarelli</surname><given-names>D.</given-names></name><name><surname>Harkiss</surname><given-names>G.</given-names></name><name><surname>Arbuthnott</surname><given-names>G.</given-names></name><name><surname>Metzger</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>1994</year>). <article-title>The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: involvement of cytokines</article-title>. <source/>Virology
<volume>205</volume>, <fpage>519</fpage>–<lpage>529</lpage>. <pub-id pub-id-type="doi">10.1006/viro.1994.1673</pub-id><pub-id pub-id-type="pmid">7526541</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitaksalee</surname><given-names>R.</given-names></name><name><surname>Sanvarinda</surname><given-names>Y.</given-names></name><name><surname>Sinchai</surname><given-names>T.</given-names></name><name><surname>Sanvarinda</surname><given-names>P.</given-names></name><name><surname>Thampithak</surname><given-names>A.</given-names></name><name><surname>Jantaratnotai</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Autophagy inhibition by caffeine increases toxicity of methamphetamine in SH-SY5Y neuroblastoma cell line</article-title>. <source/>Neurotox. Res.
<volume>27</volume>, <fpage>421</fpage>–<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-014-9513-9</pub-id><pub-id pub-id-type="pmid">25588864</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocernich</surname><given-names>C. B.</given-names></name><name><surname>Sultana</surname><given-names>R.</given-names></name><name><surname>Hone</surname><given-names>E.</given-names></name><name><surname>Turchan</surname><given-names>J.</given-names></name><name><surname>Martins</surname><given-names>R. N.</given-names></name><name><surname>Calabrese</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Effects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes</article-title>. <source/>J. Neurosci. Res.
<volume>77</volume>, <fpage>532</fpage>–<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.20182</pub-id><pub-id pub-id-type="pmid">15264223</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocernich</surname><given-names>C. B.</given-names></name><name><surname>Sultana</surname><given-names>R.</given-names></name><name><surname>Mohmmad-Abdul</surname><given-names>H.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Butterfield</surname><given-names>D. A.</given-names></name></person-group> (<year>2005</year>). <article-title>HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations</article-title>. <source/>Brain Res. Brain Res. Rev.
<volume>50</volume>, <fpage>14</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2005.04.002</pub-id><pub-id pub-id-type="pmid">15890409</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potula</surname><given-names>R.</given-names></name><name><surname>Persidsky</surname><given-names>Y.</given-names></name></person-group> (<year>2008</year>). <article-title>Adding fuel to the fire: methamphetamine enhances HIV infection</article-title>. <source/>Am. J. Pathol.
<volume>172</volume>, <fpage>1467</fpage>–<lpage>1470</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2008.080130</pub-id><pub-id pub-id-type="pmid">18458093</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourroy</surname><given-names>B.</given-names></name><name><surname>Carre</surname><given-names>M.</given-names></name><name><surname>Honore</surname><given-names>S.</given-names></name><name><surname>Bourgarel-Rey</surname><given-names>V.</given-names></name><name><surname>Kruczynski</surname><given-names>A.</given-names></name><name><surname>Briand</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway</article-title>. <source/>Mol. Pharmacol.
<volume>66</volume>, <fpage>580</fpage>–<lpage>591</lpage>.<pub-id pub-id-type="pmid">15322250</pub-id></mixed-citation>
</ref>
<ref id="B236">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prendergast</surname><given-names>M. A.</given-names></name><name><surname>Rogers</surname><given-names>D. T.</given-names></name><name><surname>Mulholland</surname><given-names>P. J.</given-names></name><name><surname>Littleton</surname><given-names>J. M.</given-names></name><name><surname>Wilkins</surname><given-names>L. H.</given-names><suffix>Jr.</suffix></name><name><surname>Self</surname><given-names>R. L.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the <italic>N</italic>-methyl-D-aspartate receptor</article-title>. <source/>Brain Res.
<volume>954</volume>, <fpage>300</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(02)03360-7</pub-id><pub-id pub-id-type="pmid">12414113</pub-id></mixed-citation>
</ref>
<ref id="B237">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>H.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Andras</surname><given-names>I. E.</given-names></name><name><surname>Eum</surname><given-names>S. Y.</given-names></name><name><surname>Hennig</surname><given-names>B.</given-names></name><name><surname>Toborek</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier</article-title>. <source/>Brain Res.
<volume>1184</volume>, <fpage>333</fpage>–<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2007.09.063</pub-id><pub-id pub-id-type="pmid">17976544</pub-id></mixed-citation>
</ref>
<ref id="B238">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puccini</surname><given-names>J. M.</given-names></name><name><surname>Marker</surname><given-names>D. F.</given-names></name><name><surname>Fitzgerald</surname><given-names>T.</given-names></name><name><surname>Barbieri</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>C. S.</given-names></name><name><surname>Miller-Rhodes</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders</article-title>. <source/>J. Neurosci.
<volume>35</volume>, <fpage>5271</fpage>–<lpage>5283</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.0650-14.2015</pub-id><pub-id pub-id-type="pmid">25834052</pub-id></mixed-citation>
</ref>
<ref id="B239">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>V.</given-names></name><name><surname>Rapaka</surname><given-names>R.</given-names></name><name><surname>Frankenheim</surname><given-names>J.</given-names></name><name><surname>Avila</surname><given-names>A.</given-names></name><name><surname>Sorensen</surname><given-names>R.</given-names></name><name><surname>Rutter</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>National Institute on Drug Abuse symposium report: drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia</article-title>. <source/>J. Neurovirol.
<volume>19</volume>, <fpage>119</fpage>–<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1007/s13365-013-0153-2</pub-id><pub-id pub-id-type="pmid">23456951</pub-id></mixed-citation>
</ref>
<ref id="B240">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>V.</given-names></name><name><surname>Rapaka</surname><given-names>R.</given-names></name><name><surname>Shurtleff</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia</article-title>. <source/>Mol. Neurobiol.
<volume>44</volume>, <fpage>102</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-011-8195-z</pub-id><pub-id pub-id-type="pmid">21717292</pub-id></mixed-citation>
</ref>
<ref id="B241">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L.</given-names></name><name><surname>Gang</surname><given-names>L.</given-names></name><name><surname>Hang</surname><given-names>K. W.</given-names></name><name><surname>Ling</surname><given-names>C. H.</given-names></name><name><surname>Xiaofeng</surname><given-names>Z.</given-names></name><name><surname>Zhen</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Programmed neuronal cell death induced by HIV-1 tat and methamphetamine</article-title>. <source/>Microsc. Res. Tech.
<volume>74</volume>, <fpage>1139</fpage>–<lpage>1144</lpage>. <pub-id pub-id-type="doi">10.1002/jemt.21006</pub-id><pub-id pub-id-type="pmid">21563266</pub-id></mixed-citation>
</ref>
<ref id="B242">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahn</surname><given-names>K. A.</given-names></name><name><surname>Slusher</surname><given-names>B. S.</given-names></name><name><surname>Kaplin</surname><given-names>A. I.</given-names></name></person-group> (<year>2012</year>). <article-title>Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition</article-title>. <source/>Curr. Med. Chem.
<volume>19</volume>, <fpage>1335</fpage>–<lpage>1345</lpage>. <pub-id pub-id-type="doi">10.2174/092986712799462649</pub-id><pub-id pub-id-type="pmid">22304712</pub-id></mixed-citation>
</ref>
<ref id="B243">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>S. H.</given-names></name><name><surname>Potula</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Eidem</surname><given-names>T.</given-names></name><name><surname>Papugani</surname><given-names>A.</given-names></name><name><surname>Reichenbach</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells</article-title>. <source/>J. Cereb. Blood Flow Metab.
<volume>29</volume>, <fpage>1933</fpage>–<lpage>1945</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2009.112</pub-id><pub-id pub-id-type="pmid">19654589</pub-id></mixed-citation>
</ref>
<ref id="B244">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>V. R.</given-names></name><name><surname>Sas</surname><given-names>A. R.</given-names></name><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>Siddappa</surname><given-names>N. B.</given-names></name><name><surname>Bimonte-Nelson</surname><given-names>H.</given-names></name><name><surname>Berman</surname><given-names>J. W.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>HIV-1 clade-specific differences in the induction of neuropathogenesis</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>10010</fpage>–<lpage>10016</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.2955-08.2008</pub-id><pub-id pub-id-type="pmid">18829958</pub-id></mixed-citation>
</ref>
<ref id="B245">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappaport</surname><given-names>J.</given-names></name><name><surname>Joseph</surname><given-names>J.</given-names></name><name><surname>Croul</surname><given-names>S.</given-names></name><name><surname>Alexander</surname><given-names>G.</given-names></name><name><surname>Del Valle</surname><given-names>L.</given-names></name><name><surname>Amini</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat</article-title>. <source/>J. Leukoc. Biol.
<volume>65</volume>, <fpage>458</fpage>–<lpage>465</lpage>.<pub-id pub-id-type="pmid">10204574</pub-id></mixed-citation>
</ref>
<ref id="B246">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rau</surname><given-names>T. F.</given-names></name><name><surname>Kothiwal</surname><given-names>A. S.</given-names></name><name><surname>Rova</surname><given-names>A. R.</given-names></name><name><surname>Brooks</surname><given-names>D. M.</given-names></name><name><surname>Poulsen</surname><given-names>D. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Treatment with low-dose methamphetamine improves behavioral and cognitive function after severe traumatic brain injury</article-title>. <source/>J. Trauma. Acute Care Surg
<volume>73</volume>, <fpage>S165</fpage>–<lpage>S172</lpage>. <pub-id pub-id-type="doi">10.1097/TA.0b013e318260896a</pub-id><pub-id pub-id-type="pmid">22847088</pub-id></mixed-citation>
</ref>
<ref id="B247">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>L. A.</given-names></name><name><surname>Bujarski</surname><given-names>S.</given-names></name><name><surname>Courtney</surname><given-names>K. E.</given-names></name><name><surname>Moallem</surname><given-names>N. R.</given-names></name><name><surname>Lunny</surname><given-names>K.</given-names></name><name><surname>Roche</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study</article-title>. <source/>Neuropsychopharmacology
<volume>40</volume>, <fpage>2347</fpage>–<lpage>2356</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.83</pub-id><pub-id pub-id-type="pmid">25801501</pub-id></mixed-citation>
</ref>
<ref id="B248">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>J. L.</given-names></name><name><surname>Mahajan</surname><given-names>S. D.</given-names></name><name><surname>Sykes</surname><given-names>D. E.</given-names></name><name><surname>Schwartz</surname><given-names>S. A.</given-names></name><name><surname>Nair</surname><given-names>M. P.</given-names></name></person-group> (<year>2007</year>). <article-title>Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC)</article-title>. <source/>Biochim. Biophys. Acta
<volume>1774</volume>, <fpage>433</fpage>–<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2007.02.001</pub-id><pub-id pub-id-type="pmid">17363347</pub-id></mixed-citation>
</ref>
<ref id="B249">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>A.</given-names></name><name><surname>Amenta</surname><given-names>F.</given-names></name></person-group> (<year>1994</year>). <article-title>Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study</article-title>. <source/>J. Neuroimmunol.
<volume>53</volume>, <fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">8051291</pub-id></mixed-citation>
</ref>
<ref id="B250">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>A.</given-names></name><name><surname>Bronzetti</surname><given-names>E.</given-names></name><name><surname>Felici</surname><given-names>L.</given-names></name><name><surname>Greco</surname><given-names>S.</given-names></name><name><surname>Amenta</surname><given-names>F.</given-names></name></person-group> (<year>1998</year>). <article-title>Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study</article-title>. <source/>J. Neuroimmunol.
<volume>92</volume>, <fpage>191</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">9916894</pub-id></mixed-citation>
</ref>
<ref id="B251">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>A.</given-names></name><name><surname>Bronzetti</surname><given-names>E.</given-names></name><name><surname>Felici</surname><given-names>L.</given-names></name><name><surname>Tayebati</surname><given-names>S. K.</given-names></name><name><surname>Amenta</surname><given-names>F.</given-names></name></person-group> (<year>1997</year>). <article-title>Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study</article-title>. <source/>Neurosci. Lett.
<volume>229</volume>, <fpage>130</fpage>–<lpage>134</lpage>.<pub-id pub-id-type="pmid">9223608</pub-id></mixed-citation>
</ref>
<ref id="B252">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>A.</given-names></name><name><surname>Bronzetti</surname><given-names>E.</given-names></name><name><surname>Mignini</surname><given-names>F.</given-names></name><name><surname>Tayebati</surname><given-names>S. K.</given-names></name><name><surname>Zaccheo</surname><given-names>D.</given-names></name><name><surname>Amenta</surname><given-names>F.</given-names></name></person-group> (<year>1999</year>). <article-title>Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes</article-title>. <source/>J. Neuroimmunol.
<volume>96</volume>, <fpage>234</fpage>–<lpage>240</lpage>.<pub-id pub-id-type="pmid">10337922</pub-id></mixed-citation>
</ref>
<ref id="B253">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>M. J.</given-names></name><name><surname>Guiraud</surname><given-names>P.</given-names></name><name><surname>Didier</surname><given-names>C.</given-names></name><name><surname>Seve</surname><given-names>M.</given-names></name><name><surname>Flores</surname><given-names>S. C.</given-names></name><name><surname>Favier</surname><given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Human immunodeficiency virus type 1 Tat protein impairs selenoglutathione peroxidase expression and activity by a mechanism independent of cellular selenium uptake: consequences on cellular resistance to UV-A radiation</article-title>. <source/>Arch. Biochem. Biophys.
<volume>386</volume>, <fpage>213</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1006/abbi.2000.2197</pub-id><pub-id pub-id-type="pmid">11368344</pub-id></mixed-citation>
</ref>
<ref id="B254">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddle</surname><given-names>E. L.</given-names></name><name><surname>Fleckenstein</surname><given-names>A. E.</given-names></name><name><surname>Hanson</surname><given-names>G. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Mechanisms of methamphetamine-induced dopaminergic neurotoxicity</article-title>. <source/>AAPS J.
<volume>8</volume>, <fpage>E413</fpage>–<lpage>E418</lpage>. <pub-id pub-id-type="doi">10.1007/BF02854914</pub-id><pub-id pub-id-type="pmid">16808044</pub-id></mixed-citation>
</ref>
<ref id="B255">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Noorbakhsh</surname><given-names>B.</given-names></name><name><surname>Seminerio</surname><given-names>M. J.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Sigma-1 receptors: potential targets for the treatment of substance abuse</article-title>. <source/>Curr. Pharm. Des.
<volume>18</volume>, <fpage>902</fpage>–<lpage>919</lpage>. <pub-id pub-id-type="doi">10.2174/138161212799436601</pub-id><pub-id pub-id-type="pmid">22288407</pub-id></mixed-citation>
</ref>
<ref id="B256">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Turner</surname><given-names>R. C.</given-names></name><name><surname>Naser</surname><given-names>Z. J.</given-names></name><name><surname>Mccurdy</surname><given-names>C. R.</given-names></name><name><surname>Huber</surname><given-names>J. D.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2013</year>). <article-title>SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation</article-title>. <source/>Exp. Neurol.
<volume>247</volume>, <fpage>134</fpage>–<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2013.04.009</pub-id><pub-id pub-id-type="pmid">23631864</pub-id></mixed-citation>
</ref>
<ref id="B257">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Turner</surname><given-names>R. C.</given-names></name><name><surname>Naser</surname><given-names>Z. J.</given-names></name><name><surname>Mccurdy</surname><given-names>C. R.</given-names></name><name><surname>O’callaghan</surname><given-names>J. P.</given-names></name><name><surname>Huber</surname><given-names>J. D.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation</article-title>. <source/>Exp. Neurol.
<volume>254</volume>, <fpage>180</fpage>–<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2014.01.020</pub-id><pub-id pub-id-type="pmid">24508558</pub-id></mixed-citation>
</ref>
<ref id="B258">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohr</surname><given-names>O.</given-names></name><name><surname>Sawaya</surname><given-names>B. E.</given-names></name><name><surname>Lecestre</surname><given-names>D.</given-names></name><name><surname>Aunis</surname><given-names>D.</given-names></name><name><surname>Schaeffer</surname><given-names>E.</given-names></name></person-group> (<year>1999a</year>). <article-title>Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system</article-title>. <source/>Nucleic Acids Res.
<volume>27</volume>, <fpage>3291</fpage>–<lpage>3299</lpage>.<pub-id pub-id-type="pmid">10454636</pub-id></mixed-citation>
</ref>
<ref id="B259">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohr</surname><given-names>O.</given-names></name><name><surname>Schwartz</surname><given-names>C.</given-names></name><name><surname>Aunis</surname><given-names>D.</given-names></name><name><surname>Schaeffer</surname><given-names>E.</given-names></name></person-group> (<year>1999b</year>). <article-title>CREB and COUP-TF mediate transcriptional activation of the human immunodeficiency virus type 1 genome in Jurkat T cells in response to cyclic AMP and dopamine</article-title>. <source/>J. Cell. Biochem.
<volume>75</volume>, <fpage>404</fpage>–<lpage>413</lpage>.<pub-id pub-id-type="pmid">10536364</pub-id></mixed-citation>
</ref>
<ref id="B260">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roshal</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Planelles</surname><given-names>V.</given-names></name></person-group> (<year>2001</year>). <article-title>Apoptosis in AIDS</article-title>. <source/>Apoptosis
<volume>6</volume>, <fpage>103</fpage>–<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1023/A:1009636530839</pub-id><pub-id pub-id-type="pmid">11321033</pub-id></mixed-citation>
</ref>
<ref id="B261">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumbaugh</surname><given-names>J. A.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Rothstein</surname><given-names>J.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Ceftriaxone protects against the neurotoxicity of human immunodeficiency virus proteins</article-title>. <source/>J. Neurovirol.
<volume>13</volume>, <fpage>168</fpage>–<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1080/13550280601178218</pub-id><pub-id pub-id-type="pmid">17505985</pub-id></mixed-citation>
</ref>
<ref id="B262">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumbaugh</surname><given-names>J. A.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Sacktor</surname><given-names>N.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction</article-title>. <source/>Futur HIV Ther.
<volume>2</volume>, <fpage>271</fpage>–<lpage>280</lpage>. <pub-id pub-id-type="doi">10.2217/17469600.2.3.271</pub-id><pub-id pub-id-type="pmid">19774095</pub-id></mixed-citation>
</ref>
<ref id="B263">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>J. M.</given-names></name><name><surname>Vives</surname><given-names>E.</given-names></name><name><surname>Mabrouk</surname><given-names>K.</given-names></name><name><surname>Benjouad</surname><given-names>A.</given-names></name><name><surname>Rochat</surname><given-names>H.</given-names></name><name><surname>Duval</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>1991</year>). <article-title>Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1</article-title>. <source/>J. Virol.
<volume>65</volume>, <fpage>961</fpage>–<lpage>967</lpage>.<pub-id pub-id-type="pmid">1898974</pub-id></mixed-citation>
</ref>
<ref id="B264">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacktor</surname><given-names>N.</given-names></name><name><surname>Miyahara</surname><given-names>S.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Evans</surname><given-names>S.</given-names></name><name><surname>Schifitto</surname><given-names>G.</given-names></name><name><surname>Cohen</surname><given-names>B. A.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial</article-title>. <source/>Neurology
<volume>77</volume>, <fpage>1135</fpage>–<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e31822f0412</pub-id><pub-id pub-id-type="pmid">21900636</pub-id></mixed-citation>
</ref>
<ref id="B265">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacktor</surname><given-names>N.</given-names></name><name><surname>Miyahara</surname><given-names>S.</given-names></name><name><surname>Evans</surname><given-names>S.</given-names></name><name><surname>Schifitto</surname><given-names>G.</given-names></name><name><surname>Cohen</surname><given-names>B.</given-names></name><name><surname>Haughey</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment</article-title>. <source/>J. Neurovirol.
<volume>20</volume>, <fpage>620</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1007/s13365-014-0292-0</pub-id><pub-id pub-id-type="pmid">25377444</pub-id></mixed-citation>
</ref>
<ref id="B266">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>R. N.</given-names></name><name><surname>Pahan</surname><given-names>K.</given-names></name></person-group> (<year>2006a</year>). <article-title>Regulation of inducible nitric oxide synthase gene in glial cells</article-title>. <source/>Antioxid. Redox Signal.
<volume>8</volume>, <fpage>929</fpage>–<lpage>947</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2006.8.929</pub-id><pub-id pub-id-type="pmid">16771683</pub-id></mixed-citation>
</ref>
<ref id="B267">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>R. N.</given-names></name><name><surname>Pahan</surname><given-names>K.</given-names></name></person-group> (<year>2006b</year>). <article-title>Signals for the induction of nitric oxide synthase in astrocytes</article-title>. <source/>Neurochem. Int.
<volume>49</volume>, <fpage>154</fpage>–<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2006.04.007</pub-id><pub-id pub-id-type="pmid">16740341</pub-id></mixed-citation>
</ref>
<ref id="B268">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salamanca</surname><given-names>S. A.</given-names></name><name><surname>Sorrentino</surname><given-names>E. E.</given-names></name><name><surname>Nosanchuk</surname><given-names>J. D.</given-names></name><name><surname>Martinez</surname><given-names>L. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Impact of methamphetamine on infection and immunity</article-title>. <source/>Front. Neurosci.
<volume>8</volume>:<fpage>445</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2014.00445</pub-id><pub-id pub-id-type="pmid">25628526</pub-id></mixed-citation>
</ref>
<ref id="B269">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez Mejia</surname><given-names>R. O.</given-names></name><name><surname>Ona</surname><given-names>V. O.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Friedlander</surname><given-names>R. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction</article-title>. <source/>Neurosurgery
<volume>48</volume>, <fpage>1393</fpage>–<lpage>1399</lpage><comment>; discussion 1399–1401.</comment><pub-id pub-id-type="pmid">11383749</pub-id></mixed-citation>
</ref>
<ref id="B270">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Alavez</surname><given-names>M.</given-names></name><name><surname>Conti</surname><given-names>B.</given-names></name><name><surname>Wood</surname><given-names>M. R.</given-names></name><name><surname>Bortell</surname><given-names>N.</given-names></name><name><surname>Bustamante</surname><given-names>E.</given-names></name><name><surname>Saez</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>ROS and sympathetically mediated mitochondria activation in brown adipose tissue contribute to methamphetamine-induced hyperthermia</article-title>. <source/>Front. Endocrinol. (Lausanne)
<volume>4</volume>:<fpage>44</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2013.00044</pub-id><pub-id pub-id-type="pmid">23630518</pub-id></mixed-citation>
</ref>
<ref id="B271">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Alavez</surname><given-names>M.</given-names></name><name><surname>Bortell</surname><given-names>N.</given-names></name><name><surname>Galmozzi</surname><given-names>A.</given-names></name><name><surname>Conti</surname><given-names>B.</given-names></name><name><surname>Marcondes</surname><given-names>M. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Reactive Oxygen species scavenger N-acetyl cysteine reduces methamphetamine-induced hyperthermia without affecting motor activity in mice</article-title>. <source/>Temperature
<volume>1</volume>, <fpage>227</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.4161/23328940.2014.984556</pub-id><pub-id pub-id-type="pmid">26346736</pub-id></mixed-citation>
</ref>
<ref id="B272">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>M.</given-names></name><name><surname>Eldeen</surname><given-names>M. B.</given-names></name><name><surname>Del Valle</surname><given-names>L.</given-names></name><name><surname>Reiss</surname><given-names>K.</given-names></name><name><surname>Peruzzi</surname><given-names>F.</given-names></name><name><surname>Mameli</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>p73 modulates HIV-1 Tat transcriptional and apoptotic activities in human astrocytes</article-title>. <source/>Apoptosis
<volume>10</volume>, <fpage>1419</fpage>–<lpage>1431</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-005-2467-x</pub-id><pub-id pub-id-type="pmid">16235026</pub-id></mixed-citation>
</ref>
<ref id="B273">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieber</surname><given-names>M.</given-names></name><name><surname>Chandel</surname><given-names>N. S.</given-names></name></person-group> (<year>2014</year>). <article-title>ROS function in redox signaling and oxidative stress</article-title>. <source/>Curr. Biol.
<volume>24</volume>, <fpage>R453</fpage>–<lpage>R462</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2014.03.034</pub-id><pub-id pub-id-type="pmid">24845678</pub-id></mixed-citation>
</ref>
<ref id="B274">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekine</surname><given-names>Y.</given-names></name><name><surname>Ouchi</surname><given-names>Y.</given-names></name><name><surname>Sugihara</surname><given-names>G.</given-names></name><name><surname>Takei</surname><given-names>N.</given-names></name><name><surname>Yoshikawa</surname><given-names>E.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Methamphetamine causes microglial activation in the brains of human abusers</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>5756</fpage>–<lpage>5761</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1179-08.2008</pub-id><pub-id pub-id-type="pmid">18509037</pub-id></mixed-citation>
</ref>
<ref id="B275">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Self</surname><given-names>R. L.</given-names></name><name><surname>Mulholland</surname><given-names>P. J.</given-names></name><name><surname>Harris</surname><given-names>B. R.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Prendergast</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Cytotoxic effects of exposure to the human immunodeficiency virus type 1 protein Tat in the hippocampus are enhanced by prior ethanol treatment</article-title>. <source/>Alcohol. Clin. Exp. Res.
<volume>28</volume>, <fpage>1916</fpage>–<lpage>1924</lpage>. <pub-id pub-id-type="doi">10.1097/01.ALC.0000148108.93782.05</pub-id><pub-id pub-id-type="pmid">15608609</pub-id></mixed-citation>
</ref>
<ref id="B276">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seminerio</surname><given-names>M. J.</given-names></name><name><surname>Robson</surname><given-names>M. J.</given-names></name><name><surname>Mccurdy</surname><given-names>C. R.</given-names></name><name><surname>Matsumoto</surname><given-names>R. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1beta mRNA expression in the hypothalamus</article-title>. <source/>Eur. J. Pharmacol.
<volume>691</volume>, <fpage>103</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2012.07.029</pub-id><pub-id pub-id-type="pmid">22820108</pub-id></mixed-citation>
</ref>
<ref id="B277">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Silverstein</surname><given-names>P. S.</given-names></name><name><surname>Singh</surname><given-names>D. P.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-kappaB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes</article-title>. <source/>J. Neuroinflamm.
<volume>9</volume>, <fpage>52</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-9-52</pub-id><pub-id pub-id-type="pmid">22420994</pub-id></mixed-citation>
</ref>
<ref id="B278">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>X. T.</given-names></name><name><surname>Napier</surname><given-names>T. C.</given-names></name><name><surname>Al-Harthi</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Methamphetamine and HIV-1 Tat down regulate beta-catenin signaling: implications for methampetamine abuse and HIV-1 co-morbidity</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>6</volume>, <fpage>597</fpage>–<lpage>607</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-011-9295-2</pub-id><pub-id pub-id-type="pmid">21744004</pub-id></mixed-citation>
</ref>
<ref id="B279">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>W. S.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Lokensgard</surname><given-names>J. R.</given-names></name><name><surname>Peterson</surname><given-names>P. K.</given-names></name></person-group> (<year>2003</year>). <article-title>U50,488 inhibits HIV-1 Tat-induced monocyte chemoattractant protein-1 (CCL2) production by human astrocytes</article-title>. <source/>Biochem. Pharmacol.
<volume>65</volume>, <fpage>9</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(02)01480-6</pub-id><pub-id pub-id-type="pmid">12473373</pub-id></mixed-citation>
</ref>
<ref id="B280">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>B.</given-names></name><name><surname>Raina</surname><given-names>J.</given-names></name><name><surname>Lorenzo</surname><given-names>A.</given-names></name><name><surname>Busciglio</surname><given-names>J.</given-names></name><name><surname>Gabuzda</surname><given-names>D.</given-names></name></person-group> (<year>1998</year>). <article-title>Neuronal apoptosis induced by HIV-1 Tat protein and TNF-alpha: potentiation of neurotoxicity mediated by oxidative stress and implications for HIV-1 dementia</article-title>. <source/>J. Neurovirol.
<volume>4</volume>, <fpage>281</fpage>–<lpage>290</lpage>.<pub-id pub-id-type="pmid">9639071</pub-id></mixed-citation>
</ref>
<ref id="B281">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>E. J.</given-names></name><name><surname>Shin</surname><given-names>S. W.</given-names></name><name><surname>Nguyen</surname><given-names>T. T.</given-names></name><name><surname>Park</surname><given-names>D. H.</given-names></name><name><surname>Wie</surname><given-names>M. B.</given-names></name><name><surname>Jang</surname><given-names>C. G.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cdelta gene</article-title>. <source/>Mol. Neurobiol.
<volume>49</volume>, <fpage>1400</fpage>–<lpage>1421</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-013-8617-1</pub-id><pub-id pub-id-type="pmid">24430743</pub-id></mixed-citation>
</ref>
<ref id="B282">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvers</surname><given-names>J. M.</given-names></name><name><surname>Aksenova</surname><given-names>M. V.</given-names></name><name><surname>Aksenov</surname><given-names>M. Y.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor</article-title>. <source/>Neurotoxicology
<volume>28</volume>, <fpage>1184</fpage>–<lpage>1190</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2007.07.005</pub-id><pub-id pub-id-type="pmid">17764744</pub-id></mixed-citation>
</ref>
<ref id="B283">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>P. S.</given-names></name><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Gupte</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Piepho</surname><given-names>R. W.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Methamphetamine toxicity and its implications during HIV-1 infection</article-title>. <source/>J. Neurovirol.
<volume>17</volume>, <fpage>401</fpage>–<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1007/s13365-011-0043-4</pub-id><pub-id pub-id-type="pmid">21786077</pub-id></mixed-citation>
</ref>
<ref id="B284">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinchai</surname><given-names>T.</given-names></name><name><surname>Plasen</surname><given-names>S.</given-names></name><name><surname>Sanvarinda</surname><given-names>Y.</given-names></name><name><surname>Jaisin</surname><given-names>Y.</given-names></name><name><surname>Govitrapong</surname><given-names>P.</given-names></name><name><surname>Morales</surname><given-names>N. P.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Caffeine potentiates methamphetamine-induced toxicity both in vitro and in vivo</article-title>. <source/>Neurosci. Lett.
<volume>502</volume>, <fpage>65</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2011.07.026</pub-id><pub-id pub-id-type="pmid">21803121</pub-id></mixed-citation>
</ref>
<ref id="B285">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>Vaira</surname><given-names>D.</given-names></name><name><surname>Amand</surname><given-names>M.</given-names></name><name><surname>Rahmouni</surname><given-names>S.</given-names></name><name><surname>Moutschen</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rgamma(null) mice</article-title>. <source/>Immunology
<volume>142</volume>, <fpage>562</fpage>–<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12246</pub-id><pub-id pub-id-type="pmid">24409837</pub-id></mixed-citation>
</ref>
<ref id="B286">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V. B.</given-names></name><name><surname>Wooten</surname><given-names>A. K.</given-names></name><name><surname>Jackson</surname><given-names>J. W.</given-names></name><name><surname>Maggirwar</surname><given-names>S. B.</given-names></name><name><surname>Kiebala</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Investigating the role of ankyrin-rich membrane spanning protein in human immunodeficiency virus type-1 Tat-induced microglia activation</article-title>. <source/>J. Neurovirol.
<volume>21</volume>, <fpage>186</fpage>–<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1007/s13365-015-0318-2</pub-id><pub-id pub-id-type="pmid">25636783</pub-id></mixed-citation>
</ref>
<ref id="B287">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>D. G.</given-names></name><name><surname>Guillemin</surname><given-names>G. J.</given-names></name><name><surname>Pemberton</surname><given-names>L.</given-names></name><name><surname>Kerr</surname><given-names>S.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Smythe</surname><given-names>G. A.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat</article-title>. <source/>J. Neurovirol.
<volume>7</volume>, <fpage>56</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1080/135502801300069692</pub-id><pub-id pub-id-type="pmid">11519483</pub-id></mixed-citation>
</ref>
<ref id="B288">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>S. E.</given-names></name><name><surname>Hendrick</surname><given-names>E. S.</given-names></name><name><surname>Beardsley</surname><given-names>P. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Glial cell modulators attenuate methamphetamine self-administration in the rat</article-title>. <source/>Eur. J. Pharmacol.
<volume>701</volume>, <fpage>124</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2013.01.016</pub-id><pub-id pub-id-type="pmid">23375937</pub-id></mixed-citation>
</ref>
<ref id="B289">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>S. E.</given-names></name><name><surname>Vunck</surname><given-names>S. A.</given-names></name><name><surname>Van Den Oord</surname><given-names>E. J.</given-names></name><name><surname>Adkins</surname><given-names>D. E.</given-names></name><name><surname>Mcclay</surname><given-names>J. L.</given-names></name><name><surname>Beardsley</surname><given-names>P. M.</given-names></name></person-group> (<year>2012</year>). <article-title>The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice</article-title>. <source/>Eur. J. Pharmacol.
<volume>679</volume>, <fpage>75</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2012.01.013</pub-id><pub-id pub-id-type="pmid">22306241</pub-id></mixed-citation>
</ref>
<ref id="B290">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofuoglu</surname><given-names>M.</given-names></name><name><surname>Mooney</surname><given-names>M.</given-names></name><name><surname>Kosten</surname><given-names>T.</given-names></name><name><surname>Waters</surname><given-names>A.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans</article-title>. <source/>Psychopharmacology (Berl.)
<volume>213</volume>, <fpage>61</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-010-2014-5</pub-id><pub-id pub-id-type="pmid">20838775</pub-id></mixed-citation>
</ref>
<ref id="B291">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solhi</surname><given-names>H.</given-names></name><name><surname>Malekirad</surname><given-names>A.</given-names></name><name><surname>Kazemifar</surname><given-names>A. M.</given-names></name><name><surname>Sharifi</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Oxidative stress and lipid peroxidation in prolonged users of methamphetamine</article-title>. <source/>Drug. Metab. Lett.
<volume>7</volume>, <fpage>79</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">24856264</pub-id></mixed-citation>
</ref>
<ref id="B292">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H. Y.</given-names></name><name><surname>Ju</surname><given-names>S. M.</given-names></name><name><surname>Seo</surname><given-names>W. Y.</given-names></name><name><surname>Goh</surname><given-names>A. R.</given-names></name><name><surname>Lee</surname><given-names>J. K.</given-names></name><name><surname>Bae</surname><given-names>Y. S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Nox2-based NADPH oxidase mediates HIV-1 Tat-induced up-regulation of VCAM-1/ICAM-1 and subsequent monocyte adhesion in human astrocytes</article-title>. <source/>Free Radic Biol. Med.
<volume>50</volume>, <fpage>576</fpage>–<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.12.019</pub-id><pub-id pub-id-type="pmid">21172429</pub-id></mixed-citation>
</ref>
<ref id="B293">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name><name><surname>Moore</surname><given-names>A.</given-names></name><name><surname>Hochman</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Human immunodeficiency virus type 1 Tat protein directly activates neuronal <italic>N</italic>-methyl-D-aspartate receptors at an allosteric zinc-sensitive site</article-title>. <source/>J. Neurovirol.
<volume>9</volume>, <fpage>399</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1080/13550280390201704</pub-id><pub-id pub-id-type="pmid">12775422</pub-id></mixed-citation>
</ref>
<ref id="B294">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sporer</surname><given-names>B.</given-names></name><name><surname>Linke</surname><given-names>R.</given-names></name><name><surname>Seelos</surname><given-names>K.</given-names></name><name><surname>Paul</surname><given-names>R.</given-names></name><name><surname>Klopstock</surname><given-names>T.</given-names></name><name><surname>Pfister</surname><given-names>H. W.</given-names></name></person-group> (<year>2005</year>). <article-title>HIV-induced chorea: evidence for basal ganglia dysregulation by SPECT</article-title>. <source/>J. Neurol.
<volume>252</volume>, <fpage>356</fpage>–<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-005-0626-1</pub-id><pub-id pub-id-type="pmid">15726276</pub-id></mixed-citation>
</ref>
<ref id="B295">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spudich</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>HIV and neurocognitive dysfunction</article-title>. <source/>Curr. HIV/AIDS Rep.
<volume>10</volume>, <fpage>235</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1007/s11904-013-0171-y</pub-id><pub-id pub-id-type="pmid">23860944</pub-id></mixed-citation>
</ref>
<ref id="B296">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephans</surname><given-names>S. E.</given-names></name><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name></person-group> (<year>1994</year>). <article-title>Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux</article-title>. <source/>Synapse
<volume>17</volume>, <fpage>203</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1002/syn.890170310</pub-id><pub-id pub-id-type="pmid">7974204</pub-id></mixed-citation>
</ref>
<ref id="B297">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>M. W.</given-names></name><name><surname>Tawney</surname><given-names>R. L.</given-names></name><name><surname>West</surname><given-names>C. M.</given-names></name><name><surname>Kight</surname><given-names>A. D.</given-names></name><name><surname>Henry</surname><given-names>R. L.</given-names></name><name><surname>Owens</surname><given-names>S. M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use</article-title>. <source/>MAbs
<volume>6</volume>, <fpage>547</fpage>–<lpage>555</lpage>. <pub-id pub-id-type="doi">10.4161/mabs.27620</pub-id><pub-id pub-id-type="pmid">24492290</pub-id></mixed-citation>
</ref>
<ref id="B298">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>T. W.</given-names></name></person-group> (<year>1993</year>). <article-title>Neuropharmacology of quinolinic and kynurenic acids</article-title>. <source/>Pharmacol. Rev.
<volume>45</volume>, <fpage>309</fpage>–<lpage>379</lpage>.<pub-id pub-id-type="pmid">8248282</pub-id></mixed-citation>
</ref>
<ref id="B299">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strazza</surname><given-names>M.</given-names></name><name><surname>Pirrone</surname><given-names>V.</given-names></name><name><surname>Wigdahl</surname><given-names>B.</given-names></name><name><surname>Nonnemacher</surname><given-names>M. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier</article-title>. <source/>Brain Res.
<volume>1399</volume>, <fpage>96</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2011.05.015</pub-id><pub-id pub-id-type="pmid">21641584</pub-id></mixed-citation>
</ref>
<ref id="B300">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryavanshi</surname><given-names>P. S.</given-names></name><name><surname>Ugale</surname><given-names>R. R.</given-names></name><name><surname>Yilmazer-Hanke</surname><given-names>D.</given-names></name><name><surname>Stairs</surname><given-names>D. J.</given-names></name><name><surname>Dravid</surname><given-names>S. M.</given-names></name></person-group> (<year>2014</year>). <article-title>GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice</article-title>. <source/>Br. J. Pharmacol.
<volume>171</volume>, <fpage>799</fpage>–<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12518</pub-id><pub-id pub-id-type="pmid">24236947</pub-id></mixed-citation>
</ref>
<ref id="B301">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzumura</surname><given-names>A.</given-names></name><name><surname>Ito</surname><given-names>A.</given-names></name><name><surname>Mizuno</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>). <article-title>Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development</article-title>. <source/>Mult. Scler.
<volume>9</volume>, <fpage>574</fpage>–<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1191/1352458503ms970oa</pub-id><pub-id pub-id-type="pmid">14664469</pub-id></mixed-citation>
</ref>
<ref id="B302">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzumura</surname><given-names>A.</given-names></name><name><surname>Ito</surname><given-names>A.</given-names></name><name><surname>Yoshikawa</surname><given-names>M.</given-names></name><name><surname>Sawada</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>). <article-title>Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS</article-title>. <source/>Brain Res.
<volume>837</volume>, <fpage>203</fpage>–<lpage>212</lpage>.<pub-id pub-id-type="pmid">10434004</pub-id></mixed-citation>
</ref>
<ref id="B303">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talloczy</surname><given-names>Z.</given-names></name><name><surname>Martinez</surname><given-names>J.</given-names></name><name><surname>Joset</surname><given-names>D.</given-names></name><name><surname>Ray</surname><given-names>Y.</given-names></name><name><surname>Gacser</surname><given-names>A.</given-names></name><name><surname>Toussi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Methamphetamine inhibits antigen processing, presentation, and phagocytosis</article-title>. <source/>PLoS Pathog.
<volume>4</volume>:<fpage>e28</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0040028</pub-id><pub-id pub-id-type="pmid">18282092</pub-id></mixed-citation>
</ref>
<ref id="B304">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tewari</surname><given-names>M. Monika</given-names></name><name><surname>Varghse</surname><given-names>R. K.</given-names></name><name><surname>Menon</surname><given-names>M.</given-names></name><name><surname>Seth</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Astrocytes mediate HIV-1 Tat-induced neuronal damage via ligand-gated ion channel P2X7R</article-title>. <source/>J. Neurochem.
<volume>132</volume>, <fpage>464</fpage>–<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12953</pub-id><pub-id pub-id-type="pmid">25272052</pub-id></mixed-citation>
</ref>
<ref id="B305">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>S.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Dwoskin</surname><given-names>L. P.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2012</year>). <article-title>HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum</article-title>. <source/>Synapse
<volume>66</volume>, <fpage>755</fpage>–<lpage>757</lpage>. <pub-id pub-id-type="doi">10.1002/syn.21564</pub-id><pub-id pub-id-type="pmid">22517264</pub-id></mixed-citation>
</ref>
<ref id="B306">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>S.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2006a</year>). <article-title>Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum</article-title>. <source/>Exp. Neurol.
<volume>199</volume>, <fpage>490</fpage>–<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2006.01.009</pub-id><pub-id pub-id-type="pmid">16510141</pub-id></mixed-citation>
</ref>
<ref id="B307">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>S.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2006b</year>). <article-title>Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum</article-title>. <source/>Neuroscience
<volume>137</volume>, <fpage>925</fpage>–<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.10.056</pub-id><pub-id pub-id-type="pmid">16338084</pub-id></mixed-citation>
</ref>
<ref id="B308">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>S.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Young</surname><given-names>K.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2006c</year>). <article-title>Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction</article-title>. <source/>Neurobiol. Dis.
<volume>23</volume>, <fpage>663</fpage>–<lpage>668</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2006.05.005</pub-id><pub-id pub-id-type="pmid">16828290</pub-id></mixed-citation>
</ref>
<ref id="B309">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>S.</given-names></name><name><surname>Stolberg</surname><given-names>S.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2006d</year>). <article-title>Human immunodeficiency virus-1 protein tat and methamphetamine interactions</article-title>. <source/>Ann. N. Y. Acad. Sci.
<volume>1074</volume>, <fpage>178</fpage>–<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1369.018</pub-id><pub-id pub-id-type="pmid">17105916</pub-id></mixed-citation>
</ref>
<ref id="B310">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>S.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Maragos</surname><given-names>W. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration</article-title>. <source/>Curr. HIV Res.
<volume>5</volume>, <fpage>301</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.2174/157016207780636515</pub-id><pub-id pub-id-type="pmid">17504172</pub-id></mixed-citation>
</ref>
<ref id="B311">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>E. R.</given-names></name><name><surname>Dunfee</surname><given-names>R. L.</given-names></name><name><surname>Stanton</surname><given-names>J.</given-names></name><name><surname>Bogdan</surname><given-names>D.</given-names></name><name><surname>Kunstman</surname><given-names>K.</given-names></name><name><surname>Wolinsky</surname><given-names>S. M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-associated dementia</article-title>. <source/>AIDS Res. Hum. Retrovir.
<volume>23</volume>, <fpage>575</fpage>–<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2006.0246</pub-id><pub-id pub-id-type="pmid">17451348</pub-id></mixed-citation>
</ref>
<ref id="B312">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikka</surname><given-names>T.</given-names></name><name><surname>Fiebich</surname><given-names>B. L.</given-names></name><name><surname>Goldsteins</surname><given-names>G.</given-names></name><name><surname>Keinanen</surname><given-names>R.</given-names></name><name><surname>Koistinaho</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia</article-title>. <source/>J. Neurosci.
<volume>21</volume>, <fpage>2580</fpage>–<lpage>2588</lpage>.<pub-id pub-id-type="pmid">11306611</pub-id></mixed-citation>
</ref>
<ref id="B313">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikka</surname><given-names>T. M.</given-names></name><name><surname>Koistinaho</surname><given-names>J. E.</given-names></name></person-group> (<year>2001</year>). <article-title>Minocycline provides neuroprotection against <italic>N</italic>-methyl-D-aspartate neurotoxicity by inhibiting microglia</article-title>. <source/>J. Immunol.
<volume>166</volume>, <fpage>7527</fpage>–<lpage>7533</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.166.12.7527</pub-id><pub-id pub-id-type="pmid">11390507</pub-id></mixed-citation>
</ref>
<ref id="B314">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>D.</given-names></name><name><surname>Pugliese</surname><given-names>A.</given-names></name><name><surname>Speranza</surname><given-names>F.</given-names></name></person-group> (<year>2002</year>). <article-title>Role of nitric oxide in HIV-1 infection: friend or foe?</article-title>
<source/>Lancet Infect. Dis.
<volume>2</volume>, <fpage>273</fpage>–<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(02)00262-1</pub-id><pub-id pub-id-type="pmid">12062993</pub-id></mixed-citation>
</ref>
<ref id="B315">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toussi</surname><given-names>S. S.</given-names></name><name><surname>Joseph</surname><given-names>A.</given-names></name><name><surname>Zheng</surname><given-names>J. H.</given-names></name><name><surname>Dutta</surname><given-names>M.</given-names></name><name><surname>Santambrogio</surname><given-names>L.</given-names></name><name><surname>Goldstein</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Short communication: methamphetamine treatment increases in vitro and in vivo HIV replication</article-title>. <source/>AIDS Res. Hum. Retrovir.
<volume>25</volume>, <fpage>1117</fpage>–<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2008.0282</pub-id><pub-id pub-id-type="pmid">19895343</pub-id></mixed-citation>
</ref>
<ref id="B316">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchan</surname><given-names>J.</given-names></name><name><surname>Anderson</surname><given-names>C.</given-names></name><name><surname>Hauser</surname><given-names>K. F.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine</article-title>. <source/>BMC Neurosci.
<volume>2</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2202-2-3</pub-id><pub-id pub-id-type="pmid">11252157</pub-id></mixed-citation>
</ref>
<ref id="B317">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchan-Cholewo</surname><given-names>J.</given-names></name><name><surname>Dimayuga</surname><given-names>F. O.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Keller</surname><given-names>J. N.</given-names></name><name><surname>Knapp</surname><given-names>P. E.</given-names></name><name><surname>Hauser</surname><given-names>K. F.</given-names></name><etal></etal></person-group> (<year>2009a</year>). <article-title>Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation</article-title>. <source/>J. Neurochem.
<volume>108</volume>, <fpage>202</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05756.x</pub-id><pub-id pub-id-type="pmid">19054280</pub-id></mixed-citation>
</ref>
<ref id="B318">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchan-Cholewo</surname><given-names>J.</given-names></name><name><surname>Dimayuga</surname><given-names>V. M.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Gorospe</surname><given-names>R. M.</given-names></name><name><surname>Keller</surname><given-names>J. N.</given-names></name><name><surname>Bruce-Keller</surname><given-names>A. J.</given-names></name></person-group> (<year>2009b</year>). <article-title>NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat</article-title>. <source/>Antioxid. Redox Signal.
<volume>11</volume>, <fpage>193</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2008.2097</pub-id><pub-id pub-id-type="pmid">18715150</pub-id></mixed-citation>
</ref>
<ref id="B319">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turowski</surname><given-names>P.</given-names></name><name><surname>Kenny</surname><given-names>B. A.</given-names></name></person-group> (<year>2015</year>). <article-title>The blood-brain barrier and methamphetamine: open sesame?</article-title>
<source/>Front. Neurosci.
<volume>9</volume>:<fpage>156</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2015.00156</pub-id><pub-id pub-id-type="pmid">25999807</pub-id></mixed-citation>
</ref>
<ref id="B320">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyor</surname><given-names>W. R.</given-names></name><name><surname>Glass</surname><given-names>J. D.</given-names></name><name><surname>Griffin</surname><given-names>J. W.</given-names></name><name><surname>Becker</surname><given-names>P. S.</given-names></name><name><surname>Mcarthur</surname><given-names>J. C.</given-names></name><name><surname>Bezman</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>1992</year>). <article-title>Cytokine expression in the brain during the acquired immunodeficiency syndrome</article-title>. <source/>Ann. Neurol.
<volume>31</volume>, <fpage>349</fpage>–<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1002/ana.410310402</pub-id><pub-id pub-id-type="pmid">1586135</pub-id></mixed-citation>
</ref>
<ref id="B321">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>J.</given-names></name><name><surname>Robertson</surname><given-names>K. R.</given-names></name><name><surname>Winston</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?</article-title>
<source/>AIDS
<volume>29</volume>, <fpage>253</fpage>–<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1097/qad.0000000000000538</pub-id><pub-id pub-id-type="pmid">25426811</pub-id></mixed-citation>
</ref>
<ref id="B322">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urrutia</surname><given-names>A.</given-names></name><name><surname>Rubio-Araiz</surname><given-names>A.</given-names></name><name><surname>Gutierrez-Lopez</surname><given-names>M. D.</given-names></name><name><surname>Elali</surname><given-names>A.</given-names></name><name><surname>Hermann</surname><given-names>D. M.</given-names></name><name><surname>O’Shea</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine</article-title>. <source/>Neurobiol. Dis.
<volume>50</volume>, <fpage>49</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2012.10.006</pub-id><pub-id pub-id-type="pmid">23069681</pub-id></mixed-citation>
</ref>
<ref id="B323">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valcour</surname><given-names>V.</given-names></name><name><surname>Chalermchai</surname><given-names>T.</given-names></name><name><surname>Sailasuta</surname><given-names>N.</given-names></name><name><surname>Marovich</surname><given-names>M.</given-names></name><name><surname>Lerdlum</surname><given-names>S.</given-names></name><name><surname>Suttichom</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Central nervous system viral invasion and inflammation during acute HIV infection</article-title>. <source/>J. Infect. Dis.
<volume>206</volume>, <fpage>275</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis326</pub-id><pub-id pub-id-type="pmid">22551810</pub-id></mixed-citation>
</ref>
<ref id="B324">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valderas</surname><given-names>J. M.</given-names></name><name><surname>Starfield</surname><given-names>B.</given-names></name><name><surname>Sibbald</surname><given-names>B.</given-names></name><name><surname>Salisbury</surname><given-names>C.</given-names></name><name><surname>Roland</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Defining comorbidity: implications for understanding health and health services</article-title>. <source/>Ann. Fam. Med.
<volume>7</volume>, <fpage>357</fpage>–<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1370/afm.983</pub-id><pub-id pub-id-type="pmid">19597174</pub-id></mixed-citation>
</ref>
<ref id="B325">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Bosch</surname><given-names>L.</given-names></name><name><surname>Tilkin</surname><given-names>P.</given-names></name><name><surname>Lemmens</surname><given-names>G.</given-names></name><name><surname>Robberecht</surname><given-names>W.</given-names></name></person-group> (<year>2002</year>). <article-title>Minocycline delays disease onset and mortality in a transgenic model of ALS</article-title>. <source/>Neuroimage
<volume>13</volume>, <fpage>1067</fpage>–<lpage>1070</lpage>. <pub-id pub-id-type="doi">10.1097/00001756-200206120-00018</pub-id><pub-id pub-id-type="pmid">12060810</pub-id></mixed-citation>
</ref>
<ref id="B326">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Grol</surname><given-names>J.</given-names></name><name><surname>Subauste</surname><given-names>C.</given-names></name><name><surname>Andrade</surname><given-names>R. M.</given-names></name><name><surname>Fujinaga</surname><given-names>K.</given-names></name><name><surname>Nelson</surname><given-names>J.</given-names></name><name><surname>Subauste</surname><given-names>C. S.</given-names></name></person-group> (<year>2010</year>). <article-title>HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3</article-title>. <source/>PLoS ONE
<volume>5</volume>:<fpage>e11733</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0011733</pub-id><pub-id pub-id-type="pmid">20661303</pub-id></mixed-citation>
</ref>
<ref id="B327">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vives</surname><given-names>E.</given-names></name><name><surname>Brodin</surname><given-names>P.</given-names></name><name><surname>Lebleu</surname><given-names>B.</given-names></name></person-group> (<year>1997</year>). <article-title>A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus</article-title>. <source/>J. Biol. Chem.
<volume>272</volume>, <fpage>16010</fpage>–<lpage>16017</lpage>.<pub-id pub-id-type="pmid">9188504</pub-id></mixed-citation>
</ref>
<ref id="B328">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakita</surname><given-names>H.</given-names></name><name><surname>Tomimoto</surname><given-names>H.</given-names></name><name><surname>Akiguchi</surname><given-names>I.</given-names></name><name><surname>Lin</surname><given-names>J. X.</given-names></name><name><surname>Ihara</surname><given-names>M.</given-names></name><name><surname>Ohtani</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat</article-title>. <source/>Brain Res.
<volume>992</volume>, <fpage>53</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2003.08.028</pub-id><pub-id pub-id-type="pmid">14604772</pub-id></mixed-citation>
</ref>
<ref id="B329">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>J.</given-names></name><name><surname>Winhusen</surname><given-names>T.</given-names></name><name><surname>Storkson</surname><given-names>J. M.</given-names></name><name><surname>Lewis</surname><given-names>D.</given-names></name><name><surname>Pariza</surname><given-names>M. W.</given-names></name><name><surname>Somoza</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary study</article-title>. <source/>Hum. Psychopharmacol.
<volume>29</volume>, <fpage>537</fpage>–<lpage>543</lpage>. <pub-id pub-id-type="doi">10.1002/hup.2430</pub-id><pub-id pub-id-type="pmid">25087849</pub-id></mixed-citation>
</ref>
<ref id="B330">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group> (<year>2014</year>). <article-title>Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein</article-title>. <source/>Retrovirology
<volume>11</volume>, <fpage>88</fpage>. <pub-id pub-id-type="doi">10.1186/s12977-014-0088-6</pub-id><pub-id pub-id-type="pmid">25323821</pub-id></mixed-citation>
</ref>
<ref id="B331">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Qian</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Effect of methamphetamine on the microglial damage: role of potassium channel Kv1.3</article-title>. <source/>PLoS ONE
<volume>9</volume>:<fpage>e88642</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0088642</pub-id><pub-id pub-id-type="pmid">24533129</pub-id></mixed-citation>
</ref>
<ref id="B332">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Flannery</surname><given-names>P. J.</given-names></name><name><surname>Rosenberg</surname><given-names>P. B.</given-names></name><name><surname>Fields</surname><given-names>T. A.</given-names></name><name><surname>Spurney</surname><given-names>R. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Gq-dependent signaling upregulates COX2 in glomerular podocytes</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>19</volume>, <fpage>2108</fpage>–<lpage>2118</lpage>. <pub-id pub-id-type="doi">10.1681/asn.2008010113</pub-id><pub-id pub-id-type="pmid">18667730</pub-id></mixed-citation>
</ref>
<ref id="B333">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeks</surname><given-names>B. S.</given-names></name><name><surname>Lieberman</surname><given-names>D. M.</given-names></name><name><surname>Johnson</surname><given-names>B.</given-names></name><name><surname>Roque</surname><given-names>E.</given-names></name><name><surname>Green</surname><given-names>M.</given-names></name><name><surname>Loewenstein</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>1995</year>). <article-title>Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49–58 basic domain</article-title>. <source/>J. Neurosci. Res.
<volume>42</volume>, <fpage>34</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.490420105</pub-id><pub-id pub-id-type="pmid">8531224</pub-id></mixed-citation>
</ref>
<ref id="B334">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>J. M.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Major</surname><given-names>E. O.</given-names></name><name><surname>Berman</surname><given-names>J. W.</given-names></name></person-group> (<year>1999</year>). <article-title>HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes</article-title>. <source/>J. Immunol.
<volume>163</volume>, <fpage>2953</fpage>–<lpage>2959</lpage>.<pub-id pub-id-type="pmid">10453044</pub-id></mixed-citation>
</ref>
<ref id="B335">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesselingh</surname><given-names>S. L.</given-names></name><name><surname>Power</surname><given-names>C.</given-names></name><name><surname>Glass</surname><given-names>J. D.</given-names></name><name><surname>Tyor</surname><given-names>W. R.</given-names></name><name><surname>Mcarthur</surname><given-names>J. C.</given-names></name><name><surname>Farber</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>1993</year>). <article-title>Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia</article-title>. <source/>Ann. Neurol.
<volume>33</volume>, <fpage>576</fpage>–<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1002/ana.410330604</pub-id><pub-id pub-id-type="pmid">8498837</pub-id></mixed-citation>
</ref>
<ref id="B336">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>C. A.</given-names></name><name><surname>Baldwin</surname><given-names>M.</given-names></name><name><surname>Achim</surname><given-names>C. L.</given-names></name></person-group> (<year>1996</year>). <article-title>Expression of HIV regulatory and structural mRNA in the central nervous system</article-title>. <source/>AIDS
<volume>10</volume>, <fpage>843</fpage>–<lpage>847</lpage>.<pub-id pub-id-type="pmid">8828741</pub-id></mixed-citation>
</ref>
<ref id="B337">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>R.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Peng</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Bethel-Brown</surname><given-names>C.</given-names></name><name><surname>Buch</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Cooperative induction of CXCL10 involves NADPH oxidase: implications for HIV dementia</article-title>. <source/>Glia
<volume>58</volume>, <fpage>611</fpage>–<lpage>621</lpage>. <pub-id pub-id-type="doi">10.1002/glia.20949</pub-id><pub-id pub-id-type="pmid">19941336</pub-id></mixed-citation>
</ref>
<ref id="B338">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wires</surname><given-names>E. S.</given-names></name><name><surname>Alvarez</surname><given-names>D.</given-names></name><name><surname>Dobrowolski</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Morales</surname><given-names>M.</given-names></name><name><surname>Karn</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells</article-title>. <source/>J. Neurovirol.
<volume>18</volume>, <fpage>400</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1007/s13365-012-0103-4</pub-id><pub-id pub-id-type="pmid">22618514</pub-id></mixed-citation>
</ref>
<ref id="B339">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>S. C.</given-names></name><name><surname>Jewett</surname><given-names>A.</given-names></name><name><surname>Mitsuyasu</surname><given-names>R.</given-names></name><name><surname>Bonavida</surname><given-names>B.</given-names></name></person-group> (<year>1988</year>). <article-title>Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients</article-title>. <source/>J. Immunol.
<volume>141</volume>, <fpage>99</fpage>–<lpage>104</lpage>.<pub-id pub-id-type="pmid">3132506</pub-id></mixed-citation>
</ref>
<ref id="B340">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D. C.</given-names></name><name><surname>Jackson-Lewis</surname><given-names>V.</given-names></name><name><surname>Vila</surname><given-names>M.</given-names></name><name><surname>Tieu</surname><given-names>K.</given-names></name><name><surname>Teismann</surname><given-names>P.</given-names></name><name><surname>Vadseth</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease</article-title>. <source/>J. Neurosci.
<volume>22</volume>, <fpage>1763</fpage>–<lpage>1771</lpage>.<pub-id pub-id-type="pmid">11880505</pub-id></mixed-citation>
</ref>
<ref id="B341">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Neuveut</surname><given-names>C.</given-names></name><name><surname>Tiffany</surname><given-names>H. L.</given-names></name><name><surname>Benkirane</surname><given-names>M.</given-names></name><name><surname>Rich</surname><given-names>E. A.</given-names></name><name><surname>Murphy</surname><given-names>P. M.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>97</volume>, <fpage>11466</fpage>–<lpage>11471</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.97.21.11466</pub-id><pub-id pub-id-type="pmid">11027346</pub-id></mixed-citation>
</ref>
<ref id="B342">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z.</given-names></name><name><surname>Miller</surname><given-names>G. M.</given-names></name></person-group> (<year>2009</year>). <article-title>A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>330</volume>, <fpage>316</fpage>–<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.109.153775</pub-id><pub-id pub-id-type="pmid">19364908</pub-id></mixed-citation>
</ref>
<ref id="B343">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9</article-title>. <source/>Brain Res.
<volume>1436</volume>, <fpage>13</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2011.11.052</pub-id><pub-id pub-id-type="pmid">22197032</pub-id></mixed-citation>
</ref>
<ref id="B344">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Mechanism of HIV-1-TAT induction of interleukin-1beta from human monocytes: involvement of the phospholipase C/protein kinase C signaling cascade</article-title>. <source/>J. Med. Virol.
<volume>82</volume>, <fpage>735</fpage>–<lpage>746</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21720</pub-id><pub-id pub-id-type="pmid">20336759</pub-id></mixed-citation>
</ref>
<ref id="B345">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>V. W.</given-names></name><name><surname>Krekoski</surname><given-names>C. A.</given-names></name><name><surname>Forsyth</surname><given-names>P. A.</given-names></name><name><surname>Bell</surname><given-names>R.</given-names></name><name><surname>Edwards</surname><given-names>D. R.</given-names></name></person-group> (<year>1998</year>). <article-title>Matrix metalloproteinases and diseases of the CNS</article-title>. <source/>Trends Neurosci.
<volume>21</volume>, <fpage>75</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">9498303</pub-id></mixed-citation>
</ref>
<ref id="B346">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>Q.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Di</surname><given-names>X.</given-names></name></person-group> (<year>2015</year>). <article-title>Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology</article-title>. <source/>Behav. Neurol.
<volume>2015</volume>, <fpage>103969</fpage>. <pub-id pub-id-type="doi">10.1155/2015/103969</pub-id><pub-id pub-id-type="pmid">25861156</pub-id></mixed-citation>
</ref>
<ref id="B347">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaczek</surname><given-names>R.</given-names></name><name><surname>Culp</surname><given-names>S.</given-names></name><name><surname>De Souza</surname><given-names>E. B.</given-names></name></person-group> (<year>1991</year>). <article-title>Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>257</volume>, <fpage>830</fpage>–<lpage>835</lpage>.<pub-id pub-id-type="pmid">1903446</pub-id></mixed-citation>
</ref>
<ref id="B348">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zauli</surname><given-names>G.</given-names></name><name><surname>Secchiero</surname><given-names>P.</given-names></name><name><surname>Rodella</surname><given-names>L.</given-names></name><name><surname>Gibellini</surname><given-names>D.</given-names></name><name><surname>Mirandola</surname><given-names>P.</given-names></name><name><surname>Mazzoni</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells</article-title>. <source/>J. Biol. Chem.
<volume>275</volume>, <fpage>4159</fpage>–<lpage>4165</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.275.6.4159</pub-id><pub-id pub-id-type="pmid">10660577</pub-id></mixed-citation>
</ref>
<ref id="B349">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H. S.</given-names></name><name><surname>Li</surname><given-names>H. Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>M. R.</given-names></name><name><surname>Zhou</surname><given-names>H. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation</article-title>. <source/>Free Radic Biol. Med.
<volume>47</volume>, <fpage>261</fpage>–<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.04.028</pub-id><pub-id pub-id-type="pmid">19409485</pub-id></mixed-citation>
</ref>
<ref id="B350">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Ge</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Methamphetamine modulates glutamatergic synaptic transmission in rat primary cultured hippocampal neurons</article-title>. <source/>Brain Res.
<volume>1582</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2014.07.040</pub-id><pub-id pub-id-type="pmid">25091639</pub-id></mixed-citation>
</ref>
<ref id="B351">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Chao</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Involvement of sigma-1 receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression</article-title>. <source/>J. Neuroinflamm.
<volume>12</volume>, <fpage>29</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-015-0250-7</pub-id><pub-id pub-id-type="pmid">25889537</pub-id></mixed-citation>
</ref>
<ref id="B352">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Pu</surname><given-names>S. S.</given-names></name><name><surname>Gao</surname><given-names>W. H.</given-names></name><name><surname>Chi</surname><given-names>Y. Y.</given-names></name><name><surname>Wen</surname><given-names>H. L.</given-names></name><name><surname>Wang</surname><given-names>Z. Y.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Effects of HIV-1 tat on secretion of TNF-alpha and IL-1beta by U87 cells in AIDS patients with or without AIDS dementia complex</article-title>. <source/>Biomed. Environ. Sci.
<volume>27</volume>, <fpage>111</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.3967/bes2014.024</pub-id><pub-id pub-id-type="pmid">24625401</pub-id></mixed-citation>
</ref>
<ref id="B353">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Hennig</surname><given-names>B.</given-names></name><name><surname>Toborek</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells</article-title>. <source/>J. Cereb. Blood Flow Metab.
<volume>30</volume>, <fpage>522</fpage>–<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2009.214</pub-id><pub-id pub-id-type="pmid">19794400</pub-id></mixed-citation>
</ref>
<ref id="B354">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Smart</surname><given-names>E. J.</given-names></name><name><surname>Weksler</surname><given-names>B.</given-names></name><name><surname>Couraud</surname><given-names>P. O.</given-names></name><name><surname>Hennig</surname><given-names>B.</given-names></name><name><surname>Toborek</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>7788</fpage>–<lpage>7796</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.0061-08.2008</pub-id><pub-id pub-id-type="pmid">18667611</pub-id></mixed-citation>
</ref>
<ref id="B355">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B. Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>B.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes</article-title>. <source/>Mol. Cell. Neurosci.
<volume>27</volume>, <fpage>296</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2004.07.003</pub-id><pub-id pub-id-type="pmid">15519244</pub-id></mixed-citation>
</ref>
<ref id="B356">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Ananthan</surname><given-names>S.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity</article-title>. <source/>Synapse
<volume>65</volume>, <fpage>1251</fpage>–<lpage>1254</lpage>. <pub-id pub-id-type="doi">10.1002/syn.20949</pub-id><pub-id pub-id-type="pmid">21538554</pub-id></mixed-citation>
</ref>
<ref id="B357">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Mactutus</surname><given-names>C. F.</given-names></name><name><surname>Wallace</surname><given-names>D. R.</given-names></name><name><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2009</year>). <article-title>HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>329</volume>, <fpage>1071</fpage>–<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.108.150144</pub-id><pub-id pub-id-type="pmid">19325033</pub-id></mixed-citation>
</ref>
<ref id="B358">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zidovetzki</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J. L.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Jeyaseelan</surname><given-names>R.</given-names></name><name><surname>Hofman</surname><given-names>F.</given-names></name></person-group> (<year>1998</year>). <article-title>Human immunodeficiency virus Tat protein induces interleukin 6 mRNA expression in human brain endothelial cells via protein kinase C- and cAMP-dependent protein kinase pathways</article-title>. <source/>AIDS Res. Hum. Retrovir.
<volume>14</volume>, <fpage>825</fpage>–<lpage>833</lpage>.<pub-id pub-id-type="pmid">9671211</pub-id></mixed-citation>
</ref>
<ref id="B359">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zink</surname><given-names>M. C.</given-names></name><name><surname>Uhrlaub</surname><given-names>J.</given-names></name><name><surname>Dewitt</surname><given-names>J.</given-names></name><name><surname>Voelker</surname><given-names>T.</given-names></name><name><surname>Bullock</surname><given-names>B.</given-names></name><name><surname>Mankowski</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Neuroprotective and anti-human immunodeficiency virus activity of minocycline</article-title>. <source/>JAMA
<volume>293</volume>, <fpage>2003</fpage>–<lpage>2011</lpage>. <pub-id pub-id-type="doi">10.1001/jama.293.16.2003</pub-id><pub-id pub-id-type="pmid">15855434</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>